




—15—

WORLD CONGRESS
OF gynecological
endocrinology ♀

III CONGRESSO ISGE ITALIA

MARCH 7-10 2012 FIRENZE, ITALY



FINAL PROGRAMME

Fostimon[®]

Highly purified hFSH



Evidence of life

INTRODUCTION



Dear Friends
Welcome at the 15th World Congress of Gynecological Endocrinology. On behalf of the Executive Committee of the International Society of Gynecological Endocrinology -ISGE-, we are proud of the quality achieved by this event.

The programme emphasize the role of our Society in the different areas of Gynecology, Obstetric and Reproductive Medicine:

2 Precongress courses, 10 Plenary Lectures, 30 Plenary Sessions, 2 Meet the expert sessions, 4 Educational Courses, 19 Oral Presentations, 13 Symposia Organized by various Scientific Societies, 16 Sponsored Symposia and more than 440 Posters does not need any further words.

The huge numbers of attendees, and mostly the great number of young researchers who participated to the "under 34 Competition", designates the importance of our Society in the basic and clinical science, its energy and great potential for the Gynecological Endocrinology future. I would like to thank the teamwork of the Italian Association of Gynecological Endocrinology -AIGE-, which contributed for the development and the success of this Event.

I also want to thank all our Sponsors for their support, which developed very attractive scientific events, presenting all their innovations in the therapeutic strategies, for their sponsored symposia and the beautiful exhibition area, that I invite everyone to visit.

Moreover, this year the social program is characterized, besides the usual get together party, with a wonderful concert in the Basilica of St. Lorenzo built with the joint effort of Brunelleschi and Michelangelo, where the orchestra and regional Choir of Tuscany presents the Mozart's Requiem Mess.

My greatest thanks and my warmest welcome in Florence to all of you

A.R Genazzani
President of ISGE

TABLE OF CONTENTS

The International Society of Gynecological Endocrinology	4
The ISGE Membership	7
Gynendo News	8
The International School of Gynecological and Reproductive Endocrinology	8
Secretariat and Contacts - New Registrations and Secretariat Desk - Privacy	10
General information	
Official language - Coffee - Lunch Symposia	
Insurance - Badge - Certificate of Attendance	
Customer Satisfaction	12
Social Events	13
Boards and Assemblies	13
Congress Area Map	14
Scientific information	
Congress on-line - Computer Projection	
Preview Rooms - Oral Presentations	
Poster Session - Poster award	15
The winners of the Under 34 Competition	16
Sponsors and exhibitors	22

SCIENTIFIC PROGRAMME

Continuous medical education	31
Plenary Lectures	33
The four best abstracts of the Under 34 Competition	45
Sponsored Symposia and Lectures	50
Symposia by Scientific Societies	51
Debates and Meet the expert sessions	51
Wednesday March 7th	52
Thursday March 8th	54
Friday March 9th	66
Saturday March 10th	78
List of Posters	89

THE INTERNATIONAL SOCIETY OF GYNECOLOGICAL ENDOCRINOLOGY



BOARD 2010-2014

PRESIDENT

A.R.GENAZZANI PISA, ITALY

TREASURER

B.LUNENFELD TEL-AVIV, ISRAEL

EXECUTIVE SECRETARY

T.SIMONCINI PISA, ITALY

MEMBERS

F. AL-AZZAWI LEICESTER, UK

S.BERGA ATLANTA, USA

M.Birkhaeuser BERN, SWITZERLAND

P. BOUCHARD PARIS, FRANCE

M.BRINCAT MALTA

N.R. DE MELO SAOPAULO, BRAZIL

L.DEVOTO SANTIAGO, CHILE

J.M.FOIDART LIEGE, BELGIUM

P.KENEMANS AMSTERDAM, NL

T.MARUO KOBE, JAPAN

M.MENDELSON BOSTON, USA

A.MILEWICZ WROCLAW, POLAND

F.NAFTOLIN NEW YORK, USA

E.H.Y.NG HONG KONG, CHINA

F.PETRAGLIA SIENA, ITALY

A.SCHINDLER ESSEN, GERMANY

C.SIMON VALENCIA, SPAIN

E.SIMPSON CLAYTON, AUSTRALIA

N.SISELES BUENOS AIRES, ARGENTINA

V.SMETNIK MOSCOW, RUSSIA

B.TARLATZIS THESSALONIKI, GREECE

B. Von SCHOULTZ STOCKHOLM, SWEDEN

ABOUT ISGE

The International Society of Gynecological Endocrinology is a non-profit organisation established in 1986 for the purpose of promoting science and research into all aspects of gynecological endocrinology and communication between scientists interested in these subjects.

The Society operates through the monthly **Journal of Gynecological Endocrinology**, the monthly newsletter **GynEndo News** and the biannual **World Congress**, a major scientific event which allows a perfect integration of renowned faculty members with talented young scientists presenting innovative research. Join us as a member of the International Society of Gynecological Endocrinology and be part of our active and professional scientific society.

INTERNATIONAL SCHOOL OF GYNECOLOGICAL AND REPRODUCTIVE ENDOCRINOLOGY

The International School of Gynecological and Reproductive Endocrinology is the educational branch of ISGE entitled for the organization of educational courses on behalf of the Society itself.

The mission of The International School of Gynecological and Reproductive Endocrinology is to promote clinical education world-wide by aiding the training of physicians from all nations in Gynecological Endocrinology and related fields. In order to cope with increasing health problems worldwide, particularly in developing countries, the school organizes both in-door and on-line educational programs.

GYNENDO NEWS

Gynendo News is the e-mail bulletin of the International Society of Gynecological Endocrinology. It is the voice of the Society and it carries opinions and news in Gynecological and Reproductive Endocrinology in your mailbox. If you don't receive it yet, visit now www.gynendonews.com and subscribe to Gynendo News. It's absolutely free and will be your invaluable source of updating in Gynecological Endocrinology from now on...



THE GYNECOLOGICAL ENDOCRINOLOGY JOURNAL

"Gynecological Endocrinology", the official journal of ISGE, covers all experimental, clinical and therapeutic aspects of this ever more important discipline. It includes, amongst others, papers related to the control and function of the different endocrine glands in females, the effects of reproductive events on the endocrine system, the consequences of endocrine disorders on reproduction.

If you are interested in receiving **the Printed edition** of the journal you can subscribe at the following prices:

- ♦ €95 one year (2012)
- ♦ €170 two year (2012 and 2013)

Please contact our staff at the ISGE stand in the Exhibition Area; for all further information please contact the ISGE Secretariat at ufficioisge@tiscali.it



THE INTERNATIONAL FEDERATION OF THE SOCIETIES OF GYNECOLOGICAL ENDOCRINOLOGY (FISGE)

FISGE unites all the societies of gynecological endocrinology interested in the study and the research of all aspects of gynecological endocrinology, aiming to improve the communication and the exchange of information related to the activities of each society, to promote the development of common scientific projects and to advance the interchange of young and senior researchers between those centres devoted to gynecological endocrinology all over the world.

For all further information www.gynecologicalendocrinology.org



www.twitter.com/gynendo


www.facebook.com/gynendo

THE ISGE MEMBERSHIP

NOW YOU ARE AN ISGE MEMBER

Welcome to the International Society of Gynecological Endocrinology.
Registering to the World Congress you have automatically become a member of the Society for 2 years.

TOGETHER WITH ISGE MEMBERSHIP YOU HAVE:



Free Access to the digital edition of the Gynecological Endocrinology Journal (2 years).

INTERESTED IN THE
PRINTED EDITION?
SEE PAGE 5!

Discount on all courses organized by the International School of Gynecological and Reproductive Endocrinology.

Online access to all the lectures of the 15th world congress with slides and audio and **up to €100 discount** on 16th congress registration.

Monthly newsletter with news, abstracts, reviews and other contents on the Gynecological Endocrinology topics.

HOW TO ACCESS TO ALL YOUR ISGE MEMBERS SERVICES

- 1** Visit the **Members area** on the society's official website www.gynecologicalendocrinology.org
- 2** Log in with the email and password you used to register to the 15th ISGE world congress.
- ! I DO NOT HAVE AN ACCOUNT**
Insert the access code you found in the congress kit to create a new account in the Members area of www.gynecologicalendocrinology.org
- ! I HAVE LOST MY PASSWORD**
Click on the password recovery button, you will receive a new password on the email you used for your registration

GynEndo News is the monthly newsletter of the International Society of Gynecological Endocrinology. GynEndo News is the best way to keep you updated in Gynecological Endocrinology.

Receive every month scientific contents from Gynecological Endocrinology, the official journal of the Society, and from the international press. Let the relevant news in your area come directly to your e-mail, rather than looking for them...

Receive a privileged access to scientific presentations from international congresses, including the ISGE World Congress on Gynecological Endocrinology! See the presentations stream in front of you while sitting comfortably in your office or home and see them all over again how many times you want! And this all for free!

Register today to receive the newsletter and join a community of over 30.000 members in the World!

INTERNATIONAL SCHOOL OF GYNECOLOGICAL AND REPRODUCTIVE ENDOCRINOLOGY

The International School of Gynecological and Reproductive Endocrinology is the educational branch of ISGE founded in 2010.

The main courses organized by the School in the first two years are:

- Hyperandrogenisms and reproduction
Florence, March 2010
- Therapeutical use of hormonal contraception
Florence, March 2010
- NeuroEndocrinology and female reproduction
Venice, October 2010
- "Hypothalamic amenorrhea and other menstrual cycle disorders" etio-pathogenesis, physical, psychological and reproductive impacts.
From diagnosis to therapies: which, how long, how to follow up, what goals to achieve for healthy reproductive life and aging
Florence, March 2012
- "Polycystic ovary syndrome" etiology, metabolic and fertility impact, subjective risk for reproductive and other organs diseases, therapeutic strategies from adolescence to late post-menopause
Florence, March 2012

Starting from 2013 the School will also launch its winter and summer schools. Twice a year (January and July) for one week, a selection of the best worldwide known lecturers will meet in great winter or summer resort to discuss with 300 participants the state of the art of Gynecological Endocrinology hot topics.

Next meetings will be in:

- 2013 Winter school: "Frontiers in gynecological endocrinology: the clinical impact" Madonna di Campiglio (January 27- February 3 2013)
- 2013 Summer school Malta (July 8 - 14 2013)

On the society's website, reserved for the ISGE Members the following educational materials are available:

For free:

- Hyperandrogenisms and reproduction (7 Lessons)
- Therapeutical use of hormonal contraception (8 Lessons)

Available at 20€ per course:

- NeuroEndocrinology and female reproduction (5 Courses with 5 Lessons each)



FRONTIERS IN GYNECOLOGICAL ENDOCRINOLOGY: THE CLINICAL IMPACT

The programme will cover the following areas:

- Adolescence and its disorders
- Endocrine control of follicular development and ovulation
- Fertility control
- Reconstructive surgery in Müllerian defects
- Ovarian surgery impact on endocrine and reproductive functions
- Ovulatory dysfunctions from Hypothalamic Amenorrhea to Polycystic Ovary
- Luteal phase defects
- Premature ovarian failure
- Pre-menopause
- Menopause: impact on the different systems and need of personalization
- Elderly gynecology
- Endocrine aspects of female infertility
- Medically assisted procreation: a challenge for endocrine therapies
- Female sexuality
- The breast

All topics will be divided in different lessons for a total of 25 presentations. In addition, each day will be concluded by a special lesson on Therapies updating in Gynecological Endocrinology, devoted each one to a specific area. Details concerning the Structure of the Course, the exact titles of lessons and the name of the faculty members will be available soon.

The school activities will start on Sunday afternoon and will finish the following Friday evening.

The structure will include 3 hours teaching in the morning from 8,00 to 11,00 and 3 hours in the afternoon from 4.30 to 7.30; for a total of 31 hours of formal teaching.

Each lesson will be of 45 minutes plus 15 minutes of questions and answers. Morning and afternoon sessions will be enriched at the end by further 30 minutes of general discussions.

SECRETARIATS & CONTACTS

SCIENTIFIC SECRETARIAT

Paolo Artini, Vito Cela, Franca Fruzzetti, Angiolo Gadducci, Marco Gambacciani, Carlo Luchi, Paolo Mannella, Nicola Pluchino.

Dept. of Reproductive Medicine and Child Development Division of Gynecology and Obstetrics "P. Fioretti" University of Pisa

Via Roma 67 56126 Pisa, Italy

T. +39 050503985

F. +39 0502207028

ufficioisge@tiscali.it

ORGANIZING SECRETARIAT

Biomedical Technologies srl

www.btcongress.com

Main Office

Via P. Cugia 1 - 09129 Cagliari Italia

T. +39070340293

F. +39070307727

isge2012@btcongress.com

Marketing Office

Via Metauro 19-00198 Roma

T. +39068546198

marketing@btcongress.com

CONGRESS VENUE

Firenze fiera

Piazza Adua, 1 Firenze, Italy

www.firenzefiera.it

WWW

www.isge2012.com

 twitter.com/gynendo

 facebook.com/gynendo

NEW REGISTRATIONS & SECRETARIAT DESK

CONGRESS SECRETARIAT DESK

The Congress Secretariat is located in exhibition area in Palazzo dei Congressi. The Secretariat observes the following opening hours:

Tuesday March 6th 16.00 - 19.00

Wednesday March 7th 08.00 - 18.30

Thursday March 8th 08.00 - 18.00

Friday March 8th 08.00 - 18.00

Saturday March 10th 08.00 - 13.30

ON SITE REGISTRATION FEES (21% VAT INCLUDED)

Delegate €650

Developing countries
and East Europe €450

Residents, nurses
and technicians €300

Accompanying persons €120

Daily registration €180

DELEGATES FEE INCLUDES

- Opening and closing Ceremonies
- Welcome Reception
- Access to all sessions and exhibition area
- Congress kit
- Abstract Book (in CD version)
- CME credits and/or ECM Credits
- Coffee and lunches
- Concert

ACCOMPANYING PERSON FEE INCLUDES

- Half Day city Tour
- Social events
- Opening and closing Ceremonies
- Welcome Reception
- Access to the exhibition area

PRIVACY

PERSONAL DATA PROTECTION

LAW NO. 196/2003

Personal data collected directly and/or through third parties by controller and processor Biomedical Technologies. Main Office in Cagliari Via Cugia 1, are processed in printed, computing and telematic form for fulfilling contractual and lawful obligations as well as for the effective handling of business relations. The email addresses provided may be used by Biomedical Technologies to send advertising materials on events similar to those subject of the present business relations. The non-submittal of data, where no compulsory, will be evaluated from case to case by the controller and the resulting decisions to be made will take into account the importance of the required data in respect of the business relations, management. Data may be disclosed in Italy and/or abroad, strictly in accordance with the above-mentioned purposes, and consequently processed, only in relation to the mentioned purpose, by other persons: professionals and consultants as well as by persons allowed to access to your personal data according to National or Community regulations. If necessary, for the above-mentioned reasons, your data may be disclosed to third parties. For the same reasons, our partners and/or employees may process your data in their capacity of executors or processors. The persons concerned may exercise all the rights set forth in art. 7 of L. n. 196/2003 (including the rights of data access, corrections, updating, objects to data processing and cancellation). The processor "pro tempore" is the legal representative of the company.





Endometriosis

There's a new way out of the pain

- Highly effective pain relief^{1, 2, 3, 4}
- Significant reduction of endometriotic lesions¹
- Favorable safety and tolerability profile suitable for long-term use⁴

Visanne® product description: Each tablet contains 2 mg dienogest. For oral use. **Therapeutic indication:** Treatment of endometriosis. Treatment can be started on any day of the menstrual cycle. Tablets should be taken continuously without regard to vaginal bleeding. **Contraindications:** Active venous thromboembolic disorder, arterial and cardiovascular disease, past or present (e.g. myocardial infarction, cerebrovascular accident, ischemic heart disease), diabetes mellitus with vascular involvement, presence or history of severe hepatic disease as long as liver function values have not returned to normal, presence or history of liver tumors (benign or malignant), known or suspected sex hormone-dependent malignancies, undiagnosed vaginal bleeding, hypersensitivity to the active substance or to any of the excipients. **Special warnings and precautions for use:** Serious uterine bleeding, changes in bleeding pattern, circulatory disorders, tumors, osteoporosis, other conditions like history of depression, clinically significant hypertension, recurrence of chole-

static jaundice and/or pruritus. Dienogest may have a slight effect on peripheral insulin resistance and glucose tolerance. Chloasma may occasionally occur. In women with a history of extrauterine pregnancy or an impairment of tube function, the use of Visanne® should be decided on only after carefully weighing the benefits against the risks. Persistent ovarian follicles (often referred to as functional ovarian cysts) may occur during the use of Visanne®. Each Visanne® tablet contains lactose monohydrate. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption who are on a lactose-free diet should consider the amount contained in Visanne®. Treatment should be stopped at once if there are symptoms of an arterial or venous thrombotic event or suspicion thereof. Visanne® must not be administered to pregnant women because there is no need to treat endometriosis during pregnancy. Treatment with Visanne® during lactation is not recommended. Based on the available data,

ovulation is inhibited in the majority of patients during treatment with Visanne®. However, Visanne® is not a contraceptive. **Undesirable effects:** The most frequently reported undesirable effects under treatment with Visanne® are headache, breast discomfort, depressed mood, acne and changes in the menstrual bleeding pattern. Further details see package insert leaflet, valid 17 February 2010. **Bayer HealthCare Pharmaceuticals, 13342 Berlin, Germany.** www.bayerpharma.com

References: 1. Köhler G. et al, Int.J. Gynaecol Obstet 2010; 108:21-25 | 2. Strowitzki T. et al, Eur J Obstet Gynecol Reprod Biol 2010 | 3. Strowitzki T. et al, Hum Reprod 2010; 25:633-641 | 4. Petraglia F. et al, Arch Gynecol Obstet 2012; 285(1):167-173. **Not yet marketed in Italy. Articles are available at the booth.**

A.N.: IT/GM/2012/01/15, A.D.: 03.02.2012
G.WH.GT.05.2010.0016

Visanne®
As determined as you are

GENERAL INFORMATION



LUNCH SYMPOSIA
LUNCH BOXES WILL
BE DISTRIBUTED
FROM 13.10 TO 13.30
BEFORE THE SYMPOSIUM
STARTS AND MUST
BE EATEN INSIDE THE
CONGRESS HALL.

OFFICIAL LANGUAGE

Official language of the Congress is English. Italian is the official language of the 3rd Congress of the Italian Society of Gynecological Endocrinology.

COFFEE

Get free coffee or hot drinks at any time during the congress from the automatic beverage dispensers located in the Exhibition Area.

LUNCH SYMPOSIA

March 8 13.10 - 15.10

[SEE PAGE 59/60](#)

Affari 0 Progesterone: a re-birth as leading progestin (sponsored by Besins)

Affari 1 Local estriol gel in urogenital atrophy (sponsored by Italfarmaco)

March 9 13.10 - 15.10

[SEE PAGE 70/71](#)

Affari 0 Progestins in obstetrical and gynaecological therapies

Affari 1 Human derived FSH: new evidences for old understandings
(sponsored by Ibsa)

March 10 13.10 - 15.10

[SEE PAGE 82](#)

Affari 1 Additional benefits in hormonal contraception: new evidence with E2V/DNG (sponsored by Bayer)

INSURANCE

The Congress Organizers cannot accept liability for personal injuries, loss or damage to property belonging to Congress delegates (or their accompanying persons), either during or as a result of the Congress or during their stay in Florence. It is therefore recommended that delegates arrange their own personal health, accident and travel insurance.

BADGES

All registrants including registered accompanying persons will receive a badge. Your personal badge allows you access to all Sessions, Exhibition Area and Social Events. Please remember to always wear your badge, also during social events. If you have lost your badge, a new one can be purchased at the Congress Secretariat.

CERTIFICATE OF ATTENDANCE

You will find your certificate of attendance together with your badge. Please check it and in case you need any change come from Friday 8th 14.00 to the "New Registrations Desk".

CUSTOMER SATISFACTION

Inside your congress bag you will find the Customer Satisfaction Form. Please do not ignore it. It is a Compulsory Service as Biomedical Technologies is Quality Certified and moreover you help us to improve our services. The handback of the Customer Satisfaction Form is compulsory to receive the UEMS certificate and ECM.

SOCIAL EVENTS

WEDNESDAY MARCH 7TH

Opening ceremony with Concert and Aperitif

Lyrical concert in Hall Auditorium with arias by Mozart, Verdi, Puccini.

The Concert will be followed by a Welcome Cocktail in the Exhibition area - Concert and Cocktail organized with the contribution of Teva

THURSDAY MARCH 8TH

19.45

Mozart "Requiem in Re Minore K626"

Basilica di San Lorenzo, Piazza San Lorenzo

organized with the contribution of IBSA

Collect the entrance ticket from the social events desk.

Limited seats are available, so tickets will be distributed on "first come first take" basis. No entrance can be allowed without entrance ticket.



FRIDAY MARCH 9TH

17.30 - 19.30

Poster Session and Tuscan Delights in the Exhibition Area

SATURDAY MARCH 10TH

Speaker's dinner upon invitation

organized with the contribution of Ferring

BOARDS

& ASSEMBLIES

ISGE EXECUTIVE COMMITTEE

March 6, 15.00 - 19.30 Hotel Baglioni

ISGE GENERAL ASSEMBLY

March 8, 17.30 - 18.00 Hall Verde

FISGE GENERAL ASSEMBLY

March 8, 18.10 - 18.30 Hall Verde

ISGE EDITORIAL BOARD

March 9, 08.15 - 09.30 Presidential Room

AIGE EXECUTIVE BOARD

March 9, 07.00 - 08.00 Hotel Baglioni

AIGE GENERAL ASSEMBLY (FOR ITALIAN MEMBERS)

March 9, 19.30 Hall Verde

CONGRESS

AREA MAP



Palazzo Affari



Palazzo dei Congressi

- CONGRESS HALLS
- EXHIBITION AREA

SERVICES

- PR Preview Room
- B Bar


DEDICATED ROOMS

- 5 Press room
- 6 Presidential room
- 101 Private meeting room
- 103 Private meeting room
- 104 Private meeting room
- 106 Private meeting room


Top Floor




2nd Floor




2nd Floor




1st Floor




1st Floor




Ground Floor



Ground Floor



Basement



SCIENTIFIC INFORMATION

CONGRESS ON-LINE

The 15th World Congress of Gynecological Endocrinology will be available in multimedia format through the web on the official website of the ISGE www.gynecologicalendocrinology.org.

It consists in the audio-video recorded presentations of the Congress enjoyable through the web. You can access the scientific sessions and view the sequence of the slides of the presentations while hearing the speaker's voice; it will be possible to stop, to go back, or see again what you consider more interesting at any time.

The following contents will be available:

- Plenary Lectures
- Plenary Sessions
- Sponsored Symposia

COMPUTER PROJECTION

Computer projection is provided in all conference rooms via direct link with the preview room. No projection through own computers is allowed. Kindly bring your presentation on a multimedia support (CD-Rom, Pen Drive) as a PowerPoint file. Please remember that the first slide of your presentation has to show your photo along with the name underneath. No other software is accepted. No Slide Projector is provided.

PREVIEW ROOMS

Speakers are kindly requested to hand over their Powerpoint presentation at the preview room near hall Auditorium (see page 14).

[Presentations must be brought at least one hour before their session.](#)

[Speakers presenting in the early morning sessions should ensure that they have handed over their slides during the previous afternoon.](#)

ORAL PRESENTATIONS

Oral Presentations will last about 8 minutes each plus 2 minutes discussion. The presenters are kindly requested to respect the time allotted for each presentation.

POSTER SESSION

POSTER SESSION

The Poster Session will take place on Friday March 9th from 17.30 to 19.30. During the Poster Session, Poster Authors are requested to stand by their Posters for presentation and discussion.

Posters must be set up on Friday from 13.00 to 16.00 and dismantled the same day from 19.30 to 20.00.

The maximum size of the posters must be 90cm x 90cm.

The organizers cannot be held responsible for posters not removed on time.



THE THREE BEST
POSTERS WILL BE
AWARDED

THE POSTER AWARD

Three posters will be awarded each with a free registration to the 16th ISGE World Congress (Firenze, March 5-8 2014) including a free accommodation for one person (overnight stay in a 3 stars hotel, double room). The awards will be given during the Closing Ceremony on Saturday March 10th.

THE WINNERS OF THE UNDER 34 COMPETITION

DID YOU MISS THIS EDITION OF THE UNDER 34
COMPETITION?

PARTICIPATE TO THE NEXT ONE.

MORE INFO AT PAGE 21 AND ON
WWW.GYNECOLOGICAENDOCRINOLOGY.ORG

THE UNDER 34 COMPETITION

The Scientific Contest held for the second time this year has allowed 100 excellent young scientist of under 34 years to be supported by the Society to join us in Florence, by providing free registration and accomodation. The contest has been extremely tight, and although the scientific committee could select only 100 winners, the scientific level was so high that ISGE decided to support anyway those who did not get through, by providing a reduced registration rate to the congress. This is the first of a series of moves to help the young and the brightest to contribute to ISGE and to its lively Congress.

THE FIRST 4 RANKED ABSTRACTS

The first 4 ranked abstracts will be presented in Plenary Sessions of the congress

Presentation and management of pof: findings from the west london pof database Kate Maclaran, Nick Panay

Plenary Session Adolescent gynecology and endocrinology
March 9, 16.00/17.30 Hall Affari 1 [DETAILS AT PAGE 46](#)

Anti-progestin effects of selective progesterone receptor modulators (SPRM) and sprm-like chemicals in human endometrium Lara Fischer, A. Hanjalic-Beck, S. Stanzel, W. R. Deppert, H.P. Zahradnik, W.R. Schaefer

Plenary Session - SSRM: new development, new therapeutic uses
March 10, 08.30 - 10.00 Hall Affari 1 [DETAILS AT PAGE 47](#)

Epigenetic influences regulating intratumoral estrogen production in postmenopausal breast cancer Kevin Knowler, Sarah To, Yasuhiro Miki, Kiyoshi Takagi, Hironobu Sasano, Evan Simpson, and Colin Clyne

Plenary Session Cancer stem cell: from basic science to clinical impact
March 10, 11.40 - 13.10 Hall Affari 1 [DETAILS AT PAGE 48](#)

Functional role of peroxisome proliferator-activated receptors gamma in glucidic metabolism in of granulosa cells from normal and polycystic ovary syndrome women Soledad Salinas, Pustovrh MCarolina, Godoy Ana, Argüello Begonia, Muñoz Alex, Kohen Paulina, Devoto Luigi

Plenary Session Insulin and reproductive endocrinology
March 10, 16.00 - 17.30 Hall Affari 0 [DETAILS AT PAGE 49](#)

THE OTHER WINNERS OF THE UNDER 34 COMPETITION The first author has won a free registration and accommodation

- Effects of hyperprolactinemia on the murine uterine prolactin gen and prolactin receptor expressions Vinicius Cestari, Amaral Vinicius Cestari do Amaral; Kátia Cândido Carvalho; Rodrigo Rodrigues Marcondes; Gustavo Arantes Rosa Maciel; Maria Candida Pinheiro Baracat; José Maria Soares Júnior; Edmund Chada Baracat.
- Endogenous testosterone associates with subclinical atherosclerosis in healthy recently menopausal women Eleni Armeni, Stamatelopoulos Kimon(2), Creatsa Maria(1), Rizos Demetrios(3), Georgiopoulos Georgios(2), Kazani Maria(2), Alexandrou Andreas(1), Kazani Aikaterini(1), Augoulea Areti(1), Karaflou Maria(1), Papamichael Christos(2), Lambrinoudaki Irene(1)
- Neuroendocrine regulations of the sensory and sympathetic nerve fibre imbalance in peritoneal endometriosis Julia Arnold, Barcena de Arellano ML, Büttner A, Vercellino GF, Chiantera V, Schneider A and Mechsner S
- Thyroid and parathyreoid dysfunction as a risk factor for osteoporosis in women Branka Arsenovic, Vuksanović M, Djurica S, Beljić-Živković T

- Bone turnover markers in postmenopausal women with deficient calcium intake Elena Atanasova Biljali S, Boshku A
- The effect of leuprolide therapy in Body Mass Index, ovarian and uterine volume in girls with central precocious puberty Nikolaos Athanasopoulos, E. Deligeoroglou, P.Tsimaris, E. Stergioti, K. D. Dimopoulos, V. Karountzos, G. K. Creatsas
- Chronic inflammatory factors, encoding gene polymorphisms, and their role as modulators of the clinical appearance in the polycystic ovary syndrome (PCOS) Nikolaos Athanasopoulos, Nikolaos Vrachnis, Zoi Iliodromiti, Pandelis Tsimaris, Vasilios Karountzos, Efthimios Deligeoroglou
- Whole Slide Characterization of Lymphatic Vasculature through Cervical Cancer Progression: Assessment of parameters with potential impact on tumoral dissemination Cédric Balsat, N. Signolle, S. Blacher, A. Beliard, C. Munaut, F. Goffin, A. Noel, J.M. Foidart, F. Kridelka
- The role of calcium-binding proteins in endometriosis-associated innervation Maria Luisa Barcena de Arellano, Münch S, Arnold J, Vercellino GF, Chiantera V, Mechsner S.
- Can progesterone metabolism at the pre-receptor level contribute to decreased progesterone action in endometriosis? Nataša Beranič, Tea Lanišnik Rižner
- Cyclin G2 plays a role in suppressing epithelial ovarian cancer metastasis. Stefanie Bernaudo, Dan Rosman, Zhaoqun Deng, Weining Yang, Burton Yang, and Chun Peng
- Does obesity influence disease characteristics and survival in endometrial cancer patients? Giorgio Bogani, Stefano Uccella; Antonella Cromi; Jvan Casarin; Maurizio Serati; Giorgio Formenti; Fabio Ghezzi; Pierfrancesco Bolis
- Is invasive ductal carcinoma relate to young aged women? Report on 104 operated patients in a single academic centre. Linda Bui, F.Pellini, E.Lavarini, G.P.Pollini
- Two different dosages of ethinyl-estradiol in association with drospirenone in normal weight women with polycystic ovary syndrome: comparison of clinical efficacy and metabolic impact. A long term randomized study Matteo Busacca, Romualdi D. Gagliano D. Di Florio C. Tagliaferri V. Immediata V. Lanzone A. Guido M.
- FSH secreting hypophysis tumor - a new therapeutic option Elaine Candido, Dácio Leonel de Quadros Netto, Oswaldo Grassioto, Heraldo Mendes Garmes, Cristina Laguna Benetti-Pinto
- Fetal anomalies diagnosed before the third trimester - does maternal gestational diabetes play a role? Yvonne Kwun Yue Cheng, Terence T Lao, Yuen-Ha Ting, Man-Kin Chung, Theresa KW Cheung, Tak-Yeung Leung
- Deep Endometriosis: Diagnostic Imaging Gustavo Corrêa de Almeida Teixeira, Bernardo Corrêa de Almeida Teixeira, Arildo Corrêa Teixeira
- A possible role of oxidative stress in bone resorption and postmenopausal osteoporosis Eleonora Cremonini, Cremonini G., Bonaccorsi G., Cervellati C., Castaldini C., Ferrazzini S., Capatti A., Christodoulou P., Bergamini C.M., Casali F, Fantini G.F, Patella A.,Massari L.
- The atherogenic lipid profile and blood pressure in patients with Turner syndrome. Adam Czyzyk, Podfigurna-Stopa Agnieszka, Meczekalski Blazej
- Effect of estrogen receptor β A1730G polymorphism on oxidized LDL/ β -glycoprotein I complexes response to postmenopausal HRT Maryam Darabi, Amin Mohsen Ani, Majid Asiabanha, Ahmad Movahedian, Elahe Zarean, Mojtaba Panjehpour, Mohammed Rabbani
- Is Anti-Müllerian Hormone an ultrasensitive marker of Polycystic Ovary Syndrome? Galina Davydova, G.A.Melnichenko, G.M.Savelyeva
- Longitudinal metabolic observation of metformin effects during pregnancy in women with Polycystic Ovary Syndrome Simona De Cicco, Romualdi D., Gagliano D., Busacca M., Di Florio C., Campagna G., Lanzone A., Guido M.
- Effects of high dose isoflavones in the uterus of ovariectomized rats Fernanda Deutsch Plotzky, Adriana Aparecida Ferraz Carbonel, Ricardo Santos Simões, Regiane Helena Barros Rabelo, Maria Cândida Pinheiro Baracat, José Maria Soares Junior, Edmund C. Baracat
- Effects of Basal Media and Supplements on Diethylstilbestrol-Treated Immature Mouse Primary Granulosa Cell Growth and Regulation of Steroidogenesis In Vitro Ting Ding, Luo A, Yang S, Lai Z, Wang Y, Shen W, Jiang J, Lu Y, Ma D, Wang S
- Isoflavone supplementation in postmenopausal women and its impact on quality of life Jelena Dotlic, Milan Terzic, Una Vasic, Jelena Micic, sanja Maricic, Tihomir Mihailovic, Milica Berisavac
- Potential Use of PAI-1 in Early Diagnostics of Gestational Diabetes. Karlina Elksne, Zane Pauniņa, Antra Jurka, Peteris Tretjakovs, Dace Rezeberga, Aivars Lejnieks



- Prognostic imaging and laboratory properties of cystic ovarian structures in the peri and postmenopause **Balazs Erdodi, Zoltan Toth, Attila Jakab Jr.**
- The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome **Angela Falbo, Stefano Palomba**
- Immuno-histochemical localization of endothelial nitric oxide synthase in testicular cells of men with non-obstructive azoospermia. **Khadijeh Foghi, Marefat Ghaffari Novin, Zahra Madjd Jabbari, Tohid Najafi, Mohammad Hasan Heidari**
- Immunohistochemical evaluation of caspase 3 and bax expression in uterine leiomyomas and myometrium **Natália Garcia, Borsari R, Cunha IW, Soares FA, Baracat EC, Carvalho KC.**
- The decrease of soluble HLA-G concentration in cord blood plasma after delivery correlates with the physiological induction of parturition **Valeria Genovese, Capitini Sachetto, Truglio, Viola, Repossi, Marchesi, Romano, Poma, Ierullo, Bergamaschi, Tinelli, Salvaneschi**
- Gene expression analysis of peripheral blood mononuclear cells in women with endometriosis identifies genes involved in other non-gynaecologic chronic inflammatory diseases **Davide Gentilini, Perino A, Viganò P, Chiodo I, Cucinella G, Vignali M, Di Blasio AM, Busacca M**
- Metformin versus Chromium picolinate in Clomiphene Citrate-Resistant Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial **Fariborz Ghaffarpasand, Sedigheh Amooei, Maryam Ravanbod, Mohammad Ebrahim Parsanejad**
- Study of gene expression of prolactin and prolactin receptor in the mice uterus with metoclopramide-induced hyperprolactinemia throughout the estrous cycle **Regina Gomes, Regina C. Teixeira Gomes, Carina Verna, Gabriela C. Cristofani Maioral, Roberta B. Wolff, Ricardo S. Simões, Edmund Chada Baracat, Helena B. Nader, José M. Soares Júnior**
- Lipid metabolism, insulin resistance, blood pressure and body composition with oral contraceptives containing estradiol valerate/dienogest vs ethinylestradiol/chlormadinone: a prospective, randomized trial **Giovanni Grandi, Palma Federica, Ferrari Serena, Xholli Anjeza, Cannoletta Marianna, Volpe Annibale, Cagnacci Angelo**
- The impact of ER β signaling in pelvic endometriosis **Erin Greaves Jennifer Trendell, Hilary OD Critchley, Erin Greaves, Jennifer Trendell, Hilary OD Critchley, Philippa TK Saunders**
- Anti-Müllerian hormone serum concentrations in ovulatory and anovulatory PCOS women. **Elena Grodnitskaya, Kurtser M. A.**
- Effects of inositol administration in semen parameters of patients undergoing to an IVF cycle **Ferdinando Antonio, Gulino Giuffrida E, Leonardi E, Lenzo L, Rubbino G, Fauzia M, Valenti O, Palumbo MA**
- Does vascular endothelial growth factor improve ovarian tissue recovery after cryopreservation? **Laurie Henry, Maïté Fransolet, Soraya Labied, Silvia Blacher, Carine Munaut, Alain Colige, Nathalie Kirschvink, Agnès Noël, Michelle Nisolle, Jean-Michel Foidart**
- Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis may lead to excessive hydroxy-estrogen and ROS formation **Neli Hevir, Ribič-Pucelj M. and Lanišnik Rižner T.**
- Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women. **Maria Lieta Interdonato D'Anna R, Benedetto V, Rizzo P, Raffone E, Licata G, Corrado F, Di Benedetto A.**
- Constitutive NF κ B signalling in the molecular pathogenesis of granulosa cell tumours of the ovary **Stacey Jamieson Peter J. Fuller**
- Clinical experience in diagnosis, management and treatment of adolescents with Primary Ovarian Insufficiency (POI) during the past 7 years **Vasileios Karountzos E. Deligeoroglou, P. Tsimaris, K. D. Dimopoulos, E. Stergioti, N. Athanasopoulos, A. Deliveliotou, G.K. Creatsas**
- Endometriosis in adolescence: Challenges in diagnosis and treatment **Vasileios Karountzos P. Tsimaris, K. D. Dimopoulos, E. Stergioti, N. Athanasopoulos, E. Deligeoroglou**
- Inflammatory cytokine and hormone levels in serum and peritoneal fluid of ovarian endometriosis patients **Vida Kocbek, Mueller M.D, Lanišnik Rižner T., Bersinger N.A**

- Fetal pituitary - adrenal stress responses Katarzyna Kosińska-Kaczynska, Iwona Szymusik, Dorota Bomba-Opon, Mirosław Wielgos
- Lipoxin A4 decreases lesion volume and reduces inflammatory and angiogenic mediators in a mouse model of endometriosis. Rajesh Kumar, Clerc AC, Gori I, Pellegrini C, Wyss JC, Golshayan D and Canny GO.
- Low expression of NF-κB and superoxide dismutase as a risk factor of postpartum endometritis Olga Lebedeva, N. Samborskaya, S. Pakhomov, V. Bashmakov, M. Churnosov, V. Popov, P. Kalutsky, R. Qirko
- Dyspareunia and quality of sex life in women with rectovaginal endometriosis during treatment with norethisterone acetate Umberto Leone, Roberti Maggiore Valentino Remorgida, Martina Di Luca, Pier Luigi Venturini, Simone Ferrero
- Letrozole combined with norethisterone acetate compared with oral contraceptive pill in the treatment of ovarian endometriomas Umberto Leone, Roberti Maggiore Valentino Remorgida, Laura Gabbi, Pier Luigi Venturini, Simone Ferrero
- Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression Li Li, Yibing Fu, Li Li, Xiaowen Liu, Chunyan Ma, Jie Zhang, Yulian Jiao, Li You, Zi-jiang Chen, Yueran Zhao
- Soluble receptors of VEGF and preeclampsia Sophie Lorquet, Pequeux C, Munaut C, Noël A, Foidart JM
- What is the best method for assessing insulin resistance in PCOS women: comparison of static and dynamic methods and SHBG Fabian Lunger, Ludwig Wildt, Beata Seeber,
- Distinguishing PCOS phenotypes to eliminate heterogeneity and unravel pathophysiology Sofia Makridima, Vangopoulos V., Basios G., Trakakis E., Kellaris V., Panagopoulos P., Chrelias C.
- RECK, angiogenesis related inhibitor of metalloproteinases, is upregulated in endometriosis - putative mechanism of its regulation. Radosław Maksym, M. Janiak, L. Milewski, W. Baranowski, P.I. Roszkowski, J. Malejczyk and P.K. Włodarski
- Comparison of various progestins in the preoperative treatment of endometriotic cysts Roxana Daniela Matasariu, Tirnovanu Mihaela Camelia, Gonta Olga, Holcov Monica, Dumitrascu Irina
- Thyroid function during Assisted Reproductive Technology (ART) procedures Gesthimani Mintziori, Dimitrios G. Goulis, Konstantinos Toulis, Christos Tsametsis, Christos A. Venetis, Efstratios M. Kolibianakis, Basil C. Tarlatzis
- Arterial stiffness is not modulated by the phase of the menstrual cycle but is inversely correlated with testosterone in healthy women of reproductive age. Agnieszka Mitkowska, Mitkowska A, Florczak M, Banaszewska B, Krauze T, Pawelczyk L, Guzik P, Spaczyński RZ
- Regulation of thyroid receptors mRNA and protein expression by hyperthyroidism in corpus luteum of rats in late pregnancy Paola Navas, Jahn GA; Hapon MB
- Levonorgestrel-releasing IUD for treatment of idiopathic menorrhagia. Eriseida Ndoni, Redi Hoxhallari, Erjola Piluri, Astrit Bimbashi
- Involvement of b-type natriuretic peptide in the heart hypertrophy in a female rat model of obesity induced by high-fat diet. Gleisy Kelly Neves Gonçalves, Najara de Oliveira Belo
- Comparison of reproductive outcomes using IVF-ET and ICSI in ART cycles in which only one or two oocytes are retrieved. Maria Elena Obino, Elena Carletti, Sara Pinelli, Francesca Papini, Elena Casarosa, Vito Cela, Paolo Giovanni Artini, Andrea Riccardo Genazzani
- Estrogen-dependent sympathetic nerve fibers remodeling seems to be disturbed in AM uteri Jeannette Oldeweme, de Arellano ML, Reichelt U, Mechsner S
- High insulin and testosterone disrupt glucose uptake in cultured endometrial stromal cells Paulina Ormazabal Carmen Romero, Margarita Vega.
- Immunotherapy for patients with recurrent pregnancy loss: myth of past or an option for the future Ginna Ortiz Olivera, Mendoza J.C
- Endometriosis-associated infertility: a decade's trend study of women from the Eastern Township region of Quebec, Canada Krystel Paris, Aris A
- A study on gene environmental interaction in adverse pregnancy outcomes Rahul Pathak MD Mustafa, Kiran Guleria, Rafat S. Ahmed and B.D. Banerjee



- Impact of Body Mass Index (BMI) on the efficacy of aromatase inhibitors in postmenopausal patients with breast cancer - a prospective study on serum hormone levels Georg Pfeiler Georg Pfeiler, Marie Maroske, Gabi Ban, Ruth Exner, Florian Fitzal, Anneliese Fink-Retter, Michael Seifert, Tadeusz Panhofer, Christian Singer, Michael Gnant, Peter Dubsy
- The role of inhibin B in patients with functional hypothalamic amenorrhea and anorexia nervosa Agnieszka Podfigurna-Stopa Podfigurna-Stopa A, Luisi S, Petraglia F, Meczekalski B
- Effects of Estradiol + Drospirenone on sexual function in postmenopausal women with type 2 diabetes mellitus Anna Pogorelova MD Tatyana U. Berketova, Prof. Galina A. Melnichenko, MD Anton K. Ragozin
- Prospective evaluation of bone mass in women with gonadal dysgenesis under hormone therapy - a 5-year analysis dácio quadros netto Elaine Cristina Candido; Mateus Ocanha Jorge; Cassia Raquel Teatin Juliato; Cristina Laguna Benetti-Pinto
- Estimation of instantaneous secretory rates and intrinsic characteristics of luteinizing hormone (LH) secretion in Kallmann syndrome before and after estradiol administration Federica Ricchieri Federica Ricchieri, Susanna Santagni, Alessia Prati, Annalisa Campedelli, Giovanna Bosco, Giulia Despini, Erica Rattighieri, Elisa Chierchia, Alessandro D Genazzani
- Longitudinal study of female sexual function after pelvic radiotherapy Ana Rodrigues Rubina Teixeira, Tânia Teixeira, Sofia Conde, Paula Soares, Isabel Torgal
- Effects of chlormadinone acetate (CMA) on prostaglandin biosynthesis in human endometrial explants Katrin Roth A. Stein, S. Gradowski, L. Fischer, W.R. Deppert, A. Hanjalic-Beck, W.R. Schäfer, H.P. Zahradnik
- Evaluation of vaginal trophism in peri-and postmenopausal women with and without hormone therapy Juan Manuel Sanchez, Pierino Russomanno, Lima, S; Dinardi, M; Caussade, A; Bozzolo, A
- Methylenetetrahydrofolate reductase gene polymorphism (C677T and A1298C) prevalence in nulliparous gestations complicated with preeclampsia Danny Salazar Peter Chedraui, Alejandro Villao, Gustavo S. Escobar, Cecibel Ramirez, Luis Hidalgo, Faustino R. Pérez-López, Andrea Genazzani, Tommaso Simoncini
- Effects of cyclic and daily estradiol treatment on food intake and bones of ovariectomized adult rats Aluana Santana Carlos Gaspar-Reis, RP; Santos, AS; Costa, CAS; Lisboa, PC; Nascimento-Saba, CCA.
- Tap73 is down regulated in oocytes from women of advanced reproductive age Manuela Santonocito MR Guglielmino, M Vento, M Ragusa, D Barbagallo, P Borzì, I Casciano, B Banelli, O Barbieri, S Astigiano, P Scollo, M Romani, M Purrello and C Di Pietro.
- Are teenagers well informed about sexuality? Angela Santos Neves Ana Claudia Rodrigues, Diana dos Santos, Gil Correia, Cláudia Vicente, Joana Silva, Regina Belo
- Elevated endogenous estradiol as an independent predictor of coronary heart disease and ischemic stroke in older postmenopausal women: The Three-City cohort study Valérie Scarabin, Marianne Canonico, Sylvie Brailly-Tabard, Séverine Trabado, Pierre Ducimetière, Maurice Giroud, Joanne Ryan, Catherine Helmer, Geneviève Plu-Bureau, Anne Guiochon-Mantel, Pierre-Yves Scarabin
- Inhibition of the expression of Syndecan-1 by the microRNA miR-10b leads to decreased invasiveness and proliferation of human endometriosis cells Cornelia Schneider Nadja Kässens, Prof. Dr. Ludwig Kiesel, PD Dr. Martin Götte
- The use of gonadotrophin releasing hormone (GNRH) analogue in endometrioid adenocarcinoma of the ovary: A case report and discussion Mohamad Nasir Shafiee Lim Ps, Shuhaila A, Nazimah I, Hashim O
- Risk Assessment of Thrombophilic States of Pregnancy Women Regarding the Results of Biochemical Markers of the First Trimester Svetlana Shyianova, Khazhylenko K.
- Frequency of gestational diabetes, diagnosed according to IADPSG criteria, in Caucasian women Signori C, Bonin C, Zambotti F, Dall'Alda M, Donati M, Moretta R, Di Sarra D, Bettinazzi F, Moghetti P.
- Metabolism of progesterone in endometrial cancer Maša Sinreih Beranič N., Hevir N., Šinkovec J., Šmuc T., Lanišnik Rižner T.

- Investigation of estrogen sulfotransferase (SULT1E1) expression in different human endometrial in vitro models
Melissa Straßer L. Fischer, W.R. Deppert, A. Hanjalic-Beck, W.R. Schaefer
- Biomarkers of angiogenesis and inflammatory response in peritoneal fluid of women with endometriosis. Maria Szubert Jacek Suzin, Katarzyna Kowalczyk_amico, Markus Duechler, Agata Szulawska, Małgorzata Czyż
- Randomized controlled study comparing the effectiveness of dydrogesterone and micronized progesterone in improving the sub-endometrial blood flow in idiopathic recurrent spontaneous miscarriage Shyam Thangaraju Shyam Thangaraju, Sanghamitra Ghosh, Baidyanath Chakravarty, Koel Chaudhury.
- Does leptin level influence on bone mineral density in obese children? Mariya Vishnevskaya Solntsava Anjalika
- Anti-Müllerian Hormone level in infertile women with thyroid autoimmunity: our experience Vitalina Vustenko Kvashenko V.P., Akimova I.K.
- The impact of oral contraceptives, metformin and life-style modification on the Metabolism Disorderd Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial Qiuyi Wang
- Effects of antisense oligodeoxynucleotides (AsODNs) on embryo quality and pregnancy rate in PCOS and endometriosis IVF treatment cycles. Elena Zakharova Zaletova Victoria
- Effect of estrogen therapy on cardiac autonomic neuropathy in diabetic postmenopausal women Tatiana Zelenina Natalia Vorokhobina, Natalia Belevantseva
- Follicular synchronization using transdermal estradiol patch and GnRH antagonists in the luteal phase; does it increase oocyte yield in poor responders to gonadotropin stimulation for in vitro fertilization (IVF)? A comparative study with microdose flare-up protocol Xing Zeng Baris Ata Weon Y. Son Hananel Holzer Seang L. Tan



16

WORLD CONGRESS OF GYNECOLOGICAL ENDOCRINOLOGY ♀ IV CONGRESSO ISGE ITALIA

MARCH 5-8 2014
FIRENZE ITALY

UNDER 34 COMPETITION

The International Society of Gynecological Endocrinology has decided to offer for free 100 registrations with accommodation.

How to participate in this competition?

Participants must be under the age of 34 by March 7th 2012 and can submit a maximum of 2 abstracts as first author on any of the Congress' topics by **September 29th, 2013**.

-

The Scientific Committee will evaluate the abstracts and select the 100 better works.

The first authors of the 100 selected works will receive a voucher for free registration and accommodation in a 3 stars hotel (twin accommodation).

The first 4 best ranked authors will have the opportunity to present their abstract during a Plenary Session as a Main Speaker.

The first authors of all the other accepted abstracts (not ranked in the first 100) will pay the registration to the Congress only €200

SPONSORS AND EXHIBITORS

LIST OF EXHIBITORS

- 2** Besins
- 4** Laborest
- 5** Aesculapius
- 8** Bionorica
- 10** Menarini
- 11** Italfarmaco
- 12** Gideon Richter
- 13** Pfizer
- 14** Abbot
- 15** Manetti & Roberts
- 16** Lo.li Pharma
- 17** Progine
- 18** Alfa Wassermann
- 26** MSD
- 27** Bayer
- 28** Ibsa
- 29** Theramex Teva
- L2** Galbert

BOOKSELLERS



- 22** Wisepress
- L** Cic
- L** Informa
- L** Minerva
- L** Ediermes
- L1** Wicghti Editore

SCIENTIFIC SOCIETIES

- 6** ISGE

PALAZZO AFFARI

- 1** Named
- 2** AG Pharma
- 3** Menarini
- 4** HRA Pharma



Auditorium (Palazzo dei Congressi)

Wednesday March 7 th	from 14.30 to 21.00
Thursday March 8 th	from 8.00 to 18.00
Friday March 9 th	from 8.00 to 20.00
Saturday March 10 th	from 8.00 to 13.30

Palazzo Affari

Thursday March 8 th	from 8.00 to 18.15
Friday March 9 th	from 8.00 to 18.15
Saturday March 10 th	from 8.00 to 19.00

COMPANY PROFILES

ALFA WASSERMANN SPA

18

I - 65020 Alanno (PE) - Via E. Fermi, 1
info@alfawassermann.it

www.alfawassermann.it

Founded in 1948, Alfa Wassermann S.p.A. holds a prominent position in the Italian pharmaceutical market. Its activities include research, production and commercialisation of prescription drugs and self-medication products. The head office and research laboratories are located in the company's historical headquarters in Bologna, while the modern production plant located in Alanno (Pescara) also carries out contract manufacturing. The International Division is headquartered in Milan.

The company, which employs over 670 people in Italy and over 1,200 worldwide, ended 2008 with a turnover of 273 million Euro and a 10.6% growth.

The fact that over 60% of the company's turnover is generated by its own products constitutes one of the strengths of Alfa Wassermann S.p.A. These products are the result of internal research and include several leading drugs in their relative market segments.

ABBOTT

14

Hegenheimermattweg 127
4123 Allschwil Switzerland

T. +41 (0) 61 487 0 684

F. +41 (0) 61 487 0 496

www.abbott.com

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including

nutritional, devices and diagnostics. The company employs nearly 90,000 people and markets its products in more than 130 countries. Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

AG PHARMA

2

Via Casale della Marcigliana 29
00138 Roma

T. + 39 06 8856131

F. +39 06 8889334

info@agpharma.it

AG Pharma is a company specialized in the care of patients suffering from metabolic, urogynecological and gastrointestinal disorders. It offers a range of products which act on the intestinal and vaginal microbiota while solving effectively pathologies related without causing unexpected side effects. To better complete the gynaecological range of products AG Pharma, proposes an high technological and scientific worthiness solution for disorders connected to menopause. All the products are clinically tested and are supported by a wide international literature which demonstrates their efficacy and safety. Quality control is the basis for constant research of excellence.

BAYER PHARMA AG

27

Muellerstr. 178 13342 Berlin
Germany

Bayer HealthCare Pharmaceuticals is the pharmaceutical division of Bayer HealthCare AG. We market our products in more than 100 countries, and in 2010 generated sales of almost €11 billion.

More than 38,000 members of staff currently work for Bayer HealthCare Pharmaceuticals worldwide – more than 6,200 in research and development alone. We aim to improve people's quality of life with our products. To achieve this, we concentrate on the research and development of innovative drugs

and novel therapeutic approaches. At the same time, we are constantly improving established products. In this context, Bayer HealthCare Pharmaceuticals uses experience it has gained from over a century in the business. We concentrate on four business areas in which we make essential contributions to medical progress.

General Medicine

Specialty Medicine

Women's Healthcare

Diagnostic Imaging

Specialist in women's health

With our products, we promote the health of women at different stages of life, and help them to shape their lives according to their own wishes. With this philosophy, we are consolidating our leading market position in the field of Women's Healthcare, and this applies to all three areas in which we concentrate our activities: hormonal contraception, menopause management and gynecological therapy.

Symposia

March 8 - 11.40 Auditorium

A New Evidence-based Treatment Approach for Endometriosis

March 8 - 16.00 Affari 1

Oral Contraception and beyond

March 9 - 11.40 Affari 1

New evidence supporting treatment choices for menopause management

March 9 - 16.00 Affari 0

Soluciones Innovadoras en Salud Femenina

March 10 - 10.10 Verde

Benefits and Risks of Hormonal Contraceptives

March 10 - 13.10 Affari 1

Additional benefits in hormonal contraception: new evidence with E2V/DNG

BESINS HEALTHCARE SA

2

Besins Healthcare Operations
Coordination Center Co., Ltd.
283/92 Homeplace Building, 18th
Floor, Soi Sukhumvit 55 (Thonglor),
Sukhumvit Road, Klongton Nua,
Wattana, Bangkok 10110, Thailand
Besins Healthcare is a
pharmaceutical company specialized
in the development and worldwide
diffusion of innovative drugs and
food supplements for the well-being
of men and women. The company
has established a strong reputation
in gynaecology over the last 30
years and is a renowned actor in
hormonal therapies. Our products
are distributed in more than 90
countries via our own subsidiaries or
a network of business partners. We
plan to pursue our expansion in new
territories to bring to the company
significant growth over the coming
years. Visit our site to understand why
Innovating for well-being is our claim
(www.besins-healthcare.com)

Symposia

March 8 - 13.10 Affari O

HRT - new benefits, new approaches,
old concerns

BIONORICA SE

8

Kerschensteinerstr. 11-15 92318
Neumarkt, Germany www.bionorica.de
Bionorica SE is one of the leading
companies in the area of plant-based
medicines (phytopharmaceuticals)
and is marketing products with
proven efficacy, safety and quality in
50 countries worldwide. Bionorica's
know-how in phytotherapy has grown
in nearly 80 years and the company's
development of rational herbal
medicinal drugs can be compared
to the standards of chemically
synthesised drugs. - In terms of their
pharmaceutical efficacy and safety
today modern researched phyto-
medicines have to follow allopathic
principles and have to find their
place in evidence-based medicine.
One main focus of the company's

work is the research, development
and marketing of plant-based
medicines for the treatment and
prevention of premenstrual and
menopausal symptoms.
Bionorica's products are prescribed
and recommended by physicians and
are sold exclusively in pharmacies.

Symposia

March 9 - 16.00 Onice

Phytomedicine in Gynecological
Endocrinology: New Perspectives

CIC EDIZIONI INTERNAZIONALI

L

Corso Trieste 42, 00198 Roma, Italy
t.+39068412673 f.+39068412688
info@gruppocic.it - www.gruppocic.it

Cic edizioni internazionali is a
publishing house with more than
40 years of experience and over
10 years of publishing periodicals
and volumes specializing in
various medical fields. Cic edizioni
internazionali is particularly present
in the obstetric-gynecology sector.

EDIZIONI MEDICO SCIENTIFICHE EDI.ERMES

L

Via Luigi Vittorio Bertarelli 123
00159 Roma Tel. 06 43597938
agenzia@libreriaeuropa.it
www.ediermes.it

Edi.Ermes è una casa editrice
di Milano, nata oltre trent'anni
fa, specializzata in pubblicazioni
medico-scientifiche a vari livelli, dai
testi per studenti universitari a quelli
per professionisti.

Edi.Ermes si colloca, con la sua
produzione, tra le principali case
editrici italiane del settore medico/
scientifico.

ESTETRA SA

Rue du Travail 16 Zoning Bonne
Fortune, 4460 Grace-Hollogne
Belgium

Symposia

March 8 - 16.00 Verde

Estetrol in contraception

FERRING PHARMACEUTICALS

Via Senigallia 18/2 - 20161

Milano, Italy

t. +39 02 64000143

F. +39 02 64000155

Ferring Pharmaceuticals is a
research-driven biopharmaceutical
company devoted to identifying,
developing and marketing innovative
products in the fields of reproductive
health, urology, gastroenterology,
endocrinology and osteoarthritis.
Ferring's marketing, medical
services and sales teams, led by
corporate headquarters in Saint-
Prex, Switzerland, operate from
more than 50 countries and employ
more than 4000 people throughout
the world, while treatments are
available in more than 70 countries.
This expansion has allowed Ferring
to maintain a double digit annual
growth rate over the last two
decades.

Ferring is committed to a future
where it will continue to provide
new and innovative medicines by
utilising existing and acquired skills
and the development of pioneering
technologies and, where necessary,
through partnerships with academic
institutes and other companies.

Symposia

March 10 - 11.40 Auditorium

Perinatal Medicine: a help for new
coming life

FINDERM FARMACEUTICI SRL

Viale A. De Gasperi 165/b - 95127
Catania

Finderm farmaceutici srl, based in
Catania, was established in 1995
pursuant the brilliant intuition of its
founder, Fabio Scaccia, who leads
it to become one of the leading
companies in the gynecological
field in a very short time. Nowadays,
it ranks among the first Italian
companies with its portfolio of
more than twenty products - drugs,
medical devices, cosmetics and food
supplements. Finderm Farmaceutici

srl takes care of the woman during all her life, from the adolescence to the menopause, without neglecting any of her daily problems and closely during pregnancy.

GEDEON RICHTER

12

Gedeon Richter Italia srl
Viale Cassala 16 20143 Milano
Tel. 039 02 4953 9953

Gedeon Richter, Hungarian pharmaceutical company, ever since its foundation, in 1901, has grown up to becoming a big company in 100 different countries around the world; it is present in Italy since April 2011. Gedeon Richter produces more than 100 conventional medications in over 170 different pharmaceutical formulations.

The aim of the company is to be a reliable partner for gynecologists and women offering a wide range of high quality therapeutic formulations and a complete line of gynecological products. The pipeline includes Esmya, which had the approval of CHMP on December 15th 2011, for the treatment of pre-surgical uterine fibroids.

In Italy, Gedeon Richter is marketing the oral contraceptive Belara and a food supplement for cystitis, Myrtimax. The company aims at expanding its gynecological portfolio in the hormonal contraception as well as in the treatment of gynecological benign pathologies. Discovering original drug molecule and continuous innovation are the company's strategy since its foundation.

The ability of Gedeon Richter, recognized worldwide, in steroid chemistry, its skill in developing new innovative active substances, the efficient production and its productive sites able to meet strict quality assurance requirements, are a winning combination that guarantees a solid base for future development.

HRA PHARMA

4

Via Benedetto Croce, 97 00142 Roma
HRA Pharma is an emerging European pharmaceutical company that designs products, devices and supporting services in niche areas of health and makes them available to doctors and patients worldwide.

A pioneer in emergency contraception since the launch of its first product in 1999, NorLevo®, HRA Pharma has engineered a robust portfolio and pipeline in the fields of reproductive health and endocrinology which it maximizes through in-licensing and out-licensing agreements.

The company targets and tackles therapeutic gaps and uses innovative marketing solutions and socially-conscious programs to promote healthy management of drug and diseases worldwide.

Headquartered in Paris, France with local teams based at subsidiaries in Germany (Bochum), the United Kingdom (London), Italy (Roma), Spain (Madrid) and the United States (New York City), HRA Pharma is privately-owned.

The company has forged a strong network of R&D, manufacturing, distribution and NGO partners which enables it to satisfy critical patient needs and improve patient health in over 50 countries across the globe. HRA Pharma makes the difference by combining its health mission with a socially conscious approach to ensuring that its products are accessible everywhere.

Symposia

March 8 - 15.10 Affari 2

Ulipristal nella contraccezione d'emergenza: è tempo di cambiare!

IBSA INSTITUT BIOCHIMIQUE SA **28**

IBSA Institut Biochimique SA
Via del Piano, P.O. Box 266,
6915 Pambio-Noranco, Lugano,
Switzerland

Tel: +41 58 360 10 00

Fax: +41 58 360 16 47

info@ibsa.ch

www.ibsa-international.com

IBSA is an international pharmaceutical company headquartered in Lugano, Switzerland, delivering different therapeutic solutions for follicular stimulation and luteal support. IBSA developed an entirely new purification process to obtain a full range of highly purified, human gonadotrophins: hFSH, hMG and hCG.

This unique patented process was conceived to ensure at the same time both high purity and the respect of the structure-correlate activities of the gonadotrophins (natural glycosylation).

IBSA's whole in-house manufacturing ensures the same global quality system in company owned plants, from the first steps of raw materials to the final lyophilized products. Other company's franchises include osteoarthritis, pain-management, dermatology and thyroid diseases.

Symposia

March 9 - 13.10 Affari 1

Human derived FSH: new evidences for old understandings

INFORMA HEALTHCARE

L

119 Farringdon Road, London, EC1R
3DA informahealthcare.com

Informa Healthcare is a specialist publisher with a portfolio of high quality, peer-reviewed journals, and books delivering research and analysis to better serve the academic and commercial needs within the scientific and clinical communities. Our mission as a healthcare publisher is to connect scientists, researchers,

librarians and clinicians with information they can trust and use. We have a strong list of journals and books within obstetrics & gynecology, and reproductive medicine and publish the monthly journal Gynecological Endocrinology, the official journal of the International Society of Gynecological Endocrinology. Find out more about Informa Healthcare at informahealthcare.com

ITALFARMACO

Viale Fulvio Testi 330 20126 Milano

Italfarmaco, one of the leading Italian pharmaceutical groups, operates in both the pharmaceutical and the fine chemical industries. The company was founded in Milan in 1938.

The Italfarmaco Group now markets ethical products in Italy, Switzerland, Spain, Portugal, Greece, Russia, Turkey, Chile, Peru, Morocco and also for the subsidiary Chemi SPA in USA and Brazil. Total employees is over 2100 and total turnover exceeds 500 million euros.

Its products, all of which have a high therapeutic content, are mainly used in the gynaecological, cardiovascular, immuno-oncological, dermatological, orthopaedic and neurological areas. The group owns modern, sophisticated industrial plants at which it manufactures its proprietary drugs to the highest quality standards.

The first plant, at which injectables and solid oral drugs are manufactured, is situated in Milan, and a second manufacturing unit, for the production of liquid oral drugs, is located in Madrid.

Product portfoglio expansion of the entire group and consolidation in international markets represents priority objectives.

Product portfoglio expansion is pursued through:

- increased investments in R&D in order to develop innovative

products in already established therapeutic areas;

- commercial partnerships with pharmaceutical companies in the field of therapeutic areas with an established presence.

Symposia

March 8 - 13.10 Affari 1

Local estriol gel in urogenital atrophy

March 9 - 09.40 Verde

Inositol: Clinical Experiences

LABOREST

info@laborest.com

www.laborest.com

LABOREST was born in Switzerland - San Vittore - canton of Grisons in 1991, as extraction of RESTIVA group. LABOREST target was search for natural raw materials useful for human health. In the 1995 the swiss laboratory addressed the interest to the alpha lipoic acid, known, at that time also as thioctic acid, from this etymology born TIOBEC, thioctic acid with B, E and C vitamin groups. The primary objective of LABOREST ITALIA S.p.A. is to be a reference company, as previously done to the medical specialists, including pharmacy and parapharmacy. At the same time, LABOREST, decided to dedicate his research on four specific therapeutic areas:

Orthopedics and Physical Medicine, Neurology, Angiology, Gynecology, Pediatrics, Dermatology

LABOREST has two divisions of medical information with more than 150 medical sales able to cover the entire country

EDIZIONI MINERVA MEDICA

Corso Bramante 83 10126 Torino

Tel +39 011 678282 Fax +39 011 674502

minervamedica@minervamedica.it

www.minervamedica.it

Edizioni Minerva Medica publishes specialist journals and books distributed worldwide since 1909.

Our mission is to gather, process,

and deliver content that's essential and informative. We accomplish this goal through print, CD-ROM, and internet publications. The journal Minerva Ginecologica is a publication on obstetrics and gynecology and is essential reading for 5,000 clinicians in the field of gynecology. The journal is indexed by Index Medicus/ PubMed.

MANETTI&ROBERTS

Via Baldanzese 177 50041

Calenzano Firenze

In 1921 Lorenzo Manetti and Henry Roberts founded Manetti & Roberts by merging their respective pharmaceutical laboratories based in Florence. Thanks to its advanced knowledge base, Manetti & Roberts develops products leader in their market. Thus in the Italian mass market, M&R is first in the deodorant segment and is leader in the personal hygiene category with brands such as Neutro Roberts, Borotalco and Chilly. In pharmacy, Manetti & Roberts is leader on the European market of slimming products, with brands like Somatoline and Somatoline Cosmetics. Somatoline is an OTC medicine, specific to cellulite treatment, Somatoline Cosmetics is a range of slimming products whose efficacy and safety is demonstrated by many scientific clinical tests carried out vs. placebo in independent institutes.

MENARINI OTC

Via Sette Santi 3 50131 Firenze

Menarini is the first Italian pharmaceutical group in the world and ranks 15th in Europe and 34th world-wide.

Menarini's territorial presence covers more than 100 countries in Europe, Asia, Africa and Australia and, in the year 2010, its consolidated worldwide turnover exceeded 3 million Euro with a headcount of more than 13,000. The Menarini Group currently markets

products for the most important therapeutic fields: cardiovascular, gastroenterology, oncology, metabolism, antibiotics and respiratory drugs, products for the treatment of diabetes, anti-inflammatories and analgesics and operates through several 'divisions' such as Research, Prescription Drugs, OTC, Diagnostics, Manufacturing and Field Force.

Menarini's Headquarters are located in Florence.

For further information please consult our website at www.menarini.it.

Symposia

March 10 - 09.45 Affari 2

Nutraceutica: risposte per la salute delle donne

MERCK SERONO

Via Casilina, 125 - 00176 Roma

Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. In the United States and Canada, EMD Serono operates as a separately incorporated affiliate of Merck Serono.

Merck Serono has leading brands serving patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders, as well as cardiometabolic diseases. Not all products are available in all markets. With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and endocrinology, as well as new areas potentially arising out of research and development in rheumatology.

Symposia

March 9 - 16.00 Auditorium

How To Improve Take Home Baby Rate

NAMED SRL

Via Lega Lombarda 33 - 20050

Lesmo (Mi)

Tel. +39698501 Fax. +396985030

info@named.it - www.named.it

Named, acronym of Natural Medicine, was established in 1988 and, over the years, has become an important reference in the field of natural medicine, which is registering a considerable growth in Italy and an increasing number of people approaching in latest years.

Named imports and distributes products of Companies in the vanguard such as Pascoe, Ferrosan, Melbrosin, Pekana, Meripharm, New Era, Fortest Herbs and, besides, holds the sole right on Immun'age from Osato, a food supplement obtained from FPP (Fermented Papaya Preparation) that is Carica Papaya. The commercial activity of Named has been joined, over the years, by a training activity for doctors and pharmacists carried out by some associations which cooperate in synergy with Named and whose work has become more and more widespread.

NOVO NORDISK FEMCARE AG

Andreasstrasse 15 CH-8050 Zurich

Switzerland www.novonordisk.com

Novo Nordisk is a global healthcare company with 88 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 32,500 employees in 74 countries, and markets its products in 179 countries. To find out more about our therapy options for vaginal atrophy and long term vaginal health, please visit our website on www.novonordisk.com.

Symposia

March 9 - 15.10 Auditorium

Vaginal health: a woman's right!

1

ROTTAPHARM | MADAUS

**Via Valosa di Sopra, 9 20052 Monza
Monza e Brianza**

Established in 1961,

Rottapharm | Madaus is a pharmaceutical group headquartered in Monza with branches in more than 85 countries worldwide.

In 2007, with the acquisition of the German pharmaceutical company Madaus Pharma, Rottapharm's expertise in the genito-urinary area has been strongly improved: important synergies have been identified in this area, where the group is benefiting not only the ongoing clinical research activities but also the presence on the market of Madaus leading products. Rottapharm | Madaus R&D activities are currently focused on gynecology (with prescription drugs for HRT), urology (with URIVESC), personal care (with Saugella, leading brand for intimate hygiene) and nutraceutical segment (Estromineral line for the treatment of menopausal symptoms).

SOFAR

**Via Firenze 40 20060 Trezzano Rosa
Milano**

Sofar is an Italian private, family owned pharmaceutical company founded in 1968. The current paid-up capital stock amounts to € 1.3 million.

The operational headquarters, located in Trezzano Rosa, about 20 km from Milan, are comprised of four buildings covering a total of 18000 square meters, housing offices, production, Q.C. laboratory and warehouse. The premises occupy an area of 35000 square meters facing the Milan-Venice highway, 15 minutes from Milan city, 20 minutes from Milano Linate Airport and 15 minutes from Bergamo-Orio al Serio Airport. The company employs approximately 350 people, among which are included managers, office employees, technicians, workers, and external

sales force, 120 of which are medical reps coordinated by 10 Area Managers, visiting about 1200 physicians every day.

Sofar manufactures its own medicinal specialties, nutraceuticals and medical devices in various forms: tablets, coated tablets, chewable tablets, lozenges, pills, powders, granules, capsules, liquids, syrups, suspensions, emulsions, creams, gels, ointments, lotions, pastes, suppositories, aerosols, enemas, micro-enemas, rectal foams in pressurized cans, vaginal douches. Sofar manufactures under GMP regulations and is subjected to routine inspection by the Italian Ministry of Health every two years.

Among Sofar's clients as contract manufacturer are important Italian and foreign companies, including prestigious multinationals.

Sofar exports mainly to Germany, U.K., The Netherlands, Switzerland, Spain, Belgium, Russia and Romania. The manufacture of Sofar's medicinal specialties is characterized mainly by three therapeutic lines: gastroenterology, gynaecology and dermatology. Sofar is also the European market leader in the production of a line of enemas and microenemas as laxatives and for scheduled bowel clearance in pre- and post-operative surgery, in obstetrics, and prior to endoscopy or X-ray. Sofar has broadened its commercial activity to include, in addition to the manufacture of pharmaceutical products, a qualified line of food supplements, probiotics and diagnostics. The diagnostics division is a leader in the Italian market for 13C Breath test and H2 Breath test analysis for various applications, for example: diagnosis of *Helicobacter pylori* gastric infection; monitoring and control of gastric emptying rate; monitoring and control of liver function; diagnosis of lactose malabsorption. The diagnostic line

also includes instruments for breath testing. Other important products completing the diagnostic line are rapid tests for the determination of calprotectin in the faeces and for Colon Cancer Hb/Hp detection. Sofar also has a surgical robotics division within which, in conjunction with the European Commission, Joint Research Centre of Ispra, it has developed ALF-X, an innovative tele-robotic system for laparoscopic surgery, fruit of over nine years of research. The ALF-X system is currently pending CE certification, and its marketing is expected to take place in the second half of 2011. This achievement may be considered to be the most innovative technological event in the world in the field of tele-robotic surgery.

TEVA/THERAMEX MC
6, avenue Albert II BP 59
98007 Monaco

vadancourt@theramex.mc

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's largest generic drug maker, with a global product portfolio of more than 1,300 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on neurological, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 42,000 people around the world and reached \$16.1 billion in net sales in 2010.

About Teva Women's Health in Europe
Teva's Women's Health business in Europe was established following the acquisition of Théramex in

January 2010. Teva/Theramex offers a large portfolio of products in the areas of gynaecology, osteoporosis, peri-menopause, menopause and contraceptives, and includes trusted brand names such as Orocal®, Colpotrophine®, Lutenyl®, Monazol®, Estreva®, Antadys®, Leeloo® Ge and ZOELY® the first monophasic pill containing natural estrogen.

Symposia

March 7 - 15.00 Auditorium

Progesterone: the pregnancy hormone

March 8 - 09.40 Auditorium

COCs: What is new in 2012?

March 9 - 09.45 Affari 2

Evoluzione degli Estroprogestinici:
dalla farmacologia alla scelta
ragionata

WICGHTI EDITORE

via Friuli 72 - 20135 Milano

tel. 02.55195443 fax 02.55195971

www.wichtig-publisher.com

WISEPRESS.COM

t. +44 20 8715 1812

www.wisepress.com

bookshop@wisepress.com

Wisepress.com, Europe's leading conference bookseller, has a complete range of books and journals relevant to the themes of the meeting. Books can be purchased at the stand or, if you would rather not carry them, posted to you.



—15—

WORLD CONGRESS
OF GYNECOLOGICAL
ENDOCRINOLOGY Q*

III CONGRESSO ISGE ITALIA

MARCH 7-10 2012 FIRENZE, ITALY

SCIENTIFIC PROGRAMME

Continuous Medical Education	31
Plenary Lectures	33
The four best abstracts of the Under 34 Competition....	45
Sponsored Symposia and Lectures	50
Symposia by Scientific Societies	51
Debates and Meet the expert sessions.....	51
Wednesday March 7th.....	52
Thursday March 8th	54
Friday March 9th	66
Saturday March 10th	78
List of Posters	89





INTERNATIONAL SCHOOL
OF GYNECOLOGICAL
AND REPRODUCTIVE
ENDOCRINOLOGY

THE EDUCATIONAL BRANCH OF ISGE

WINTER SCHOOL

MADONNA DI CAMPIGLIO
JAN 27 • FEB 3 2013

FRONTIERS IN GYNECOLOGICAL ENDOCRINOLOGY: THE CLINICAL IMPACT

FRONTIERS IN GYNECOLOGICAL ENDOCRINOLOGY: THE CLINICAL IMPACT

The programme will cover the following areas:

- Adolescence and its disorders
- Endocrine control of follicular development and ovulation
- Fertility control
- Reconstructive surgery in Müllerian defects
- Ovarian surgery impact on endocrine and reproductive functions
- Ovulatory dysfunctions from Hypothalamic Amenorrhea to Polycystic Ovary
- Luteal phase defects
- Premature ovarian failure
- Pre-menopause
- Menopause: impact on the different systems and need of personalization
- Elderly gynecology
- Endocrine aspects of female infertility
- Medically assisted procreation: a challenge for endocrine therapies
- Female sexuality
- The breast

All topics will be divided in different lessons for a total of 25 presentations. In addition, each day will be concluded by a special lesson on Therapies updating in Gynecological Endocrinology, devoted each one to a specific area. Details concerning the Structure of the Course, the exact titles of lessons and the name of the faculty members will be available soon.

www.gynecologicalendocrinology.org

CONTINUOUS MEDICAL EDUCATION



16 CREDITS

UEMS CREDITS (EUROPE)

The European Accreditation Council for CME is an official body of the European Association of Medical Specialists (UEMS) being established by the UEMS Management Council meeting in October 1999.

The UEMS (European Union of Medical Specialists) has assigned to the 15th World Congress of the Gynecological Endocrinology n.16 Continuous Medical Education European (CME) credits. These credits are valid for all European Community Countries and are recognized by the American Medical Association toward the Physician's Recognition Award (AMA) for Canada and North American Countries.

AMA CONVERSION

Physicians may apply to convert European credit into AMA credit by completing and returning the EACCME application, along with the appropriate application processing fee and documentation of the meeting Physicians have attended. Please check the UEMS website (www.uems.net) to ensure the activity attended is listed and marked as "Approved" before submitting the application. The credits are one-to-one



ECM CREDITS (ITALIAN DELEGATES)

The following courses are certified with ECM credits:

- **Endometriosi: i problemi complessi, i casi difficili (1 credit)**
Physicians specialized in Gynecology and Obstetrics, Endocrinology and General Medicine.
- **Nutraceutica: risposte per la salute della donna (1,5 credits)**
Physicians specialized in Gynecology and Obstetrics, Endocrinology and General Medicine.
- **Evoluzione degli estroprogestinici: dalla farmacologia alla scelta Ragionata (1,5 credits)**
Physicians specialized in Gynecology and Obstetrics, Endocrinology and General Medicine.

In order to obtain credits from the Continuous Medical Education Programme the following steps are mandatory

- Attend the full ECM sessions
 - Fill in the ECM Questionnaire that you will receive at the beginning of the course
 - Fill in the Customer Satisfaction Form
-
- Kindly remember that the Questionnaire together with the Customer Satisfaction Form will have to be handed back to the ECM Desk before the end of the Congress.
 - The Questionnaire has validity only when accompanied by the completed Customer Satisfaction Form.
 - The ECM certificate will be sent to the participants, via post or email, after evaluation of the answers.



— 16 —
WORLD CONGRESS
OF gynecological
endocrinology ♀
IV CONGRESSO ISGE ITALIA



MARCH 5-8 2014 — FIRENZE ITALY
WWW.GYNECOLOGICALENDOCRINOLOGY.ORG

PLENARY
LECTURES





LUNENFELD BRUNO (IL)
MD, PHD, FRCOG, FACOG (HONS), POGS (HONS)
Management of infertility: past, present and future

March 07, 18.10 - 19.00
Hall Auditorium

Management of infertility: past, present and future

Lunenfeld Bruno (IL)

Gonadotropin therapy is so central to infertility treatment that it is easy to overlook the considerable discovery and research that preceded production of the effective and safe products available today. The history underpinning this development spans over 500 years and provides a splendid example of how basic animal experimentation and technological advances have progressed to clinical application. The gonadotropins were discovered in 1927. Gonadotrophins, such as pregnant mare serum gonadotropin (PMSG), were first introduced for ovarian stimulation in 1930. However, use of PMSG led to antibody formation, and had to be withdrawn. Following the withdrawal of PMSG, human pituitary gonadotrophins (HPG) and urinary menopausal gonadotrophins hMG) appeared on the market and nearly 50 years ago the first child was delivered by our group in 1961 and opened the path to controlled ovarian stimulation. HPG had to be withdrawn in 1980 when it was linked to the development of Jacob-Creutzfeld disease. The availability of hMG, Clomiphene citrate, Ergot derivatives GnRH agonists and antagonists, as well as metformin, contributed to the conquest of hormone dependent infertility in both men and women. However for mechanical causes of childlessness only surgical and microsurgical procedures were available. Following Leopold Schenk's observation in 1887 that cell division occurred in cultures after sperm were added to ova the first human IVF baby was born in 1978, and IVF procedures became standard practice. The main agents for controlled ovarian stimulation for IVF were Gonadotropins and GnRH analogues. The introduction of recombinant gonadotrophins with more than 99% purity, gradually replaced hMG preparations world wide. With batch to batch consistent Gonadotropic preparations methods could be developed to predict and select the correct dose and the optimal protocol for each patient. New pharmacological agents for ovarian stimulation protocols are appearing in the market. These new developments may one day remove the need for the classical gonadotrophins in clinical work.

Bruno Lunenfeld

Born in Vienna 1927, Professor Emeritus at the Faculty of Life Sciences, Bar-Ilan University, and Ramat Gan, Israel and President of the International Society for the Study of the Aging Male, General Secretary of The Asian-Pacific Initiative on Reproductive Endocrinology, Treasurer of the International

Society of Gynaecological Endocrinology and Editor of The Aging Male.

He graduated from the medical School in Geneva Switzerland. Following his post graduate work in Geneva he joined the Weitzman Institute as Senior Scientist, and then headed the WHO International Reference Center for Fertility Promoting Drugs and acted as a Consultant and member of Expert Committees at the WHO.

Professor Lunenfeld is best known for his pioneering work in human reproduction. After describing the clinical use of hMG in men and women in 1960, his group was the first to achieve a pregnancy with hMG in 1961, demonstrated binding of hCG to LH receptors in theca cells in 1967 and were the first to induce ovulation followed by pregnancy with GnRH in an hMG-stimulated cycle in 1975. His research interests pertain to the physiology and pathology of male and female reproduction and include stimulators, modulators and regulators of sex steroids, spermatogenesis, spermiogenesis, folliculogenesis and ovulation, and the mechanism of action of gonadotrophins, GnRH and growth factors on gene expression and steroidogenesis.

He was instrumental in the study of the aging male, was the founder of the International Society for the study of the aging male (ISSAM). He organized in collaboration with the WHO the first, second and third world Congress of the aging male in Geneva.

He published more than 400 papers 19 books including a textbook on Male and Female Infertility and one the "first textbooks on Men's Health". He gave more than 700 invited lectures and chaired or co-chaired more than 100 sessions at national/international Meetings. He trained more than 200 local and foreign physicians and supervised more than 50 MD, MSC, and Ph.D. Students. Professor Lunenfeld has received several distinguished international awards for his scientific achievements, including the special recognition award of the United States Public Health Service for his outstanding contribution in the promotion of health from the Surgeon General (1983), the Verdienstkreuz 1 Klasse – one of Germany's highest honours – signed by the President of Germany, Roman Herzog (1995), the Bertarelli Foundation Award for his lifetime achievements in women's health (2002) and the World Fertility Awareness Month Lifetime Achievement Award (2005).

**S. MITCHELL HARMAN (US)****Changes in Carotid Artery Intima Media Thickness (CIMT) in Menopausal Women During 4 Years of Estrogen or Placebo Treatment: Preliminary, Blinded Results from the Kronos Early Estrogen Prevention Study (KEEPS)**

Chairmanship: Arnal Jean-Francois (FR) Nappi Carmine (IT)

March 08, 15.10 - 15.40

Hall Auditorium

Changes in Carotid Artery Intima Media Thickness (CIMT) in Menopausal Women During 4 Years of Estrogen or Placebo Treatment: Preliminary, Blinded Results from the Kronos Early Estrogen Prevention Study (KEEPS)

Harman S Mitchell (US) - Kronos Longevity Research Institute, Frederick Naftolin, D. Phil., Eliot A. Brinton, Marcelle I. Cedars, Rogerio A. Lobo, JoAnn E. Manson, George R. Merriam, Virginia M. Miller, Genevieve Neal-Perry, Nanette Santoro, Hugh S. Taylor, Mingzhu Yan, Howard N. Hodis

The KEEPS is a 4-year RCT of atheroprevention by early menopausal hormone treatment (MHT); 0.45 mg/d oral conjugated estrogen, 0.05 mg/d of transdermal estradiol, both with cyclic (200 mg/d, 12 days/month) oral progesterone, or placebos with common carotid artery intima media thickness (CIMT) by high resolution B-mode ultrasound twice at baseline and annually thereafter as the primary endpoint. KEEPS randomized 727 women, mean age 52.7 ± 2.6 (SD) years and 1.8 ± 0.8 (range 0.5–3.9) years from LMP. CIMT precision was estimated from 2 pretreatment scans, most performed <6 (mean 3.9 ± 4.2) weeks apart. Coefficients of variation (SD/mean) were $<1.0\%$ ($0.83 \pm 0.98\%$). On analysis of CIMT progression, blinded to treatment, for 377 subjects with 4 years of CIMT data (at least 1 baseline and 12, 24, 36, and 48 month data), baseline CIMT averaged 0.711 ± 0.092 mm and mean 48 month CIMT was 0.744 ± 0.096 mm, an increase of 0.033 ± 0.041 mm ($p < 0.0001$ by ANOVA). A bivariate fit of mean annual CIMT vs. mean time from baseline was linear ($r^2 = 0.971$, $p = 0.002$). However, individual changes ranged from -0.111 to 0.139 with 70 subjects showing a regression in CIMT ≥ 0.006 mm, 20 with changes between -0.005 and $+0.005$ mm, and 287 with increases ≥ 0.006 mm. Most individuals had linear changes in CIMT over time. Linear regression analyses revealed that among baseline variables of age, systolic BP, BMI, waist circumference, total, LDL, and HDL cholesterol (C), triglycerides, and fasting glucose only age ($r = 0.100$, $p = 0.05$) and LDL-C ($r = -0.120$, $p < 0.02$) significantly predicted 4-year change in CIMT. Whether or not MHT ameliorated effects of

traditional risk factors on CIMT progression is unknown due to blinding. At study end, unblinded analyses will be performed to test effects of oral vs. transdermal MHT on CIMT measurements as well as on coronary artery calcium scores by CT.

S. Mitchell Harman

Dr. S. Mitchell (Mitch) Harman graduated from Miami Beach High School in 1960 and from Emory University (BA Biology) in 1964. He completed both M.D.-Ph.D. degrees at the SUNY Health Sciences Center in Brooklyn in 1970 with thesis work on ovarian hormone changes with age. Dr. Harman trained in internal medicine at Yale and in Endocrinology at the National Institutes of Health. He is ABIM certified in internal medicine and endocrinology and metabolism. In 1974 he joined the National Institute on Aging where he founded the NIA laboratory for study of reproductive hormones and became Associate Professor of Medicine at Johns Hopkins. He is currently Director and President of the Kronos Longevity Research Institute in Phoenix, AZ, Chief of the Endocrine Section at the Phoenix VA Hospital, and Clinical Professor of Medicine at the University of Arizona College of Medicine. He is an internationally recognized expert on the effects of aging on hormone regulation and on hormone therapy in older men and women and has published more than 140 books, chapters, and peer-reviewed research papers. Currently, he is a co-principle investigator of the Testosterone Effects on Atherosclerosis in Aging Men (TEAAM) study and the coordinating principle investigator of the Kronos Early Estrogen Prevention Study (KEEPS) a 9 center trial in 728 women of menopausal hormone treatment effects on atherosclerosis progression.



PLENARY LECTURE

GUSTAFSSON JAN ÅKE (US)

**Estrogen receptors: their actions
and functional roles in health and disease**

Chairmanship: Korach Kenneth (US), Sismondi Piero (IT)

March 08, 15.10-15.40

Hall Verde

Estrogen receptors: their actions and roles in health and disease

Gustafsson Jan Åke (US) - University of Houston

It is evident to all endocrinologists that the endocrinology of the peri- and post menopausal woman is still rather unclear. It is now apparent that estrogen signaling is far more complex than was previously thought and that many signaling pathways have to be included in the equation before we can understand endocrine regulation in the aging female and how disturbances in endocrine pathways lead to diseases such as breast cancer, metabolic syndrome and cognitive defects. Two of the nuclear receptors which are involved in these diseases and which are the focus of our studies are the estrogen receptor beta, ERbeta, and the oxysterol receptor, LXRbeta. ERbeta is of interest because it is one of the two receptors mediating estrogen signaling and it is a receptor without which ovulation does not occur. It can oppose ERalpha in many signaling pathways and can have proliferative effects in the presence of tamoxifen. LXRbeta and ERbeta are both expressed in the breast and brain where they play key roles in development but their regulation during aging are unknown. We now report on the changes in expression of these receptors in the mouse and human breast as a function of age and examine the role of these two receptors in the serotonergic neurons of the dorsal raphe.

Jan-Åke Gustafsson, M.D., Ph.D.

1979 Professor of Medical Nutrition

2009 Professor of Medical Nutrition, Karolinska Institutet (20%) Robert A. Welch Professor of Dept. of Biology and Biochemistry and Director of Center for Nuclear Receptors and Cell Signaling, University of Houston, Texas (80%)

2002 Foreign Honorary Member of the US National Academy of Sciences

2011 Honorary Doctor in Medicine, University of Turku, Turku, Finland

2008 Honorary doctorate at the University of Milan

Has participated in the supervision of 104 Ph.D. students and 139 postdocs/visiting scientists.

Has 1419 peer-reviewed publications.

Has been invited to lecture at 615 international symposia.

Has so far been cited 73 237 times.

H-index: 117

**ARISI EMILIO (IT)****Ulipristal nella contraccezione d'emergenza: è tempo di cambiare! Sponsored By HRA PHARMA**

Chairmanship: Benedetto Chiara (IT)

March 08, 15.10-15.40

Hall Affari 2

Ulipristal nella contraccezione d'emergenza: è tempo di cambiare! Sponsored By HRA PHARMA**Arisi Emilio (IT)****Ospedale Reg S Chiara. dip materno-infantile**

La contraccezione d'emergenza ha subito grandi evoluzioni negli ultimi decenni. Se negli anni '60 venivano utilizzate alte dosi di estrogeni, più comunemente l'etinilestradiolo, negli anni '70 sono stati usati gli estrogeni progestinici. Negli anni '80 e negli anni '90 i soli progestinici sono stati usati per la loro grande maneggevolezza clinica, per i minori fenomeni collaterali e per una più elevata sicurezza anticoncezionale, come confermato anche da studi OMS. Il farmaco ora usato è il levonorgestrel (LNG), dapprima usato in due dosi refratte da 0.750 mg a distanza di 12 ore e poi in unica dose da 1.5 mg quanto prima dopo il rapporto sessuale temuto fecondante, ottenendo così una migliore compliance e gli stessi livelli di sicurezza. Negli anni più recenti è stato introdotto l'ulipristal acetato (UPA) alla dose di 30 mg una tantum, ormai in uso in tutti i paesi dell'Unione europea e in USA, approvato dall'AIFA il 17 novembre 2011, in via di immissione in commercio anche in Italia nei prossimi mesi. Il vantaggio di UPA è rappresentato da una più elevata e prolungata capacità di blocco sulla ovulazione rispetto al LNG, che si traduce clinicamente in una elevata e prolungata efficacia nel ridurre il rischio di gravidanza indesiderata già nelle prime 24 ore. Tale meccanismo può essere alla base anche della attività che si mantiene fino 5 gg dal rapporto presunto fecondante rispetto ai 3 gg del LNG. È soprattutto per questo che bisogna cambiare, per rendere disponibile alle donne ed alle coppie uno strumento più capace di soccorrerle nel momento in cui altri metodi abbiano fallito.

Arisi Emilio

Dopo aver lavorato in vari ospedali, dal 1° ottobre 1993 al 30 giugno 2010 è stato Direttore della U.O. di Ostetricia e Ginecologia dell'Ospedale Regionale "S. Chiara" di Trento. Ha al suo attivo più di 500 pubblicazioni, dedicate a contraccezione, aborto volontario, oncologia ginecologica, gravidanza e menopausa, inclusi articoli su riviste nazionali ed internazionali, relazioni a congressi nazionali ed internazionali, ed alcuni volumi. È membro del consiglio nazionale dell'AOGOI, di cui è segretario regionale per il Trentino-Alto Adige. È stato consigliere della SIGO per due mandati. È Presidente della SMIC (Società Medica Italiana per la Contraccezione), ed è Direttore scientifico della rivista "Contraccezione Sessualità Salute Riproduttiva", organo ufficiale della SMIC.



NAPPI ROSSELLA E. (IT)

Vaginal health: a woman's right!

Sponsored By Novo Nordisk

Chairmanship: Panay Nick (GB) Polatti Franco (IT)

March 9, 15.10-15.40

Hall Auditorium

Vaginal health: a woman's right!

Rossella E. Nappi

Approximately 50% of postmenopausal women will experience symptoms relating to vaginal atrophy, with subsequent impact on sexual function and quality of life. Despite the high prevalence and diversity of uro-genital symptoms (irritation, itching, discharge, dyspareunia, frequency, urgency, nocturia, dysuria, incontinence and recurrent infections) associated with estrogen depletion, only around one-quarter of symptomatic women seek medical help. Women are often reluctant to consult their doctors about vaginal symptoms, perhaps due to embarrassment, cultural values, or acceptance of such symptoms as an inevitable consequence of aging. In addition, they have a low understanding of vaginal atrophy as a chronic condition. That being so, medical practitioners should proactively raise the topic of vaginal health and discuss treatment options as appropriate, so that more women can receive timely and effective therapy.

Treatment with local estrogen is a relatively simple therapeutic strategy that can transform a woman's quality of life by rapidly improving vaginal atrophy. Women should be made aware that there are a number of different options available for local estrogen therapy (e.g. tablets, creams, suppositories, rings), and the best choice for each individual patient is largely a matter of personal preference. Whichever option is chosen, low doses are recommended. Recently, estradiol tablets (Vagifem® 10µg) have been shown to be the lowest dose of local estrogen commercially available which provides effective relief from the most bothersome symptoms of vaginal atrophy, by maintaining systemic estrogen levels within the normal postmenopausal range. The safety profile of such a treatment (administered daily for the first two weeks of treatment, after which one tablet is taken twice weekly) supports the view that ultra-low doses might be the preferred option for postmenopausal women treated with local vaginal estrogen.

Rossella E. Nappi

Associate Professor of Obstetrics and Gynecology, Research Center for Reproductive Medicine and Director of the Gynecological Endocrinology & Menopause Unit, IRCCS San Matteo Foundation, University of Pavia (Italy) MD, PhD

Gynecologist, Endocrinologist, Sexologist

-

Dr Nappi's major interest is focused on psychoneuroendocrinology of female reproductive life and women's sexuality. She has published more than 150 scientific articles in peer-reviewed journals and international books.

She is a well known speaker on women's health from adolescence to menopause and has been featured in many international meetings.

She is past president of the International Society for the Study of Women Sexual Health (ISSWSH) (200-7-2008) and member of the advisory board of the International Menopause Society (IMS).

**LOBO ROGER (US)****Variation in menstrual function as a predictor of metabolic and cardiovascular risks in women**Chairmanship: Lambrinoudaki Irene (GR)
Guaschino Secondo (IT)

March 09, 15.10-15.40

Hall Verde

Variations in menstrual function as a predictor of metabolic and cardiovascular risks in women**Lobo Roger (US) - Columbia University**

Normal menstrual function is a very predictable event and occurs in the vast majority of women. Oligo/amenorrhea occurs in a variety of states, and it is suggested here, that this occurrence may signify metabolic and /or cardiovascular (CV) risks. In women with hypoestrogenism due to ovarian failure or hypothalamic dysfunction, evidence suggests that there is accelerated atherosclerosis and endothelial dysfunction. Recent data have shown that even when the hypoestrogenic amenorrhea is exercise-induced, CV function remains abnormal suggesting a larger negative influence of hypoestrogenism over the benefits of exercise on CV function. On the other hand, in hyperandrogenic women, only those with menstrual dysfunction exhibit signs of insulin resistance and abnormal CV risk parameters. Thus, women with the ovulatory phenotype of PCOS exhibit mild or no abnormal findings of metabolic and CV risk. This is also the case in "idiopathic" hyperandrogenic women with normal menses and normal appearing ovaries on ultrasound. In the oligomenorrheic phenotype of women with PCOS, these risks may be associated with a higher prevalence of increased abdominal fat. Does menstrual function per se lead to these putative risks, or is this relationship in reverse? It is suggested that external factors and inadequate compensatory mechanisms in certain women which lead to menstrual aberrations, also herald metabolic and CV risks. Attention to menstrual dysregulation in women should be viewed as an important barometer of the prevalence of metabolic and CV risks. Bairey Merz CN. J Am Coll Cardiol 2003; 41: 413-9 O'Donnell. J Clin Endocrinol Metab 2011; 96: 3638-48 Carmina E. J Clin Endocrinol Metab 2005; 90: 2545-49 Jovanovic VP. Fertil Steril 2010; 94: 826-32 Panidis D. Human Reproduction 2011, Dec. 5

Rogério A. Lobo

Rogério A. Lobo, M.D. received his medical degree from Georgetown University Medical School in Washington, D.C., and completed his residency in Obstetrics and Gynecology at the Chicago Lying-in Hospital at the University of Chicago. He went on to complete a clinical research fellowship in the Division of Reproductive Endocrinology and Infertility at the University of Southern California Medical Center in Los Angeles.

He has since held numerous teaching positions, including Assistant and Associate Professor in the Department of Obstetrics and Gynecology at the University of Southern California in Los Angeles, where he was later promoted to full Professor. In 1995 he came to the Columbia University College of Physicians and Surgeons in New York City where he was named the Willard C. Rappleye Professor of Obstetrics and Gynecology, and Chairman of the Department

Dr. Lobo has functioned as Editor, Editorial Board member and/or Consultant for over 30 peer-reviewed medical journals in his field, and has authored over 400 articles and 20 books. Dr. Lobo helped found the Journal of the Society for Gynecologic Investigation and served as Editor-in-Chief from its inception until July, 2006. He was President of the Society for the years 1997-1998. He has contributed Chapters to and edited several important medical textbooks. His book Treatment of the Post-Menopausal Women is in its Third Edition and published this year. (2007) Another text, Menopause, was published in early 2000.

Dr. Lobo has done extensive research in many areas of reproductive endocrinology and infertility. In 2010 he became President of the American Society For Reproductive Medicine.



JOLE BALDARO VERDE (IT)

L'età conquistata è davvero una conquista per la donna?

Chairmanship: Boncinelli Vieri (IT) Volpe Annibale (IT)

March 09, 15.10-15.40

Hall Affari 2

L'età conquistata è davvero una conquista per la donna?

Jole Baldaro Verde

Le mutate condizioni di vita e i nuovi medicinali hanno consentito, al genere umano, di “conquistare” almeno dieci anni di vita che, tuttavia, per il significato che ancora oggi viene dato al piacere che si ottiene dal rapporto sessuale, ha comportato, ancora una volta, vantaggi per il genere maschile e un ulteriore conflitto per quello femminile. Per comprenderne la dinamica occorre rifarsi al significato che, per l'umanità intera, ha il rapporto sessuale. Per la donna, fino alla scoperta, avvenuta soltanto nel 1960, della famosa “pillola”, il rapporto sessuale è stato ritenuto, esattamente come per la femmina dei mammiferi, finalizzato alla procreazione. La maternità “responsabile e scelta”, in modo autonomo dalla donna, è quindi possibile solo da pochissimi anni. Per il maschio, dal momento della scoperta scientifica della paternità, il rapporto sessuale ha invece avuto, oltre al significato di “rito di passaggio” dall'infanzia all'età adulta, quello di “conferma” della propria identità sessuale e del proprio potere procreativo. L'allungamento della vita, per l'abbassamento degli androgeni, impediva peraltro agli uomini delle passate generazioni questa conferma. La scoperta di medicine, a partire dal famoso Viagra, che permettono ai maschi di godere dell'età conquistata è recente ed è possibile perché la seduttività maschile è stata, da sempre, legata all'intelligenza, al ruolo sociale, al danaro. La pillola ha sganciato, come detto, la sessualità femminile dalla maternità, regalando quindi, anche al rapporto sessuale femminile, il significato di “qualificare” una relazione. Tuttavia la seduttività femminile è, da sempre, centrata sulla bellezza e sulla giovinezza e se la donna, nell'età conquistata, ha perso l'una e l'altra non avrà alcuna possibilità di goderla ancora. La cultura quindi dovrebbe battersi per ottenere per tutto il genere umano un cambiamento sui significati da dare, in ogni età della vita, al rapporto sessuale ed al piacere che lo dovrebbe accompagnare.

Jole Baldaro Verde

Jole Baldaro Verde è nata a Napoli ma risiede e lavora a Genova. Si laurea prima in Materie Letterarie e in seguito in Medicina e Chirurgia con Specializzazione in Pediatria e in Psicologia dell'Età Evolutiva.

È fondatrice, direttore e formatore della Scuola per la Ricerca e la Formazione in Sessuologia di Genova ed è stata presidente della Federazione Italiana di Sessuologia Scientifica (FISS), dal novembre 2002 al dicembre 2004. Nel 2007 ha ricevuto la Gold Medal Award assegnata dalla WAS (World Association for Sexual Health). È stata professore Associato, Cattedra di Teorie della Personalità, dal 1987 al 1994. L'attività scientifica di ricerca è testimoniata da 259 pubblicazioni, di cui ben 221 attinenti alla Sessuologia.



PLENARY LECTURE

HUBER JOHANNES C. (AT)

**Esthetic endocrinology, the effect of sexual steroids
on body composition, hair and skin**

March 10, 15.20 - 15.50 Hall Affari 0

Chairmanship: Moscarini Massimo (IT), Birkhaeuser Martin. (CH)

March 9, 15.10-15.40

Hall Auditorium

Esthetic endocrinology, the effect of sexual steroids on body composition, hair and skin

Huber Johannes C. (AT) Med. Univ. Wien

Steroid hormones are also involved in metabolism, body composition and lipolysis. Cortisol stimulates visceral obesity, which is antagonised by progesterone. On the other side, estradiol and progesterone enhance lipoprotein-lipase activity in the area gluteofemoralis. Androgens have a strong lipolytic effect, can be used topically and seem also effective in the treatment of the so called "cellulite". Matrix metalloproteinase activity is responsible for the "fine wrinkles" in the skin and can be suppressed by progesterone, which is available in a 3% cream. Progesterone can be also combined with alpha lipoic acid to improve skin quality. Endocrine disturbances can be involved in the loss of hair. The combined application of estradiol and progesterone on the scalp is a therapeutic option in patients with sexual steroid insufficiency. Subclinical hypothyroidism can be also responsible for effluvium, like hyperandrogenaemia, which can be treated with a cyproterone acetate cream.

Huber Johannes

Prof. Johannes Huber, chairman of the department for gynecological endocrinology till September 2011, chairman of the bioethical commission of the Austrian chancellor between 2001 - 2007 head of the outpatient department for woman health (Menox) and the outdoor clinic for esthetic endocrinology.

He is author of papers and reviews in this scientific area.

**NAFTOLIN FREDERICK (US)****Attacking the nexus of atheroprotection with sex steroids**

Chairmanship: Gustafsson Jan-Ake (US) Greco Pantaleo (IT)

March 10, 15.20-15.50

Hall Affari 2

Attacking the nexus of atheroprotection with sex steroids

Anna-Maria Curatola, PhD, Kui Huang, PhD, and Frederick Naftolin, MD, PhD

New York University, New York, USA

Introduction. Atherosclerosis is an inflammatory process that requires the presence of elements of cellular immunity. Therefore, adhesion of monocytes to the vascular endothelium is necessary for atheroma formation. This adhesion requires binding of endothelial neural cell adhesion molecule (NCAM) to monocyte NCAM. NCAM:NCAM; so-called "tethering" of monocytes to the endothelium prior to entry into the sub-endothelial tissue. NCAM:NCAM tethering is blocked by sialylation of NCAM (polysialylated NCAM; PSA-NCAM). We previously showed that estrogen induces NCAM sialylases in the brain, including brain blood vessel endothelium. We tested the ability of sex steroids to induce PSA-NCAM in human vascular endothelium and found that estradiol (E2), testosterone (T) and dihydrotestosterone (DHT) induced PSA-NCAM and decreased monocyte adhesion to coronary vascular endothelium from men and women. In consideration of possible clinical applications we tested whether their prohormone dehydroepiandrosterone (DHEA) has similar effects.

Experimental. (1) DHEA was administered to cultured human coronary artery endothelial cells (HCAECs) from men and women. Monocyte binding was assessed using fluorescence-labeled monocytes. (2) HCEACs were incubated with E2, DHT, DHEA alone, or with trilostane, fulvestrant or flutamide. Expression of PSA-NCAM was assessed by immunohistochemistry and Western blotting. **RESULTS:** Dehydroepiandrosterone inhibited monocyte adhesion to HCAECs by ~50% ($P < 0.01$). Fulvestrant or flutamide blockade of DHEA's inhibition of monocyte binding appeared to be gender-dependent. The DHEA-induced expression of PSA-NCAM was completely blocked by trilostane.

Conclusions. Sex steroids are promising antagonists to intravascular cellular inflammation, in part by inhibiting monocyte adherence to the vascular endothelium. Sialylation of NCAM appears to be one

of the mechanisms of this blockade of this vascular nexus for atherosclerosis. But, clinical considerations make unlikely the use of androgens or estrogens to prevent atherosclerosis by treating reproductive-aged men and women. In these preliminary in vitro studies, DHEA increased PSA-NCAM expression and inhibited monocyte binding in an estrogen- and androgen receptor-dependent manner. Dehydroepiandrosterone appears to act via its end metabolites, E2 and DHT. Dehydroepiandrosterone could furnish clinical prevention against atherogenesis and arteriosclerosis.

Frederick Naftolin

Professor Frederick Naftolin is a founding member and sits on the Executive Committee of the International Society of Gynecological Endocrine Society (ISGE). His Training includes MD - University of California, San Francisco, residency in Obstetrics and Gynecology - University of California, Los Angeles, fellowship in endocrinology, University of Washington and D Phil in Neuroendocrinology - Oxford University. He was Chairman of Obstetrics and Gynecology at McGill University Faculty of medicine, 1975-8 and Chairman of Obstetrics and Gynecology at Yale University School of Medicine 1978-2000. He has been Professor and Head of Reproductive Biology Research in the Department of Obstetrics and Gynecology, New York University School of Medicine since 2005. In 1988 Professor Naftolin was the inaugural Plenary Speaker for the ISGE at its first Congress, Crans-Montana, Switzerland.



REES MARGARET (GB)

Challenges for women in science in the 21st century

Chairmanship: Sitruk Ware Regine (US) Caserta Donatella (IT)

March 10, 15.20-15.50 Hall Verde

Challenges for women in science in the 21st century

Rees Margaret (GB) - University of Oxford

Women are still under represented in senior academic scientific positions. Some countries are worse than others. This is of concern in that women undergraduate students outnumber men in many specialities especially medicine. Thus junior academic women have few senior role models and anticipate lower salaries than men. Women have to juggle with many lives: mother, carer of elderly relatives as well as professional commitments. This is not recognised by male colleagues. It has to be recognised that men and women take on different roles as they advance through their scientific careers. Thus institutions and funding bodies need to recognize the full scope of the roles that women in science play.

Margaret Rees

Reader Emeritus in Reproductive Medicine, University of Oxford, UK

President- elect of EMAS and Editor-in- Chief of Maturitas, she has an international reputation of leadership in women's midlife health. This expertise has been recognised leading to, a Readership in Reproductive Medicine at Oxford University and Visiting Professorships at Glasgow University, the University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School and in the Departments of Obstetrics and Gynaecology at the Karolinska Institute in Sweden and the University of Turku in Finland.

Prof Margaret Rees MA DPhil FRCOG

Editor in Chief Maturitas

Reader Emeritus in Reproductive Medicine, University of Oxford

Visiting Professor, Faculty of Medicine, University of Glasgow and Adjunct Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the

University of Medicine and Dentistry of New Jersey

Women's Centre,

John Radcliffe Hospital,

Oxford, OX3 9DU UK



The international Academy
on Human Reproduction

15th world congress on human reproduction

Venezia 13/16 March 2013
www.humanrep2013.com



THE FOUR BEST
ABSTRACTS
OF THE UNDER 34
COMPETITION



MACLARAN KATE (GB)

Presentation and management of POF: Findings from the West London POF database

Chairmanship: Ibañez Lourdes (ES) Sultan Charles (FR)

March 09, 16.00 - 17.30

Hall Affari 1

Adolescent gynecology and endocrinology

Presentation and management of POF: Findings from the West London POF database

Maclaran Kate, Nick Panay (GB)

Imperial College London

Objective: Premature Ovarian Failure (POF) is an increasingly common condition with important physical and psychological consequences. Unfortunately, it remains a vastly under-researched area. Here we present the development and analysis of a POF patient registry, to learn more about the symptomatology, aetiology and management of POF. Methods: A retrospective analysis of 450 women with POF attending dedicated clinics at The West London Menopause and PMS Centre, London, UK. Results: Average age of diagnosis was 30.3 years. 55.1% of cases were idiopathic, and 42% were iatrogenic. The most common symptoms were hot flushes (59.2%), sweating (41.5%), vaginal dryness (23.8%), depression/anxiety (20.3%), and low libido (14.8%). 25% were asymptomatic. Iatrogenic POF and older age at diagnosis were associated with increased symptoms. Over one third of patients had low bone mineral density (BMD) at diagnosis (29.7% osteopenia, 5% osteoporosis). Patients with idiopathic POF had significantly lower BMD compared to iatrogenic POF (1.108 g/cm³, 1.174, p=0.0043). Lower baseline estradiol, but not the presence of vasomotor symptoms, was associated with lower BMD. Bone loss occurred at an average rate of -1.26% per year and occurred more rapidly in idiopathic (-1.39%) compared to malignant (-0.43%) aetiologies. The majority of women used HRT (87.2%) with only 5.8% using the combined oral contraceptive pill and 3.5% using no treatment. Over 5 years, 6% discontinued hormone replacement, 2 due to medical reasons, but only 2 had reached the average age of menopause.

Conclusion: Underlying aetiology of POF can influence symptomatology and bone density, this knowledge may help provide a targeted approach to management. Many patients discontinue treatment before the average age of menopause, highlighting the need for regular follow-up to ensure patient satisfaction with HRT.

Maclaran Kate

I am an Obstetric and Gynaecology specialist trainee, currently working as a Clinical Research Fellow at Imperial College London. My clinical work is as part of the team at the West London Menopause and Premenstrual Syndrome Centre at Queen Charlotte's & Chelsea and Chelsea & Westminster Hospitals, with Consultant Mr Nick Panay.

Research interests include Premature Ovarian Failure and androgen therapy. I have been involved in developing an on-line registry, gathering long-term follow-up data from patients with Premature Ovarian Failure. In addition, I am undertaking an MD project investigating the cardiovascular effects of postmenopausal testosterone therapy.

**FISCHER LARA (DE)****Anti-progestin effects of selective progesterone receptor modulators (SPRM) and SPRM-like chemicals in human endometrium**

March 10, 08.30 - 10.00

Hall Affari 1

SSRM: new development, new therapeutic uses

Anti-progestin effects of selective progesterone receptor modulators (SPRM) and SPRM-like chemicals in human endometrium

Fischer Lara (DE)

University Hospital Freiburg, Germany

A. Hanjalic-Beck, S. Stanzel, W. R. Deppert, H.P. Zahradnik, W.R. Schaefer

A receptive endometrium is of crucial importance for successful embryo implantation. Endometrial receptivity is controlled by progesterone and can be impaired by progesterone-antagonists, SPRMs and SPRM-like chemicals. The progesterone receptor is an important target for drugs and endocrine disrupting chemicals. Anti-progestin compounds have the potential to interfere with embryo implantation. We developed a tissue-specific in vitro assay based on the human endometrial epithelial Ishikawa cell line to analyze the effects of anti-progestin compounds on pre-selected gene expression biomarkers. After priming with 17 β -estradiol the cells were incubated with combinations of progesterone and test compounds. The estrogen sulfotransferase (SULT1E1) and the progesterone receptor (PR) were identified by microarray analysis as appropriate gene expression biomarkers for anti-progestin compounds. Sigmoidal dose-response curves were established by reverse transcription quantitative real-time PCR (RT-qPCR). In this model the SPRMs mifepristone, ulipristalacetate and ZK137316 antagonized in a dose-dependent manner the effects of progesterone on both target genes (EC₅₀ approx. 10⁻⁹ M). For other chemicals with anti-progestin effects like 4-nonylphenol, bisphenol A and the plant compound apigenin similar effects were observed at higher EC₅₀-values (EC₅₀ > 10⁻⁶ M). Methylacetoacetate was used as negative control and displayed no effects. The effects on the PR were confirmed by Western Blotting. Our Ishikawa model is suitable to study quantitatively effects of anti-progestin-like chemicals on endometrial biomarkers and demonstrates that wide-spread environmental chemicals

exert weak PR antagonistic effects on the human endometrium.

Fischer Lara

I studied biology at the University of Freiburg (2000-2006). In my diploma thesis, I investigated the role of the enzyme lecithin:retinol-acyltransferase-2 in the vitamin A metabolism in zebrafish (lab of J. von Lintig). This enzyme is of importance for visual cycle and vitamin A storage in liver. In my doctoral thesis (start 2007; University Hospital Freiburg, Endocrinology Laboratory of W. Schäfer) I work on human in vitro-models for detecting effects of endocrine active chemicals on endometrial function. Our focus is on estrogenic and antigestagenic chemicals as well as selective progesterone receptor modulators (SPRM). Antigestagenic chemicals are a potential health risk since they can disturb embryo implantation. My work was part of the EU-project "ReProTect" whose aim was to develop new in vitro-tests to reduce animal experimentation in reproductive toxicology. I'm now in the final stage of my doctoral thesis.

**KNOWER KEVIN (AU)****Epigenetic influences regulating intratumoral estrogen production in postmenopausal breast cancer**

March 10, 11.40 - 13.10

Hall Affari 1

Cancer stem cell: from basic science to clinical impact

Epigenetic influences regulating intratumoral estrogen production in postmenopausal breast cancer**Knower Kevin (AU) - Prince Henry's Institute
Sarah To, Yasuhiro Miki, Kiyoshi Takagi, Hironobu Sasano, Evan Simpson, and Colin Clyne**

The epithelial?stromal microenvironment of breast cancer results in global gene expression changes compared to normal tissue. Despite these transcriptome changes, genetic alterations are restricted to epithelial cells, underlying epigenetic influences on gene regulation in the stroma. Estrogen receptor positive (ER+) tumors in postmenopausal women are dependent on sustained intratumoral estrogen production through the enzyme aromatase, encoded by the gene CYP19A1. In postmenopausal women, breast adipose fibroblasts (BAFs) are the major site for estrogen, in which the promoter I.4 (PI.4) drives basal CYP19A1 transcription. Tumor-derived factors, however, elevate CYP19A1 expression by the promoters I.3 (PI.3) and II (PII). This study aimed at identifying whether epigenetic mechanisms contribute to CYP19A1 upregulation in the breast. We show that (i) inhibition of DNA methylation results in a significant induction in PI.4-derived CYP19A1 mRNA in BAFs and the epithelial cell lines MCF10A, MCF-7, and MDA-MB-231, albeit via PII; (ii) upstream co-activators of PII-derived CYP19A1, including LRH-1 and EP2, are under epigenetic regulation; (iii) paracrine signaling factors secreted by malignant epithelial cells that upregulate PII-derived CYP19A1 in BAFs are epigenetically silenced in nonmalignant cells. To further in vitro studies, DNA and RNA were isolated from epithelial and stromal cells from women with ER- and ER+ invasive tumors by laser capture microdissection. Sodium bisulfite sequencing and qRT-PCR revealed genomic regions of CYP19A1 and upstream regulators that were differentially regulated between tumors and matched normal tissue. This study uncovers a new layer of complexity in the regulation of aromatase and evokes the possibility that changes in the DNA methylome through tumor

progression may give rise to a subsequent increase in estrogen levels in the breast.

Kevin Knower

Dr Kevin Knower completed a Bachelor of Science with Honours degree in 2001 and in 2006 received his PhD from the Department of Biochemistry and Molecular Biology, Monash University, Melbourne, Australia. In 2007, he joined the Cancer Drug Discovery lab at Prince Henry's Institute working with Dr Colin Clyne and Professor Evan Simpson. In 2009, he received a prestigious International fellowship from the U.S. Department of Defense Breast Cancer Research Training Program. Dr Knower's research focuses on identifying the epigenetic mechanisms regulating genes that are involved in estrogen biosynthesis in the breast and how these processes are altered in breast cancer. His recent work has identified the importance that DNA methylation plays in the regulation of aromatase expression in the breast. Such findings have the potential to lead to new epigenetic therapeutic measures for targeting estrogen-dependent breast cancers.

**SALINAS SOLEDAD (CL)**

Functional role of peroxisome proliferator-activated receptors gamma in glucidic metabolism in of granulosa cells from normal and polycystic ovary syndrome women

March 10, 16.00 - 17.30

Hall Affari O

Insulin and reproductive endocrinology

Functional role of peroxisome proliferator-activated receptors gamma in glucidic metabolism in of granulosa cells from normal and polycystic ovary syndrome women
Salinas Soledad (CL)

Pustovrh M Carolina, **Godoy Ana**, **Argüello Begonia**, **Muñoz Alex**, **Kohen Paulina**, **Devoto Luigi**. Institute of Maternal and Child Research.(IDIMI) Department of Obstetrics and Gynecology. Hospital San Borja Arriarán. Faculty of Medicine University of Chile. Santiago Chile

Polycystic ovary syndrome PCOS is a common endocrine and metabolic disorders affecting 5-10% of reproductive age women. 40-50% exhibit hyperinsulinemia and insulin resistance PPAR γ are transcription factors that regulate metabolism of glucose and insulin I Rosiglitazone Rz is a potent agonist of PPAR γ receptors, regulating expression of genes involved in glucose metabolism Glucose metabolism and insulin signaling pathway in granulosa cells GCs of PCOS women are virtually unknown. The aim of this study was to determine the role of PPAR γ and its agonist Rz in the metabolic pathway of I in GCs of PCOS women Follicular fluid FF and GCs were collected from PCOS n=15 and normal women n=18 from the IVF program of our institute IDIMI GLUTs and PPAR γ genes expression were evaluated by qRT-PCR, proteins were determined by ICQ and Western blot Glucose was measure by glucose oxidase and its uptake was assessed by incorporation of 2-desoxy-glucose 2-DG in basal and stimulated condition and in cells pre incubated with Rz Glucose levels in FF of PCOS follicles were significant higher compared to control $p < 0,005$. PCOS GCs shows decrease in mRNA levels of GLUT1 and GLUT4 $p < 0,01$. Same decrease was observed at protein level. Basal glucose uptake is significantly low in PCOS GC. Addition of insulin 100ng/ml to culture medium enhanced glucose uptake in control group without change in PCOS GCs PCOS GC expressed significant lower PPAR γ mRNA $p < 0,05$. Incubation with Rz 0,1 μ M for 12 hours significantly improved the incorporation of 2-DG $p < 0,05$ in PCOS GC, increasing GLUT4 mRNA and its protein

PCOS GCs have different metabolic and molecular profile than GCs of normal women GLUTs are decreased in PCOS GC and revealed resistance to insulin modulation The activation of PPAR γ by a pharmacological agonist Rz improves glucose uptake in the GC of these women, through the increase of GLUT4

Soledada Abril Salinas Quero

Medical degree graduated from the University of Chile year 2006

Chilean board in Obstetrics and Gynecology 2011.

Elegible MD PhD Disertation december 2012

Service responsibility in Reproductive Endocrinology

Institute of Maternal and Child Research.(IDIMI)

Department of Obstetrics and Gynecology.

San Borja Arriarán Hospital. University of Chile

Main interest:

Clinical interest: Reproductive endocrinology, Infertility

Reserch interest: Insulin resistance in reproductive tissue

SPONSORED SYMPOSIA AND LECTURES

MARCH 7

15.00 17.00
Auditorium OS Progesterone: the pregnancy hormone
 Sponsored by **Teva**

MARCH 8

09.40 11.10
Auditorium SS COCs: What is new in 2012?
 Sponsored by **Teva**

11.40 13.10
Auditorium SS A New Evidence-based Treatment Approach for Endometriosis Sponsored by **Bayer**

13.10 15.10
Affari 0 LS HRT - new benefits, new approaches, old concerns Sponsored by **Besins**
Affari 1 LS Local estriol gel in urogenital atrophy
 Sponsored by **Italfarmaco**

15.10 15.40
Affari 2 PL Ulipristal nella contraccezione d'emergenza: è tempo di cambiare! Sponsored by **HRA Pharma**

16.00 17.30
Affari 1 SS Oral Contraception and beyond Sponsored by **Bayer**
Verde SS Estetrol in contraception Sponsored by **Estetra**

OS Opening Symposium
LS Lunch Symposium
SS Sponsored Symposium
IC Italian Course
SC Spanish Course
MTE Meet the Expert
DB Debate

MARCH 9

09.40 11.10
Verde SS Inositol: Clinical Experiences Sponsored by **Italfarmaco**

09.45 13.15
Affari 2 IC Evoluzione degli Estroprogestinici: dalla farmacologia alla scelta ragionata Sponsored by **TEVA**

11.40 13.10
Affari 1 SS New evidence supporting treatment choices for menopause management Sponsored by **Bayer**

13.10 15.10
Affari 1 LS Human derived FSH: new evidences for old understandings Sponsored by **Ibsa**

15.10 15.40
Auditorium PL Vaginal health: a woman's right!
 Sponsored by **Novo Nordisk**

16.00 17.30
Auditorium SS How To Improve Take Home Baby Rate
 Sponsored by **Merck Serono**

Affari 0 SC Soluciones Innovadoras en Salud Femenina
 Sponsored by **Bayer**

Onice SS Phytomedicine in Gynecological Endocrinology: New Perspectives Sponsored by **Bionorica**

MARCH 10

09.45 13.15
Affari 2 IC Nutraceutica: risposte per la salute delle donne Sponsored by **Menarini**

10.10 11.10
Verde SD Benefits and Risks of Hormonal Contraceptives
 Sponsored by **Bayer**

11.40 13.10
Auditorium SS Perinatal Medicine: a help for new coming life Sponsored by **Ferring**

13.10 15.10
Affari 1 LS Additional benefits in hormonal contraception: new evidence with E2V/DNG
 Sponsored by **Bayer**

Symposia by Scientific Societies

MARCH 8

16.00 17.30

Affari 0 European Society of Obstetrics and Gynecology
german-french language Endocrine and nonendocrine
aspects of stem cells

MARCH 9

08.30 09.30

Auditorium Mediterranean Society for Reproductive
Medicine Up-date on ovarian stimulation

Affari 0 Asociación Latinoamericana de Endocrinología
Ginecológica Health concern in latin-american countries

Affari 1 Association Française pour l'Etude de la
Ménopause Life events, life style and quality of life

Affari 2 Federazione Italiana di Sessuologia Scientifica
Approccio integrato nell'anorgasmia femminile

Verde RCHA Gynecological and obstetric management
of females with hereditary angioedema: a disease which
can kill women with estrogens...

Onice Sociedade Brasileira de Ginecologia Endócrina
on health benefits of menstrual suppression

09.40 11.10

Onice Polish Group of Gynecological Endocrinology
Contemporary Gynecological Endocrinology

11.40 13.10

Onice German Endometriosis Society - Deep infiltrating
Endometriosis (DIE): Surgical and Medical Management

MARCH 10

08.30 10.00

Verde International Menopause Society Understanding
weight change in midlife

Onice Multidisciplinary Italian Society for Woman's Health
New Fields in Woman's Health

11.40 13.10

Verde European Society of Gynecology Hot issues in
gynecology in 2012

16.00 17.30

Verde International Academy on Human Reproduction
Complication of art practice

Debates and Meet the Expert Sessions

MARCH 10

10.10 11.10

Affari 0 MTE Surgical approach to Müllerian defects

Affari 1 DB Ovarian cancer and assisted reproduction

Wednesday, March 7, 2012

Precongress courses



WED MARCH 7TH

HALL ONICE

09.00/13.00

PRE-CONGRESS COURSE

"Hypothalamic amenorrhea and other menstrual cycle disorders" etiopathogenesis, physical, psychological and reproductive impacts.

From diagnosis to therapies: which, how long, how to follow up, what goals to achieve for healthy reproductive life and aging

Naftolin Frederick (US) The normal Hypothalamic-Pituitary Axis and downstream diseases

Genazzani Alessandro D. (IT) Restoration of neuroendocrine control and function: integrative and hormonal strategies

Brincat Mark (MT) Endometriosis and Menstrual Disorders

Schindler Adolf E. (DE) Progestogens in menstrual cycle disorders

HALL 9

09.00 - 13.00

PRE-CONGRESS COURSE

"Polycystic ovary syndrome" etiology, metabolic and fertility impact, subjective risk for reproductive and other organs diseases, therapeutic strategies from adolescence to late post-menopause

Tarlatzis Basil (GR) Diagnostic Criteria and phenotypes of PCOS

Milewicz Andrzej (PL) PCOS-Controversies- diagnosis and therapy

Devoto Luigi (CL) Induction of ovulation in polycystic ovary syndrome. Should be patient tailored?

Berga Sarah (US) Ontogeny, Pathogenesis, and Therapies

AUDITORIUM

15.00 - 17.00	OPENING SYMPOSIUM SPONSORED BY IBSA Progesterone: the pregnancy hormone CHAIRMANSHIP: SCARSELLI GIANFRANCO (IT) TARLATZIS BASIL (GR) Genazzani Andrea R. (IT) Progesterone and pregnancy: an overview De Geyter Christian (CH) A new form of luteal support: evidence from a randomised study Baker Valerie (US) Luteal phase support for IVF: results from a multi-center US study De Ziegler Dominique (FR) Progesterone and pregnancy, so far ...
17.30 - 18.10	OPENING CEREMONY Palumbo Giuseppe (IT), Brincat Mark (MT), Naftolin Frederick (US), Bouchard Philippe (FR), Maruo Takeshi (JP), Valensise Herbert (IT), Simoncini Tommaso (IT), Genazzani Andrea R. (IT)
18.10 - 19.00	OPENING LECTURE Lunenfeld Bruno (IL) Management of infertility: past, present and future
19.00 - 20.00	OPENING Concert and Aperitif Sponsored by Teva Lyrical concert in Hall Auditorium with arias by Mozart, Verdi, Puccini.

Thursday, March 8, 2012

THU MARCH 8TH

	AUDITORIUM	AFFARI 0	AFFARI 1
08.30-09.30	Oral Presentation OP1 Gynecological Endocrinology	Oral Presentation OP 3 Contraception	Oral Presentation OP4 PCOS
09.40-11.10	Sponsored Symposium Teva COCs: What is new in 2012?	Plenary Session Pain in gynecology	Plenary Session New paradigms in ER signaling
11.10-11.40	Visit to the Exhibition Area		
11.40-13.10	Sponsored Symposium Bayer A New Evidence-based Treatment Approach for Endometriosis	Plenary Session Menarche: the event after a long personal history	Plenary Session GnRH and gonadotrophins and cancer
13.10-15.10		Lunch Symposium Sponsored by Besins HRT - new benefits, new approaches, old concerns	Lunch Symposium Sponsored by Italfarmaco Local estriol gel in urogenital atrophy
15.10-15.40	Plenary Lecture Harman S Mitchell (US) Changes in CIMT in menopausal women during 4 years of estrogen or placebo treatment: preliminary, blinded results from the Kronos Early Estrogen Prevention Study (KEEPS)		
16.00-17.30	Plenary Session Infertility: an office-based approach	Scientific Society Symposium European Society of Obstetrics and Gynecology german-french language Endocrine and nonendocrine aspects of stem cells	Sponsored Symposium Bayer Oral Contraception and beyond
17.30-18.00			
19.30	Social Event - Concert Sponsored by Ibsa		

AFFARI 2	VERDE	ONICE
Oral Presentation OP9 Gynecological Oncology	Oral Presentation OP8 Pregnancy	Oral Presentation OP11 Infertility
Plenary Session Reconstructive surgery for reproductive health	Plenary Session Bone and Phospho-calcium metabolism	Oral Presentation OP13 Medically-Assisted Procreation
Plenary Session Ovarian surgery and fertility preservation	Plenary Session Obesity: menstrual and reproductive impact	Oral Presentation OP14 Menopause

Plenary Lecture Sponsored by HRA Pharma Arisi Emilio (IT) Ulipristal nella contraccezione d'emergenza: è tempo di cambiare!	Plenary Lecture Gustafsson Jan Ake (US) Estrogen receptors: their actions and functional roles in health and disease	
Italian Course (15.45 18.15) Sponsored by MSD Il management clinico della donna nell'ambulatorio del ginecologo dall'età fertile alla menopausa	Sponsored Symposium Estetra Estetrol in contraception	Oral Presentation Sociedad Argentina de Endocrinología Ginecológica y Reproductiva Aspectos relevantes en endocrinología ginecológica y reproductiva - Relevant subjects in endocrinology gynecological and reproductive
	ISGE General Assembly	
	FISGE General Assembly	



Symposia

Bayer Healthcare Pharmaceuticals

Bayer Healthcare Pharmaceuticals cordially invites you to our symposia:

A New Evidence-Based Treatment Approach for Endometriosis

Chaired by Felice Petraglia (Italy) & Jennifer Blake (Canada)

March 8, 2012 · 11:40 a.m. – 1:10 p.m. · Hall Auditorium

Oral Contraception and Beyond

Chaired by Ali Kubba (UK), Bo von Schoultz (Sweden)

March 8, 2012 · 4:00 p.m. – 5:30 p.m. · Hall Affari 1

New Evidence Supporting Treatment Choices for Menopause Management

Chaired by Fernand Labrie (Canada) & Tobie de Villiers (South Africa)

March 9, 2012 · 11:40 a.m. – 1:10 p.m. · Hall Affari 1

Innovative Solutions to Meet Women's Healthcare Needs (in Spanish)

Chaired by Carlos Petta (Brazil) & Nilson R. de Melo (Brazil)

March 9, 2012 · 3:40 p.m. – 6:10 p.m. · Hall Affari 0

Benefits and Risks of Hormonal Contraceptives

Chaired by Philip Smits (Germany)

March 10, 2012 · 10:10 a.m. – 11:10 a.m. · Hall Verde

Additional Benefits in Hormonal Contraception: New Evidence with E₂V/DNG

Chaired by Martin Birkhäuser (Switzerland)

March 10, 2012 · 1:10 p.m. – 3:10 p.m. · Hall Affari 1



15TH WORLD CONGRESS OF GYNECOLOGICAL ENDOCRINOLOGY
MARCH 7–10, 2012 · FLORENCE, ITALY

AUDITORIUM

08.30 - 09.30

ORAL PRESENTATION

OP1 Gynecological Endocrinology

CHAIRMANSHIP: FRUZZETTI FRANCA (IT) PRIMIERO FRANCESCO MARIA (IT)

Athanasopoulos Nikolaos (GR) The effect of leuprolide therapy in Body Mass Index, ovarian and uterine volume in girls with central precocious puberty

Ilovayskaya Irena (RU) Bone metabolism in women with hypogonadotropic hypogonadism

Dati Eleonora (IT) Bone mineral density (BMD) in women with complete Androgen Insensitivity Syndrome (cAIS).

Czyzyk Adam (PL) The atherogenic lipid profile and blood pressure in patients with Turner syndrome.

Ricchieri Federica (IT) Estimation of instantaneous secretory rates and intrinsic characteristics of luteinizing hormone (LH) secretion in Kallmann syndrome before and after estriol administration

Taavoni Simin (IR) Anthropometric parameters and metabolic profile in turner's syndrome patients in adult life: a case-series in a teaching hospital

Maenaka Takahide (JP) Evaluation of Turner Syndrome complications

09.40 - 11.10

SYMPOSIUM SPONSORED BY TEVA

COCs: What is new in 2012?

CHAIRMANSHIP: BENEDETTO CHIARA (IT) PINTIAUX AXELLE (BE)

Lidegaard Øjvind (DK) Risk of venous thrombosis in users of hormonal contraception.

Lete Inaki (ES) Interest of estradiol

Jamin Christian (FR) Estradiol monophasic pill: who is it for?

Fruzzetti Franca (IT) Estradiol monophasic pill: To bleed or not to bleed?

11.10 - 11.40

VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10

SYMPOSIUM SPONSORED BY BAYER

A New Evidence-based Treatment Approach for Endometriosis

CHAIRMANSHIP: BLAKE JENNIFER (CA) PETRAGLIA FELICE (IT)

Singh Sony (CA) The burden and management of endometriosis

Hornung Daniela (DE) Exploring endometriosis candidate biomarkers in a prospective study of 124 women undergoing laparoscopy

Tinneberg Hans-Rudolf (DE) Innovation in endometriosis treatment

Chern Bernard (SG) Clinical experience with dienogest

15.10 - 15.40

PLENARY LECTURE

CHAIRMANSHIP: ARNAL JEAN-FRANCOIS (FR) NAPPI CARMINE (IT)

Harman S Mitchell (US)

Changes in carotid artery intima media thickness (CIMT) in menopausal women during 4 years of estrogen or placebo treatment: preliminary, blinded results from the Kronos Early Estrogen Prevention Study (KEEPS)

16.00 - 17.30**PLENARY SESSION****Infertility: an office-based approach****CHAIRMANSHIP: MIJATOVIC VELJA (NL) PATRIZIO PASQUALE (US)****Ben Rafael Zion (IL)** Prevention of Ovarian Hyperstimulation**Gianaroli Luca (IT)** One Stop Clinic: a novel approach for infertile couples**Blockeel Christophe (BE)** Improving Live Birth Rates in IVF; Potential mechanisms of benefit of HCG driven LH activity**Messinis Ioannis (GR)** Novel aspects in the ovarian control of LH secretion**AFFARI 0****08.30 - 09.30****ORAL PRESENTATION****OP 3 Contraception****CHAIRMANSHIP: BRUNI VINCENZINA (IT) PAOLETTI ANNA MARIA (IT)****Elshayp Ali Farid (EG)** Conception effect of contraception**Mozzanega Bruno (IT)** Levonorgestrel-only Emergency Contraceptive Pills (LNG-ECPs): mechanism of action and official information.**Elshayp Ali Farid (EG)** Emergency contraception breaking topic (updated trend).**Silva Bruna (BR)** Effect of combined hormonal contraceptives on morphology of mouse lacrimal glands.**Mozzanega Bruno (IT)** Ulipristal Acetate: the mechanism of action.**Del Pup Lino (IT)** How to improve user satisfaction and continuation with the new hormonal contraceptive containing estradiol and norgestrel acetate**Elshayp Ali Farid (EG)** Micro RNAs and contraception**Grandi Giovanni (IT)** Lipid metabolism, insulin resistance, blood pressure and body composition with oral contraceptives containing estradiol valerate/dienogest vs ethinylestradiol/chlormadinone: a prospective, randomized trial**09.40 - 11.10****PLENARY SESSION****Pain in gynecology****CHAIRMANSHIP: FOIDART JEAN-MICHEL (BE) MESSINIS IOANNIS (GR)****Graziottin Alessandra (IT)** Dyspareunia and pelvic comorbidities: from epidemiology to pathophysiology**Pélissier-Langbort Clara (FR)** Mastodynia in 2012: why?**Mijatovic Velja (NL)** Adenomyosis in the infertility clinic**Vercellini Paolo (IT)** A commonsense approach to the medical management of symptomatic endometriosis**11.10 - 11.40****VISIT TO THE EXHIBITION AREA AND COFFEE BREAK**

11.40 - 13.10 PLENARY SESSION**Menarche: the event after a long personal history****CHAIRMANSHIP: BRINCAT MARK (MT) PÉLISSIER-LANGBORT CLARA (FR)****Rozenberg Serge (BE)** Do we have to change the proper age of menarche?**Sultan Charles (FR)** Early puberty in girls = a medical, psychological and social concern**Bruni Vincenzina (IT)** Eating disorders in adolescents: impact on menarche**Castelo-Branco Camil (ES)** The management of Turner's Syndrome in adult life**13.10 - 15.10 LUNCH SYMPOSIUM SPONSORED BY BESINS****HRT - new benefits, new approaches, old concerns****CHAIRMANSHIP: ARCHER DAVID (US) DE MELO NILSON R. (BR)****Prior Jerylinn C. (CA)** Thyroid Physiology and Progesterone Therapy? new data in a placebo-controlled hot flush trial**Archer David (US)** Estrogen, transdermal estradiol and skin effects**Söderqvist Gunnar (SE)** Percutaneous estradiol/oral micronized progesterone gives less adverse effects and different gene regulation than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo.**16.00 - 17.30 SYMPOSIUM BY SCIENTIFIC SOCIETY****Endocrine and nonendocrine aspects of stem cells - Organized by Europ. Soc. Gynecol Obstet. German-French Language****CHAIRMANSHIP: DRUCKMANN RENÉ (FR) SCHINDLER ADOLF E. (DE)****Zech Nicholas (AT)** The rationale behind collecting cord blood**Kuepker Wolfgang (DE)** The stem cell theory insight into potential pathways of endometriosis development**Bouquet de Joliniere Jean (FR)** Ectopic glands and embryonic ducts in female fetuses: is this a new basis of pathophysiology of endometriosis**Wyns Christine (BE)** Future of fertility preservation**Preisegger Karl-Heinz (AT)** Stem cell preservation for nuclear accidents**AFFARI 1****08.30 - 09.30 ORAL PRESENTATION****OP4 Pcos****CHAIRMANSHIP: ARDUINI DOMENICO (IT) PALOMBA STEFANO (IT)****Sabbadin Chiara (IT)** In vitro and in vivo effects of INOSITOL in patients with PCOS**Pellegrino Martina (IT)** Addition of Myo-inositol in the treatment of PCOS women with resistance to clomiphene: a prospective, observational, cross-over, pilot study .**Interdonato Maria Lieta (IT)** Myo-inositol may prevent metabolic and hypertensive disorders in PCOS pregnant women.**Mioni Roberto (IT)** Effects of metformin on anti-müllerian hormone concentrations in hyperinsulinemic women with polycystic ovary syndrome**Palomba Stefano (IT)** Systemic and local effects of metformin administration in patients with polycystic ovary syndrome (PCOS): relationship to the ovulatory response

van Trotsenburg Mick (NL) PCO and genderdysphoria

Lunger Fabian (AT) What is the best method for assessing insulin resistance in PCOS women: comparison of static and dynamic methods and SHBG

Di Florio Christian (IT) Is there a dose-response relationship of metformin treatment in patients with polycystic ovary syndrome? Results from a multicentric study.

Gagliano Donatella (IT) Metformin effects on ovarian ultrasound appearance and steroidogenic function in normal-weight normoinsulinemic women with polycystic ovary syndrome: a randomized double-blind placebo-controlled clinical trial.

09.40 - 11.10

PLENARY SESSION

New paradigms in ER signaling

CHAIRMANSHIP: HUHTANIEMI ILPO (GB) NAFTOLIN FREDERICK (US)

Simoncini Tommaso (IT) Unconventional signaling of estrogen to cancer progression

Korach Kenneth (US) Differential Cellular Roles of Estrogen Receptor Signaling and Responses in the Female Reproductive Tract

Arnal Jean-Francois (FR) From in vivo gene targeting of Estrogen Receptors to Optimisation of their Modulation in Menopause

Söderqvist Gunnar (SE) HRT with percutaneous Estradiol/oral micronized Progesterone regulates the expression of Estrogen receptor genes differently from oral CEE/ MPA in normal breast tissue.

11.10 - 11.40

VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10

PLENARY SESSION

GnRH and gonadotrophins and cancer

CHAIRMANSHIP: LUNENFELD BRUNO (IL) SCHINDLER ADOLF E. (DE)

Huhtaniemi Ilpo (GB) Gonadotrophins and cancer

Leung Peter (CA) GnRH-II and Ovarian Cancer

Naftolin Frederick (US) Ovarian Epithelial cancer is a primary disease of the ovary marked by over-expression of Ezrin

13.10 - 15.10

LUNCH SYMPOSIUM SPONSORED BY ITALFARMACO

Local estriol gel in urogenital atrophy

CHAIRMANSHIP: NAPPI ROSSELLA E. (IT)

Parazzini Fabio (IT) Prevalence of urogenital symptoms in postmenopausal women

Salvatore Stefano (IT) Urogenital effects of estrogen therapies

Cano Antonio (ES) Clinical data on the use of a formulation of estriol gel in postmenopausal women

16.00 - 17.30

SYMPOSIUM SPONSORED BY BAYER

Oral Contraception and Beyond

CHAIRMANSHIP: KUBBA ALI (GB) VON SCHOULTZ BO (SE)

Panay Nicholas (GB) YAZ: a breakthrough in real-life contraceptive effectiveness

Koren Gideon (CA) Oral contraception and folate: changing "preconceptions"

Primiero Francesco Maria (IT) Oral contraception and period postponement: embracing new attitudes

AFFARI 2

08.30 - 09.30

ORAL PRESENTATION

OP9 Gynecological Oncology

CHAIRMANSHIP: ANGIOLI ROBERTO (IT) SCIARRA JOHN (US)

Capodicasa Valentina (IT) A screening program for endometrial cancer in a asymptomatic postmenopausal population in our city: preliminary data

Ravn Pernille (DK) The prevalence of endometrial hyperplasia and endometrial cancer in Danish women with PCOS or hyperandrogenism.

Bogani Giorgio (IT) Does obesity influence disease characteristics and survival in endometrial cancer patients?

Laurelli Giuseppe (IT) Conservative treatment of early endometrial cancer (EC)

Marra Chiara (IT) Treatment of simple and complex endometrial hyperplasia without atypia with natural progesterone: response rate to different dose.

Aminsharifi Alireza (IR) Preventive role of exogenous testosterone on cisplatin-induced gonadal toxicity: an experimental placebo-controlled prospective trial

Balsat Cédric (BE) Whole slide characterization of lymphatic vasculature through cervical cancer progression: assessment of parameters with potential impact on tumoral dissemination

09.40 - 11.10

PLENARY SESSION

Reconstructive surgery for reproductive health

CHAIRMANSHIP: DONNEZ JACQUES (BE) KOENINCKX PHILIPPE (BE)

Fedele Luigi (IT) Mini-invasive approaches for the conservative treatment of cervico-vaginal atresia

Adamyan Leila V. (RU) The scope of reproductive functions from the view of genital malformations

Sciarra John (US) Alternatives to Hysterectomy

11.10 - 11.40

VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10

PLENARY SESSION

Ovarian surgery and fertility preservation

CHAIRMANSHIP: ADAMYAN LEILA V. (RU) BACCHI MODENA ALBERTO (IT)

Koeninckx Philippe (BE) How can we reconcile radicality of surgery with functions preservation in endometriosis

Cela Vito (IT) Robotic surgery of ovarian tissue preservation

Donnez Jacques (BE) Fertility preservation: is ovarian tissue cryopreservation and reimplantation the best option?

Mettler Liselotte (DE) Criteria for endoscopic ovarian fertility preserving surgery

15.10 - 15.40

PLENARY LECTURE SPONSORED BY HRA PHARMA

CHAIRMANSHIP: BENEDETTO CHIARA (IT)

Arisi Emilio (IT)

Ulipristal nella contraccezione d'emergenza: è tempo di cambiare!

THU MARCH 8TH

15.40 - 18.10

ITALIAN COURSE ORGANIZED BY MSD

Il management clinico della donna nell'ambulatorio del ginecologo dall'età fertile alla menopausa

CHAIRMANSHIP: BENEDETTO CHIARA (IT) NAPPI ROSSELLA E. (IT)

Nappi Rossella E. (IT) Introduzione: L'evoluzione della donna dall'età Fertile alla Menopausa

Primiero Francesco Maria (IT) Contraccezione in Libertà quali i benefici della contraccezione non orale.

Lello Stefano (IT) Trattamento dei sintomi della Menopausa: Solievo per il corpo, rassicurazione per la mente

Alvigi Carlo (IT) Patient Friendly IVF: pro-cons

Benedetto Chiara (IT) Conclusioni

VERDE

08.30 - 09.30

ORAL PRESENTATION

OP8 Pregnancy

CHAIRMANSHIP: LUCHI CARLO (IT) VALENSISE HERBERT (IT)

Vanya Melinda (HU) Maternal and neonatal outcomes in women with multiple sclerosis exposed to disease-modifying drugs

Lorquet Sophie (BE) Soluble receptors of VEGF and preeclampsia

Luchi Carlo (IT) TThe 9 Weeks Scan: fetal anatomy at 9 weeks of gestation

Serafini Audrey Silvia (IT) Obstetric outcomes in donor oocyte twin pregnancies: a comparison with ART and spontaneous pregnancies.

Becker Caroline (BR) Detection of normal values of complement factor h in plasma of pregnancies up to 20 weeks

Kakrani Divya (IN) Fetal sacral length measurement as a new parameter for assessment of mean gestational age (MGA) and its comparison with other parameters like abdominal circumference (AC), femur length (FL), biparietal diameter (BPD), head circumference (HC)

09.40 - 11.10

PLENARY SESSION

Bone and Phospo-calcium metabolism

CHAIRMANSHIP: BEN RAFAEL ZION (IL) ROZENBERG SERGE (BE)

Brincat Mark (MT) Cartilage and muscle in the Menopause Transition

Hadji Peyman (DE) Treatment options for women with postmenopausal osteoporosis

Smetnik Vera (RU), Burduli A. (RU) Androgens and bone in patients with amenorrhea

11.10 - 11.40

VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10	PLENARY SESSION
	<p>Obesity: menstrual and reproductive impact</p> <p>CHAIRMANSHIP: SISELES NESTOR (AR) VUJOVIC SVETLANA (RS)</p> <p>Berga Sarah (US) Stress, Rank, and Obesity: Understanding the Reproductive Consequences of Obesity</p> <p>Hirschberg Angelica L (SE) Endometrial factors and reproductive function in women with polycystic ovary syndrome</p> <p>Milewicz Andrzej (PL) 1) PCOS-Controversies-diagnosis and therapy OR - 2) - Metabolic disorders in women over 60 yrs old and serum vitD and its receptor gene polymorphisms POLSENIOR study</p> <p>Bevilacqua Maurizio (IT) Cellulite Pathophysiology</p>
15.10 - 15.40	PLENARY LECTURE
	<p>CHAIRMANSHIP: KORACH KENNETH (US) SISMONDI PIERO (IT)</p> <p>Gustafsson Jan Ake (US)</p> <p>Estrogen receptors: their actions and roles in health and disease</p>
16.00 - 17.30	SYMPOSIUM SPONSORED BY ESTETRA
	<p>Estetrol in contraception</p> <p>CHAIRMANSHIP: COELINGH BENNINK HERJAN J.T. (NL) GENAZZANI ANDREA R. (IT)</p> <p>Foidart Jean-Michel (BE) Ovulation inhibition and safety of various combinations of Estetrol (E4) plus Drospirenone (DRSP) or Levonorgestrel (LNG)</p> <p>Bouchard Philippe (FR) Estetrol, a unique Fetal Human Estrogen</p> <p>Cornelis Kluft (NL) Impact of oral contraceptives containing Estetrol on haemostasis</p>
17.30 - 18.00	ISGE GENERAL ASSEMBLY
18.10 - 18.30	FISGE GENERAL ASSEMBLY

ONICE

08.30 - 09.30	ORAL PRESENTATION
	<p>OP11 Infertility</p> <p>CHAIRMANSHIP: GENAZZANI ALESSANDRO D (I) GOPAL SANTHOSH (IN)</p> <p>Irina Enachescu (RO) Role of doppler velocimetry in infertility treatment</p> <p>Grigore Mihaela (RO) 2D versus 3D ultrasound assessment for infertility evaluation on the 3rd day of the cycle</p> <p>Niu Zhihong (CN) The choice of endometrial preparation protocols in frozen-thawed embryo transfer cycles for the patients with endomyosis</p> <p>Mayer Richard (AT) The role of endometrial- and subendometrial vascularisation parameters and endometrial volume in the prediction of clinical pregnancy measured 30 minutes prior to frozen embryo transfer</p> <p>Salehpour Saghar (IR) N-acetyl-cysteine as an adjuvant to clomiphene citrate for successful induction of ovulation in infertile patients with polycystic ovary syndrome</p> <p>Rocca Morena (IT) Metformin and gonadotropins for in vitro fertilization treatment in polycystic ovary syndrome patients with reduced ovarian reserve</p> <p>Grande Giuseppe (IT) Seminal plasma proteomics for the identification of novel fertility markers</p> <p>Barcena de Arellano Maria Luisa (DE) The role of calcium-binding proteins in endometriosis-associated innervation</p>

09.40 - 11.10

ORAL PRESENTATION

OP13 Medically-Assisted Procreation**CHAIRMANSHIP: CELA VITO (IT) TOLINO ACHILLE (IT)**

Morewood Tom (GB) Ovarian tissue cryopreservation – maximising post-thaw tissue conservation and functionality

Carlomagno Gianfranco (IT) Myo-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: Randomized controlled trial

Dehghankhalili Maryam (IR) Effect of Piroxicam Administration on pregnancy rate in intrauterine insemination (IUI) cycles: a randomized clinical trial

Zeng Xing (CA) Follicular synchronization using transdermal estradiol patch and GnRH antagonists in the luteal phase; does it increase oocyte yield in poor responders to gonadotropin stimulation for in vitro fertilization (IVF)? A comparative study with microdose flare-up protocol

Ruggiero Maria (IT) Impact of different controlled ovarian hyperstimulation protocols on transcriptome profile of human cumulus cells.

Mintziori Gesthimani (GR) Thyroid function during assisted reproductive technology (ART) procedures

Al-Inany Hesham (EG) Pharmacoeconomics for Progesterone in Luteal Phase Support: a systematic review of different types and modes of administration

Chausiaux Oriane (GB) Luteal phase variability in the infertile woman

Di Luigi Gianluca (IT) Induction of ovulation and ovarian cancer in female mice

Imhof Martin (AT) Micronutrient supplementation improves sperm quality a controlled study

11.40 - 13.10

ORAL PRESENTATION

OP14 Menopause**CHAIRMANSHIP: LELLO STEFANO (IT) NOCI IVO (IT)**

Syed Abdul Rahman Syed Alwi (MY) Menopausal symptoms and Quality of Life among indigenous menopausal women of Borneo Island.

Taavoni Simin (IR) Effect of valerian on uncomfortable breathing, coughing and snoring during usual sleep habit in menopausal women: a randomized placebo- controlled clinical trial

Pogorelova Anna (RU) Effects of Estradiol + Drospirenone on sexual function in postmenopausal women with type 2 diabetes mellitus

Taavoni Simin (IR) Effect of Ginkgo Biloba on menopausal women's sexual function: a randomized placebo controlled trial, Tehran, 2011

Zelenina Tatiana (RU) Effect of estrogen therapy on cardiac autonomic neuropathy in diabetic postmenopausal women

Santamaria Angelo (IT) One-year effects of myo-inositol supplementation in postmenopausal women with metabolic syndrome: a prospective, randomized placebo-controlled study

Yureneva Svetlana (RU) Modulatory effect of farnesyl pyrophosphate synthase (FDPS) rs2297480 polymorphism on the response to long-term amino-bisphosphonate treatment in postmenopausal osteoporosis

Darabi Amin Maryam (IR) Effect of estrogen receptor β A1730G polymorphism on oxidized LDL/ β 2-glycoprotein I complexes response to postmenopausal HRT

Toshihiko Kinoshita (JP) Sex steroid levels in adipose tissue and serum in women

Palomba Stefano (IT) Six weeks of structured exercise training and hypocaloric diet increases the probability of ovulation after clomiphene citrate in overweight and obese patients with polycystic ovary syndrome: a randomized controlled trial

16.00 - 17.30

SYMPOSIUM BY SCIENTIFIC SOCIETY

Aspectos relevantes en endocrinología ginecológica y reproductiva - Relevant subjects in endocrinology gynecological and reproductive - Organized by Sociedad Argentina de Endocrinología Ginecológica y Reproductiva (SAEGRE)

CHAIRMANSHIP: SISELES NESTOR (AR)

Moses Nora (AR) Utility of Metphormine in reproductive desire and women with recurring abortions - Utilidad de la Metformina en deseo reproductivo y en mujeres abortadoras recurrentes

Nölting Manuel (AR) Ovarian Protection with GnRh -a during chemotherapy. - Protección Ovárica GnRh en pacientes con indicación de quimioterapia.

Firpo Claudia Graciela (AR) Thyroid malfunction and pregnancy: motherly and fetal aspects - Disfunción tiroidea y embarazo: aspectos maternos y fetales

Monastero Adriana (AR) Prolactin´s immunomodulating role in Stress and Tumoral pathology - Rol inmunomodulador de la Prolactina en el Stress y patología Tumoral

THU MARCH 8TH

Friday, March 9th

FRI MARCH 9TH

	AUDITORIUM	AFFARI 0	AFFARI 1
08.30-09.30	Scientific Society Symposium Mediterranean Society for Reproductive Medicine Up-date on ovarian stimulation	Scientific Society Symposium Asociación Latinoamericana de Endocrinología Gynecologica Health concern in latin-american countries	Scientific Society Symposium Association Française pour l'Etude de la Ménopause Life events, life style and quality of life
09.40-11.10	Plenary Session The oocyte: insight from basic research	Plenary Session Climacteric symptoms: markers of vulnerability?	Plenary Session Progesterone receptor: the next target for gynecological disorders
11.10-11.40	Visit to the Exhibition Area		
11.40-13.10	Plenary Session Adaptive disorders and gynecological endocrinology	Plenary Session Polycystic ovary syndrome	Sponsored Symposium Bayer New evidence supporting treatment choices for menopause management
13.10-15.10		Lunch Symposium Progestins in obstetrical and gynaecological therapies	Lunch Symposium Sponsored by Ibsa Human derived FSH: new evidences for old understandings
15.10-15.40	Plenary Lecture Sponsored by Novo Nordisk Nappi Rossella E. (IT) Vaginal health: a woman's right!		
16.00-17.30	Sponsored Symposium Merck Serono How To Improve Take Home Baby Rate	SPANISH COURSE 15.40 Sponsored by Bayer Soluciones Innovadoras en Salud Femenina	Plenary Session Adolescent gynecology and endocrinology
17.30-19.30	Poster Session		
19.30	Social Event - Concert Sponsored by Ibsa		

AFFARI 2	VERDE	ONICE	HALL 9
Scientific Soc. Symposium Federazione Italiana di Sessuologia Scientifica Approccio integrato nell'anorgasmia femminile	Scientific Soc. Symposium RCHA Gynecological and obstetric management of females with hereditary angioedema: a disease which can kill women with estrogens...	Scientific Soc. Symposium Sociedade Brasileira de Ginecologia Endócrina SOBRAGE symposium on health benefits of menstrual suppression	Oral Presentation OP12 Medically-Assisted Procreation
Italian Course (9.45-13.15) Sponsored by TEVA Evoluzione degli Estroprogestinici: dalla farmacologia alla scelta ragionata	Sponsored Symposium Italfarmaco Inositol: Clinical Experiences	Scientific Soc. Symposium Polish Group of Gynecological Endocrinology Contemporary Gynecological Endocrinology	Oral Presentation OP16 Endometrium and endometriosis
	Plenary Session Hormonal regulation of normal or restricted fetal growth	Scientific Soc. Symposium German Endometriosis Society - Deep infiltrating Endometriosis (DIE): Surgical and Medical Management	Oral Presentation OP19 Gynecology

Plenary Lecture Baldaro Verde Jole (IT) L'età conquistata è davvero una conquista per la donna?	Plenary Lecture Lobo Roger (US) Variation in menstrual function as a predictor of metabolic and cardiovascular risks in women		
Italian Course (14.40-18.20) Organized by AIGE Endometriosis: i problemi complessi, i casi difficili	Plenary Session Frontiers in Gynecological Endocrinology	Sponsored Symposium Bionorica Phytomedicine in Gynecological Endocrinology: New Perspectives	Oral Presentation OP17 Pelvic Floor
	FISGE General Assembly		

AUDITORIUM

08.30 - 09.30

SYMPOSIUM BY SCIENTIFIC SOCIETY

Up-date on ovarian stimulation - Organized by **SOCIETY FOR REPRODUCTIVE MEDICINE (MSRM)**
CHAIRMANSHIP: MOTRENKO SIMIC TATJANA (RS)

Messinis Ioannis (GR) The role of LH in ovarian stimulation

Makrigiannakis Antonis (GR) Ovarian stimulation in poor responders

Inaudi Pieraldo (IT) Ovarian stimulation in PCOS: improve the quality while lowering the risks

Manna Claudio (IT) Meiotic spindle presence in ART oocytes after ovarian stimulation with rFSH-LH, rFSH and HMG

09.40 - 11.10

PLENARY SESSION

The oocyte: insight from basic research

CHAIRMANSHIP: INAUDI PIERALDO (IT) TARLATZIS BASIL (GR)

Patrizio Pasquale (US) Improving IVF efficiency by interpreting the genetic dialogue of oocytes and cumulus cells

Picton Helen (GB) Insights into oocytes: molecular and cellular markers of oocyte quality in health and infertility

Eichenlaub-Ritter Ursula (DE) Insights from proteome, epigenome and redox analysis to assess oocyte quality

Hourvitz Ariel (IL) Molecular characterization of the human ovulatory cascade? Lesson from the IVF/IVM model

11.10 - 11.40

VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10

PLENARY SESSION

Adaptive disorders and gynecological endocrinology

CHAIRMANSHIP: MAKI PAULINE (US) SWAAB DICK (NL)

Matsumoto Tamaki (JP) Premenstrual syndrome and autonomic nervous system activity: does heart rate variability serve as an index of mind-body interaction?

Nappi Rossella E. (IT) Estrogen withdrawal headache: a very common entity in gynecological practice.

Studd John (GB) Bipolar disorder or PMDD

Lambrinoudaki Irene (GR) Personality traits and postmenopausal health

15.10 - 15.40

PLENARY LECTURE SPONSORED BY NOVO NORDISK

CHAIRMANSHIP: PANAY NICHOLAS (GB) POLATTI FRANCO (IT)

Nappi Rossella E. (IT)

Vaginal health: a woman's right!

16.00 - 17.30 SYMPOSIUM SPONSORED BY MERCK SERONO

How To Improve Take Home Baby Rate

CHAIRMANSHIP: FILICORI MARCO (IT) PATRIZIO PASQUALE (US)

La Marca Antonio (IT) Personalized treatment regimen to improve oocytes recruitment

Guglielmino Antonio (IT) New opportunities in oocytes evaluation

Ruvolo Gianni (IT) Treatment of patient with high sperm DNA fragmentation levels

Revelli Alberto (IT) How to surely improve the "take home healthy baby rate" in IVF: avoid multiple pregnancies

17.30 - 19.30 POSTER - Poster Session and Tuscan Delights in the Exhibition Area

AFFARI O

08.30 - 09.30 SYMPOSIUM BY SCIENTIFIC SOCIETY

ALEG Symposium: Health concern in latin-american countries - Organized by ALEG

CHAIRMANSHIP: MONTANO RENE (CL)

Lima Selva (UY) Cardiovascular disease in climacteric (actually American)

de la Parra de Abadie Carmen Ines (AR) Obesity, epidemic in developing countries

Manzur Alejandro (CL) Reproductive consequences of obesity

Espinoza Teresa (BO) Osteoporosis in latinoamerican countries

09.40 - 11.10 PLENARY SESSION

Climacteric symptoms: markers of vulnerability?

CHAIRMANSHIP: SMETNIK VERA (RU) VON SCHOULTZ BO (SE)

Gambacciani Marco (IT) Vasomotor symptoms as markers of cardiovascular vulnerability

Rocca Walter (US) Long-term consequences of early bilateral oophorectomy

Palacios Santiago (ES) Vasomotor symptoms, depression and SNRIs

Duru Sushil Shah (IN) Premature Ovarian Failure- Dilemmas and decisions

11.10 - 11.40 VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10 PLENARY SESSION

Polycystic ovary syndrome

CHAIRMANSHIP: EICHENLAUB-RITTER URSULA (DE) PICTON HELEN (GB)

Genazzani Alessandro D. (IT) Neuroendocrine and endocrine dysfunctions in hyperinsulinemic PCOS patient: the role of metformin

Ibañez Lourdes (ES) Adolescent PCOS: update on treatment

Devoto Luigi (CL) Gluco-transporters expression in human endometrium from normal and polycystic ovary syndrome women

Tarlatzis Basil (GR) Long term health risks in women with PCOS

13.10 - 15.10**LUNCH SYMPOSIUM****Progestins in obstetrical and gynaecological therapies****CHAIRMANSHIP: DAYA SALIM (CA) REES MARGARET (GB)**

Szekeres-Bartho Julia (HU) Dydrogesterone supplementation in threatened abortion and threatened preterm delivery

van de Weijer Peter (NL) Distinctive features of progestogens in treatment of dysfunctional uterine bleeding

Stevenson John (GB) Metabolic impact of dydrogesterone in HRT

15.40 - 18.10**SPANISH COURSE SPONSORIZED BY BAYER****Soluciones Innovadoras en Salud Femenina****CHAIRMANSHIP: DE MELO NILSON R. (BR) PETTA CARLOS (BR)**

Martin Ricardo (CO) Es necesario un nuevo tratamiento para la Endometriosis?

Auge Luis M (AR) Visanne, un tratamiento específico para Endometriosis

Acuña Juan Manuel (CO) AO con Folato: una nueva era en preconcepción

Calaf Joaquin (ES) Nueva evidencia con Qlaira

Aldrighi Jose (BR) Drospirenona: una progestina única para la menopausia

AFFARI 1**08.30 - 09.30****SYMPOSIUM BY SCIENTIFIC SOCIETY****Life events, life style and quality of life - Organized by AFEM****CHAIRMANSHIP: LACHOWSKY MICHELE (FR)**

Hassoun Danielle (FR) Failures of contraception: women at risk or women in risky situation?

Marie Scemama Lydia (FR) Menopause & Life style: way of life (alcohol, smoking, lack of physical activity..)

Lachowsky Michele (FR) Gynecological cancers & sexuality, the role of the partner

09.40 - 11.10**PLENARY SESSION****Progesterone receptor: the next target for gynecological disorders****CHAIRMANSHIP: BRINTON DIAZ ROBERTA (US) DEVOTO LUIGI (CL)**

Schindler Adolf E. (DE) Progestogen receptor and pregnancy

Sitruk Ware Regine (US) Progestins and myelin repair

Pluchino Nicola (IT) Progesterone and Progestins role during brain development and senescence

Ruan Xiangyan (CN) Breast cancer and progestogens? Could certain cell components predict the risk?

11.10 - 11.40**VISIT TO THE EXHIBITION AREA AND COFFEE BREAK**

11.40 - 13.10

SYMPOSIUM SPONSORED BY BAYER

New evidence supporting treatment choices for menopause management

CHAIRMANSHIP: DE VILLIERS TOBIAS (ZA) LABRIE FERNAND (CA)

Simoncini Tommaso (IT) New concepts in Menopause management for the treatment of Vulvo-Vaginal Atrophy

Archer David (US) Clinical evidence for the efficacy of intravaginal DHEA for the treatment of Vulvo-Vaginal Atrophy

Gambacciani Marco (IT) The unique profile of Angeliq in Menopause Management

Collins Peter (GB) Latest evidence in Menopause Management on cardiovascular outcomes and their implication for clinical practice

13.10 - 15.10

LUNCH SYMPOSIUM SPONSORED BY IBSA

Human derived FSH: new evidences for old understandings

CHAIRMANSHIP: LOCKWOOD GILLIAN (GB) LUNENFELD BRUNO (IL)

Van Wely Madelon (NL) Past and present meta-analysis comparing recombinant and human derived FSH

La Marca Antonio (IT) Fostimon in GnRH-Agonist cycles: a retrospective analysis

Kemeter Peter (AT) Role of FSH glycosylation in GnRH-Antagonist cycles: results from a prospective pilot study

16.00 - 17.30

PLENARY SESSION

Adolescent gynecology and endocrinology

CHAIRMANSHIP: IBAÑEZ LOURDES (ES) SULTAN CHARLES (FR)

Meczekalski Blazej (PL) Hypothalamic amenorrhea as neuroendocrinological and metabolic disorder

Deligeoroglou Efthimios (GR) Meeting the needs of adolescents with endometriosis

Chedraui Peter (EC) Adolescent pregnancy and its impact over maternal and perinatal outcome

Maclaran Kate (GB) Presentation and management of POF: Findings from the West London POF database

AFFARI 2

08.30 - 09.30

SYMPOSIUM BY SCIENTIFIC SOCIETY

Approccio integrato nell'anorgasmia femminile - Organized by FISS

CHAIRMANSHIP: BERNORIO ROBERTO (I) BRUNI VINCENZINA (IT)

Nappi Rossella E. (IT) Neurofisiologia dell'orgasmo e classificazione

Ricottilli Francesco (IT) Diagnostica neurologica con "genito sensory analyzer"

Rossi Roberta (IT) Diagnostic algorithms and psychosexual integration

09.40 - 13.10

ITALIAN COURSE

Evoluzione degli Estroprogestinici: dalla farmacologia alla scelta ragionata - Organized by TEVA

CHAIRMANSHIP: VOLPE ANNIBALE (IT) DE SETA FRANCESCO (IT)

Lello Stefano (IT) Evoluzione degli Estroprogestinici

Bruni Vincenzina (IT) Criteri di scelta

Paoletti Anna (IT) E2-Nomac: profilo clinico

15.10 - 15.40	PLENARY LECTURE CHAIRMANSHIP: BONCINELLI VIERI (IT) VOLPE ANNIBALE (IT) Baldaro Verde Jole (IT) L'età conquistata è davvero una conquista per la donna?
15.40 - 18.10	ITALIAN COURSE ORGANIZED BY AIGE Endometriosis: i problemi complessi, i casi difficili CHAIRMANSHIP: FEDELE LUIGI (IT) MASTRANTONIO PASQUALE (IT) Vercellini Paolo (IT) Outcome del trattamento chirurgico per infertilità associata ad endometriosi Luisi Stefano (IT) Terapia medica nel dolore pelvico da Endometriosi Cela Vito (IT) Trattamento chirurgico dell'endometriosi profonda

VERDE

08.30 - 09.30	SYMPOSIUM BY SCIENTIFIC SOCIETY Gynecological and obstetric management of females with hereditary angioedema: a disease which can kill women with estrogens... - Organized by Reference Centre of Hereditary Angioedema CHAIRMANSHIP: GOMPEL ANNE (FR) Bouillet Laurence (FR) What are hereditary angioedemas? Taquet Marie-Caroline (FR) Outcome and management of pregnancy in women with Hereditary Angioedema Gompel Anne (FR) Contraception in women with HAE
09.40 - 11.10	SYMPOSIUM SPONSORED BY ITALFARMACO E LO.LI PHARMA Inositol: Clinical Experiences CHAIRMANSHIP: FACCHINETTI FABIO (IT) GIANAROLI LUCA (IT) D'Anna Rosario (IT) Myo-inositol and menopause Bevilacqua Arturo (IT) Myo-inositol and embryo quality Calogero Aldo E. (IT) Myo-inositol and sperm quality Montanino Oliva Mario (IT) Myo-inositol and in-vitro fertilization (IVF) Facchinetti Fabio (IT) Myo-inositol plus D-chiro-inositol: a rationale for the combined therapy
11.10 - 11.40	VISIT TO THE EXHIBITION AREA AND COFFEE BREAK
11.40 - 13.10	PLENARY SESSION Hormonal regulation of normal or restricted fetal growth CHAIRMANSHIP: CARP HOWARD (IL) SZEKERES-BARTHO JULIA (HU) Genazzani Andrea R. (IT) Endothelial dysfunction and the NO system: relevance for intrauterine growth restriction Foidart Jean-Michel (BE) Early diagnosis of pre-eclampsia in the first trimester of pregnancy and beyond Lyall Fiona (GB) The origins of pre-eclampsia and fetal growth restriction: the placental bed and beyond. Westwood Melissa (GB) Maternal growth factor regulation of fetal growth

15.10 - 15.40	Plenary Lecture CHAIRMANSHIP: GUASCHINO SECONDO (IT) LAMBRINOUDAKI IRENE (GR) Lobo Roger (US) Variations in menstrual function as a predictor of metabolic and cardiovascular risks in women
16.00 - 17.30	Plenary Session Frontiers in Gynecological Endocrinology CHAIRMANSHIP: LEUNG PETER C.K. (CA) MELIS GIAN BENEDETTO (IT) Zullo Fulvio (IT) Letrozole vs. clomiphene citrate plus IUI for women recently surgically treated for severe or recurrent endometriosis: a randomized controlled trial. Donnez Jacques (BE) Detailed analysis of Menstrual Bleeding during Treatment of Uterine Fibroids (UF) with the Selective Progesterone Receptor Modulator Esmya (ulipristal acetate) Barlow David H. (GB) Pre-Operative Treatment with Esmya Improves Haematological Conditions in Anaemic Patients with Uterine Fibroids Miller Virginia (US) Genetic polymorphisms associated with subclinical atherosclerosis in women of the Kronos Early Estrogen Prevention Study
ONICE	
08.30 - 09.30	SYMPOSIUM BY SCIENTIFIC SOCIETY SOBRAGE symposium on health benefits of menstrual suppression - Organized by Brazilian Society Of Gynecological Endocrinology CHAIRMANSHIP: MAIA JR. HUGO (BR) Maia Jr. Hugo (BR) Progesterone withdrawal and the activation of inflammation in the endometrium Bonassi Machado Rogerio (BR) Clinical trials with extended regimens of oral contraceptives in Brazil Magalhaes J. Pedro (BR) Clinical experience with the use of Mirena in the treatment of menorrhagia and dysmenorrhea
09.40 - 11.10	SYMPOSIUM BY SCIENTIFIC SOCIETY Contemporary Gynecological Endocrinology - Organized by Polish Group Of Gynecological Endocrinology CHAIRMANSHIP: MECZEKALSKI BLAZEJ (PL) Czajkowski Krzysztof (PL) Endocrinology of early pregnancy Jedrzejczak Piotr (PL) Will male factor dominate partners' infertility? Smolarczyk Roman (PL) Hyperthyroidism and hypothyroidism in pregnant women Szpirek Dariusz (PL) Hormone-secreting ovarian tumors - the way of diagnosis and management Meczekalski Blazej (PL) Endocrine disorders associated with glucose intolerance and reproductive disorders
11.10 - 11.40	VISIT TO THE EXHIBITION AREA AND COFFEE BREAK

11.40 - 13.10

SYMPOSIUM BY SCIENTIFIC SOCIETY

Deep infiltrating Endometriosis (DIE): Surgical and Medical Management - Organized by German Endometriosis Society

CHAIRMANSHIP: KIESEL LUDWIG (DE) SCHWEPPE KARL WERNER (DE)

Kiesel Ludwig (DE) Pathogenesis and Diagnosis of Deep Infiltrating Endometriosis (DIE)

Schweppe Karl Werner (DE) Surgical management of deep infiltrating endometriosis(DIE)?

Schindler Adolf E. (DE) Medical options and post-operative treatment

Buehler Klaus (DE) Deep infiltrating Endometriosis and infertility

16.00 - 17.30

SYMPOSIUM SPONSORED BY BIONORICA

Phytomedicine in Gynecological Endocrinology: New Perspectives

CHAIRMANSHIP: RAUS KAREL (CZ) WUTTKE WOLFGANG (DE)

Seidlova-Wuttke Dana (DE) New horizons for treating postmenopausal diseases with Black cohosh

Wuttke Wolfgang (DE) Plant derived alternatives for hormone replacement therapy (HRT)

Raus Karel (CZ) Critical review of the use of vitex agnus castus and other phytomedicines in gynecology

Popp Michael A. (DE) "Phytoneering" - the decisive factors in research and production of highly effective and safe phyto-medicines

HALL 9

08.30 - 09.30

Oral Presentation

OP12 Medically-Assisted Procreation

CHAIRMANSHIP: HOURVITZ ARIEL (IL) PLUCHINO NICOLA (IT)

Lockwood Gillian (GB) A new rival for AMH? Circulating LH/hCG receptor may identify pre-treatment IVF patients at risk of Ovarian Hyperstimulation Syndrome (OHSS) and poor implantation

Azem Foad (IL) Can dopamine agonist cabergoline reduce ovarian hyperstimulation syndrome in art treatment cycles? A prospective randomized study

Li Hang Wun Raymond (HK) Role of baseline anti-Müllerian hormone level in the stimulation cycle of in-vitro fertilisation treatment in predicting outcome of subsequent frozen embryo transfers

Henry Laurie (BE) Does vascular endothelial growth factor improve ovarian tissue recovery after cryopreservation?

Bildircin Fatma Devran (TR) The efficacy of 5-Hydroxytryptophan administration on oocyte quality

Santonocito Manuela (IT) TAp73 is down regulated in oocytes from women of advanced reproductive age

Inaudi Pieraldo (IT) How to improve the quality of the embryo transfer procedure

OP16 Endometrium and endometriosis**CHAIRMANSHIP: ANGIONI STEFANO (IT) COLACURCI NICOLA (IT)**

Bouquet De Joliniere Jean (CH) Identification of displaced endometrial glands and embryonic duct remnants in female foetal reproductive tract: possible pathogenetic role in endometriotic and pelvic neoplastic processes

Schneider Cornelia (DE) Inhibition of the expression of Syndecan-1 by the microRNA miR-10b leads to decreased invasiveness and proliferation of human endometriosis cells

Maia Jr. Hugo (BR) Nuclear factor kappa B (NF-kappa B) expression in the endometrium of the normal and pathological uterus

Szubert Maria (PL) Biomarkers of angiogenesis and inflammatory response in peritoneal fluid of women with endometriosis.

Elshayp Ali Farid (EG) Effect of Nano Gold on mitochondrial biomarkers in endometriosis

Greaves Erin (GB) The impact of ER β signaling in pelvic endometriosis

Muscat Baron Yves (MT) Gastro-intestinal symptoms and dietary intolerance in women with endometriosis

Scillitani Giuseppina (IT) Inflammatory pathway in eutopic endometrium of women with endometriosis

Thangaraju Shyam (IN) Implantation failure in endometriosis is mediated by estrogen dependent activation of COX-2

Barcena de Arellano Maria Luisa (DE) Peritoneal endometriotic lesions promote neurotrophic events

OP19 Gynecology**CHAIRMANSHIP: CARUSO SALVATORE (IT) LUISI STEFANO (IT)**

Bui Linda (IT) Is invasive ductal carcinoma relate to young aged women? Report on 104 operated patients in a single academic centre.

Kumar Rajesh (CH) Lipoxin A4 decreases lesion volume and reduces inflammatory and angiogenic mediators in a mouse model of endometriosis.

Maksym Radoslaw (PL) RECK, angiogenesis related inhibitor of metalloproteinases, is upregulated in endometriosis? putative mechanism of its regulation.

Colette Sebastien (BE) Aromatase inhibitors for endometriosis: myth or reality?

Hevir Neli (SI) Disturbed balance between phase I and II metabolizing enzymes in ovarian endometriosis may lead to excessive hydroxy-estrogen and ROS formation

Deutsch Plotzky Fernanda (BR) Effects of high dose isoflavones in the uterus of ovariectomized rats

Giannini Andrea (JO) Changes in central and in peripheral content of Brain-derived Neurotrophic Factor (BDNF) in female ovx rats treated with androgens.

Rolim Rosa Lima Sonia M. (BR) Comparative study of the effects of Isoflavones from Glycine max (L.) Merr. and of Conjugated Equine Estrogen on the vaginal epithelium and endometrium of postmenopausal women.

Silva Filho Agnaldo (BR) Long term results of levonorgestrel-releasing intrauterine system versus thermal balloon ablation for the treatment of heavy menstrual bleeding: a randomized controlled trial

Matasariu Roxana Daniela (RO) Desorgestrel prevention of recurrences after surgical treatment of ovarian endometriotic cysts

OP17 Pelvic Floor**CHAIRMANSHIP: DESSOLE SALVATORE (IT) MANNELLA PAOLO (IT)**

Ricciardi Luigi (IT) New mini-resectoscope as alternative to traditional hysteroscopy in the treatment of uterine lesions

Afshari Poorandokht (IR) Comparison effect of kegel exercise and interferential current in treatment women with stress urinary incontinence

Pulcinella Ruggero (IT) Off limits myomas: hysteroscopic treatment

Araujo Viana Gersia (IT) Endometritis in infertile patients: the role of hysteroscopy and bacterial endotoxin.

Elshayp Ali Farid (EG) Transvaginal radiofrequency a new modality for treatment of fibroids

Elshayp Ali Farid (EG) Bee Propolis as a Novel source of contraception

Tagliaferri Valeria (IT) Follicular loss in endoscopic surgery for ovarian endometriosis: quantitative and qualitative observations.

Donati Elisabetta (LA) Prospective study on a sample group of 48 women a year after the application of perineal card in AOUP

Uccella Stefano (IT) Does uterine weight influence the route of hysterectomy?



International Menopause Society
promoting education and research on all aspects of adult women's health

14TH WORLD CONGRESS ON **MENOPAUSE**



**CAN
CUN
2014**

May 1–4 2014 Cancun, Mexico
Cancun Center Conventions & Exhibitions
www.imsconcun2014.com



Saturday, March 10, 2012

	AUDITORIUM	AFFARI 0	AFFARI 1
08.30-10.00	Plenary Session From endocrine workup to hormone use to improve art	Plenary Session Human sexuality	Plenary Session SSRM: new development, new therapeutic uses
10.10-11.10		Meet the Expert Surgical approach to Müllerian defects	Debate Ovarian cancer and assisted reproduction
11.10-11.40	Visit to the Exhibition Area		
11.40-13.10	Sponsored Symposium Ferring Perinatal Medicine: a help for new coming life	Plenary Session Ovarian ageing and failure	Plenary Session Cancer stem cell: from basic science to clinical impact
13.10-15.10			Lunch Symposium Sponsored by Bayer Additional benefits in hormonal contraception: new evidence with E2V/DNG
15.20-15.50		Plenary Lecture Huber Johannes C. (AT) Esthetic endocrinology, the effect of sexual steroids on body composition, hair and skin	
16.00-17.30		Plenary Session Insulin and reproductive endocrinology	Plenary Session Endometriosis and reproduction
17.30-19.00		Plenary Session Contraception in the early and late reproductive years	Plenary Session Endometrial hyperplasia
19.10-19.30		Closing Ceremony	

SAT MARCH 10TH

AFFARI 2	VERDE	ONICE	HALL 9
Plenary Session Hormonal treatments for threatened and recurrent abortion	Scientific Soc. Symposium International Menopause Society Understanding weight change in midlife	Scientific Soc. Symposium Multidisciplinary Italian Society for Woman's Health New Fields in Woman's Health	
Italian Course 9.45-13.15 Sponsored by Menarini Nutraceutica: risposte per la salute delle donne	Sponsored Debate Bayer Benefits and Risks of Hormonal Contraceptives	Oral Presentation OP7 Pregnancy	Oral Presentation OP10 Gynecological Oncology
	Scientific Soc. Symposium European Society of Gynecology Hot issues in gynecology in 2012	Oral Presentation OP2 Gynecological Endocrinology	Oral Presentation OP18 Menopause

Plenary Lecture Naftolin Frederick (US) Attacking the nexus of atheroprotection with sex steroids	Plenary Lecture Rees Margaret (GB) Challenges for women in science in the 21 st century		
Plenary Session Brain-specific adaptive processes and menopausal transition	Scientific Soc. Symposium International Academy on Human Reproduction Complication of art practice	Oral Presentation OP5 PCOS	Oral Presentation OP15 Gynecology
Plenary Session Metabolic changes through menopause and ageing	Plenary Session Steroids and breast cancer	Oral Presentation OP6 Pregnancy	

AUDITORIUM

08.30 - 10.00

PLENARY SESSION

From endocrine workup to hormone use to improve art

CHAIRMANSHIP: BARRI PEDRO N. (ES) FAUSER BART (NL)

Artini Paolo G. (IT) Embryo development using fresh and vitrified oocytes

Ng Ernest HY (HK) The role and use of AMH in reproductive medicine

Simon Carlos (ES) Modeling Human Endometrial Decidualization from the Interaction between Proteome and Secretome.

Maruo Takeshi (JP) The role of progesterone and thyroid hormone in trophoblast invasion in early placental development

11.40 - 13.10

SYMPOSIUM SPONSORED BY

Perinatal Medicine: a help for new coming life - Sponsored By FERRING

CHAIRMANSHIP: CARP HOWARD (IL) MASSOBRIO MARCO (IT)

Frusca Tiziana (IT) Labour induction: why and when

Rizzo Nicola (IT) Controversies in the management of preterm labour

Draycott Timothy (GB) New Developments in the prevention of PPH

AFFARI 0

08.30 - 10.00

PLENARY SESSION

Human sexuality

CHAIRMANSHIP: BERGA SARAH (US) GRAZIOTTIN ALESSANDRA (IT)

Swaab Dick (NL) Gender identity, sexual orientation and the brain

Bitzer Johannes (CH) Female sexual dysfunction - the hormones, the brain or the partner

van Lunsen Rik HW (NL) Androgens matter: discrete but significant effects of androgens on women's sexual responsivity

Zimmerman Yvette (NL) Clinical effects of normalising testosterone levels during oral contraception

10.10 - 11.10

MEET THE EXPERT

Surgical approach to Müllerian defects

CHAIRMANSHIP: PERINO ANTONIO (IT) SPINILLO ARSENIO (IT)

Creatsas George (GR) Creatsas vaginoplasty: experience from 200 cases

Adamyan Leila V. (RU) Reconstructive surgery on müllerian defects

11.40 - 13.10

PLENARY SESSION

Ovarian ageing and failure

CHAIRMANSHIP: KAAJA RISTO (FI) STEVENSON JOHN (GB)

Fauser Bart (NL) Ovarian aging and implications for fertility female health

Panay Nicholas (GB) Premature Ovarian Insufficiency? Working towards an International Database

Al-Azzawi Farook (GB) Strategies in Genetic studies of Premature Ovarian Failure

Ishizuka Bunpei (JP) Ovulation induction in patients with primary ovarian insufficiency

15.20 - 15.50	PLENARY LECTURE CHAIRMANSHIP: BIRKHAUSER MARTIN (CH) MOSCARINI MASSIMO (IT) Huber Johannes C. (AT) Esthetic endocrinology, the effect of sexual steroids on body composition, hair and skin
16.00 - 17.30	PLENARY SESSION Insulin and reproductive endocrinology CHAIRMANSHIP: GENAZZANI ALESSANDRO D. (IT) MILEWICZ ANDRZEJ (PL) De Leo Vincenzo (IT) Insulin sensitizer and inositol in the treatment of infertile PCOS patients Vujovic Svetlana (RS) Effects of the weight loss on the insulin metabolism and gonadal axis in the extremely obese patients with sleep apnea syndrome Di Renzo Giancarlo (IT) Burden of diabetes in pregnancy Salinas Soledad (CL) Functional role of peroxisome proliferator-activated receptors gamma in glucidic metabolism in of granulosa cells from normal and polycystic ovary syndrome women
17.30 - 19.00	PLENARY SESSION Contraception in the early and late reproductive years CHAIRMANSHIP: KIESEL LUDWIG (DE) NG ERNEST HY (HK) De Melo Nilson R. (BR) Bariatric surgery contraception health Serfaty David (FR) First prescription of combined oral contraception Clausen Helle Vibeke (DK) OC before fertility treatment Birkhaeuser Martin (CH) Hormonal contraception: its impact on peak bone mass
19.10 - 19.30	CLOSING CEREMONY - Closing Ceremony

AFFARI 1

08.30 - 10.00	PLENARY SESSION SSRM: new development, new therapeutic uses CHAIRMANSHIP: MUECK ALFRED (DE) TAYLOR ROBERT (US) McDonnell Donald (US) Definition of the molecular mechanisms underlying the pharmacological activities of SERMs and TSECs Bouchard Philippe (FR) MPRMS: the ratio of their clinical use in gynecology Lamberts Steven (NL) The Medical Treatment of Cushing's Disease Fischer Lara (DE) Anti-progestin effects of selective progesterone receptor modulators (SPRM) and SPRM-like chemicals in human endometrium
10.10 - 11.10	DEBATE Ovarian cancer and assisted reproduction CHAIRMANSHIP: KENEMANS PETER (NL) SIMON CARLOS (ES) Gadducci Angiolo (IT) Ovarian cancer and assisted reproduction Barri Pedro N. (ES) Ovarian cancer and assisted reproduction

11.40 - 13.10**PLENARY SESSION****Cancer stem cell: from basic science to clinical impact****CHAIRMANSHIP: MARUO TAKESHI (JP) SIMPSON EVAN (AU)****Taylor Hugh (US)** Endometrial Stem Cells**Lindeman Geoffrey (AU)** Mammary stem cells and breast cancer - cues from steroid hormones**Knower Kevin (AU)** Epigenetic influences regulating intratumoral estrogen production in postmenopausal breast cancer**13.10 - 15.10****LUNCH SYMPOSIUM SPONSORED BY BAYER****Additional benefits in hormonal contraception: new evidence with E2V/DNG****CHAIRMANSHIP: BIRKHAUSER MARTIN (CH)****Birkhaeuser Martin (CH)** Introduction: non-contraceptive benefits of E2V/DNG**Nappi Rossella E. (IT)** E2V/DNG: a unique combined oral contraceptive**Nappi Rossella E. (IT)** Addressing OC-associated female sexual dysfunction: results from the STABLE study**Merki-Feld Gabriele (CH)** Improving hormonal withdrawal-associated symptoms: results from the HARMONY studies**Bitzer Johannes (CH)** Reducing heavy menstrual bleeding: results from two parallel studies**Birkhaeuser Martin (CH)** Q&A and closing remarks**16.00 - 17.30****PLENARY SESSION****Endometriosis and reproduction****CHAIRMANSHIP: GOLDSTEIN STEVEN (US) LAMBERTS STEVEN (NL)****Petraglia Felice (IT)** Possible role of endometrial activins in endometriosis**Taylor Robert (US)** The Role of Neuroangiogenesis in the Pathology of Endometriosis**Kiesel Ludwig (DE)** Stem cells in endometrium and in endometriosis**Andersson Karin L (SE)** Epigenetic modifications of the HOXA10 gene in endometriosis**17.30 - 19.00****PLENARY SESSION****Endometrial hyperplasia****CHAIRMANSHIP: HIRSCHBERG ANGELICA L (SE) TAYLOR HUGH (US)****Goldstein Steven (US)** Modern evaluation of the endometrium**Campagnoli Carlo (IT)** Effects of life-style and metabolic factors on (post-menopausal) endometrium**Archer David (US)** Endometrial bleeding the role of the pericyte and endothelial cell**Ber Amos (IL)** Can the levonorgestrel Intrauterine system become a first line treatment for endometrial hyperplasia?**Del Pup Lino (IT)** Prevention and early diagnosis of gynaecological malignancies in Hereditary Non-Polyposis Cancer (or Lynch) Syndrome

AFFARI 2

08.30 - 10.00

PLENARY SESSION

Hormonal treatments for threatened and recurrent abortion

CHAIRMANSHIP: CARTA GASPARE (IT) WESTWOOD MELISSA (GB)

Szekeres-Bartho Julia (HU) Progestagen treatment for threatened and recurrent abortion; molecular mechanisms

Carp Howard (IL) hCG supplementation in recurrent miscarriage - An update

Yamada Hideto (JP) Immunological etiologies in recurrent spontaneous abortion and intravenous immunoglobulin therapy

Schenker Joseph (IL) Recent approach to thyroid disorders in pregnancy

10.10 - 13.10

CORSO ECM Sponsored by MENARINI

Nutraceutica: risposte per la salute delle donne

CHAIRMANSHIP: CICINELLI ETTORE (IT) GENAZZANI ALESSANDRO D. (IT)

Gambacciani Marco (IT) Gravidanza e nutraceutica: cosa cambia

Surico Nicola (IT) Vulvo vaginiti da candida: un nuovo modo di gestire la patologia

Nappi Rossella E. (IT) Sindrome premestruale: oltre il farmaco.... come gestirla, come affrontarla

15.20 - 15.50

PLENARY LECTURE

CHAIRMANSHIP: GRECO PANTALEO (IT) GUSTAFSSON JAN AKE (US)

Naftolin Frederick (US)

Attacking the nexus of atheroprotection with sex steroids

16.00 - 17.30

PLENARY SESSION

Brain-specific adaptive processes and menopausal transition

CHAIRMANSHIP: ROCCA WALTER (US) STUDD JOHN (GB)

Brinton Diaz Roberta (US) Role of the adrenergic system in the hot flush: Target of opportunity or masking the problem?

Maki Pauline (US) Cognitive function in relation to hot flashes in women undergoing stellate ganglion block: baseline findings

Lumsden Mary Ann (GB) The role of neurotransmitters in the aetiology of vasomotor symptoms

Henderson Victor (US) Soy isoflavones and cognition after menopause

17.30 - 19.00

PLENARY SESSION

Metabolic changes through menopause and ageing

CHAIRMANSHIP: BOUCHARD PHILIPPE (FR) HARMAN S MITCHELL (US)

Siseles Nestor (AR) Clinical Cardiovascular trials of HRT

Stevenson John (GB) Menopause and the metabolic syndrome

Kaaja Risto (FI) Diabetes and HRT

Wuttke Wolfgang (DE) The effects of a "rediscovered" substance, namely β -Ecdysone

SAT MARCH 10TH

08.30 - 10.00	SYMPOSIUM BY SCIENTIFIC SOCIETY Understanding weight change in midlife - Organized by International Menopause Society (IMS) CHAIRMANSHIP: CHEDRAUI PETER (EC) DE VILLIERS TOBIAS (ZA) <p>Lumsden Mary Ann (GB) Weight gain in midlife women: pathophysiology of the metabolic consequences. Overweight and metabolism (some basic mechanisms, relation with menopause transition, metabolic syndrome, hypertension, hyperlipidaemia, PCOS, etc.)</p> <p>Villaseca Paulina (CL) Weight gain in midlife women: clinical outcomes</p> <p>Duru Sushil Shah (IN) Weight gain in midlife women: potential treatment approaches. Therapies (diet, exercise medications, surgical, traditional medicine, non-medical techniques eh hypnosis or acupuncture)</p>
10.10 - 11.10	DEBATE Sponsored by BAYER Benefits and Risks of Hormonal Contraceptives CHAIRMANSHIP: SMITS PHILIP (DE) <p>Smits Philip (DE) Introduction and Overview of Post-Approval Surveillance Studies</p> <p>Shulman Lee (US) Observational studies</p> <p>Szarewski Anne (GB) Clinician's Perspective</p>
11.40 - 13.10	SYMPOSIUM BY SCIENTIFIC SOCIETY Hot issues in gynecology in 2012 - Organized by European Society of Gynecology CHAIRMANSHIP: GENAZZANI ANDREA R. (IT) SERFATY DAVID (FR) <p>Bouchard Philippe (FR) Hot issues in gynecological endocrinology in 2012</p> <p>Tsatsaris Vassilis (FR) The placenta and the gynecologist in 2012</p> <p>Foidart Jean-Michel (BE) Minimally invasive gynecological surgery in 2012</p>
15.20 - 15.50	PLENARY LECTURE CHAIRMANSHIP: CASERTA DONATELLA (IT) SITRUK WARE REGINE (US) <p>Rees Margaret (GB)</p> <p>Challenges for women in science in the 21st century</p>
16.00 - 17.30	SYMPOSIUM BY SCIENTIFIC SOCIETY Complication of ART practice - Organized by International Academy For Human Reproduction (IAHR) CHAIRMANSHIP: SCHENKER JOSEPH (IL) SCIARRA JOHN (US) <p>Mettler Liselotte (DE) The magic of the ovary: puberty and reproductive age</p> <p>Genazzani Andrea R. (IT) Ovary and senium</p> <p>Schenker Joseph (IL) Ethics and respect</p>
17.30 - 19.00	PLENARY SESSION Steroids and breast cancer CHAIRMANSHIP: LINDEMAN GEOFFREY (AU) ZERVOUDIS STEFANOS (GR) <p>Simpson Evan (AU) Estrogen formation in the breast of post-menopausal women is inhibited by Metformin</p> <p>Mueck Alfred (DE) Are estrogen metabolites 'carcinogenic'?</p> <p>von Schoultz Bo (SE) Can we define HRT regimens that are safe?</p> <p>Kenemans Peter (NL) Androgens and breast cancer risk</p>

08.30 - 10.00

SYMPOSIUM BY SCIENTIFIC SOCIETY

New Fields in Woman's Health - Organized by Multidisciplinary Italian Society for Woman's Health (M.I.S.W.H.)

CHAIRMANSHIP: FILIPPONI PAOLO (IT) GALLINA SABINA (IT)

Lello Stefano (IT) Osteoporosis: up to date

Meczekalski Blazej (PL) Recent advances in Premenstrual Syndrome

Stomati Massimo (IT) New fields in Central Nervous System

Maffei Silvia (IT) New biomarkers in women's cardiovascular diseases

Agostinelli Daniele (IT) Discussant

10.10 - 11.10

ORAL PRESENTATION

OP7 Pregnancy

CHAIRMANSHIP: FRUSCA TIZIANA (IT) ZULLO FULVIO (IT)

Vladic Stjernholm Ylva (SE) Natural progesterone for preventing premature birth? long term effects on the newborn

Thangaraju Shyam (IN) Randomized controlled study comparing the effectiveness of dydrogesterone and micronized progesterone in improving the sub-endometrial blood flow in idiopathic recurrent spontaneous miscarriage

Gnatko Elena (UA) Cervical nitric oxide level in pregnant women with cervical insufficiency

Wu Hsien-Ming (TW) Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the motility of human decidual endometrial stromal cells

Gole Evangelia (GR) Gestational diabetes mellitus and neonatal hypocalcemia. The impact of Calcium Sensing Receptor genetic variants.

Mando' Chiara (IT) Ferroportin gene and protein expression in human IUGR placentas

De Cicco Simona (IT) Longitudinal metabolic observation of metformin effects during pregnancy in women with Polycystic Ovary Syndrome

11.40 - 13.10

ORAL PRESENTATION

OP2 Gynecological Endocrinology

CHAIRMANSHIP: DE LEO VINCENZO (IT) LOVERRO GIUSEPPE (IT)

Pu Danhua (CN) Skewed X chromosome inactivation may be not associated with premature ovarian failure

Amaral Vinicius Cestari (BR) Effects of metoclopramide-induced hyperprolactinemia on the pituitary prolactin gen and receptor of murine

Kalina Maria (PL) Assessment of puberty and pituitary-gonadal axis in girls and young women with Nijmegen breakage syndrome, a cancer-prone disease with the DNA repair defect. Evidence from a longitudinal study

Santagni Susanna (IT) Estriol administration modulates LH secretion in women with functional hypothalamic amenorrhea (FHA)

Tropea Anna (IT) Can phenols influence human luteal cells function?

Chedraui Peter (EC) Introduction and global overview on the incidence of obesity in the Western World, Asia, Africa, and Latin America

Podfigurna-Stopa Agnieszka (PL) The role of inhibin B in patients with functional hypothalamic amenorrhea and anorexia nervosa

Mitkowska Agnieszka (PL) Arterial stiffness is not modulated by the phase of the menstrual cycle but is inversely correlated with testosterone in healthy women of reproductive age.

Gubernatorova Ekaterina (RU) Effects of cranial and craniospinal irradiation on reproductive system of women childhood cancer survivors

Turp Ahmet Berkiz (TR) Biologic Interpretation of Titian's Venus of Urbino correlated with pheromones and sexual arousal

Chedraui Peter (EC) Nitric oxide and pro-inflammatory cytokine levels in postmenopausal women with the metabolic syndrome

16.00 - 17.30

ORAL PRESENTATION

OP5 Pcos

CHAIRMANSHIP: RUGGIERO MARIA (IT) STOMATI MASSIMO (IT)

Petrella Elisabetta (IT) Endothelial function and glucose metabolism in overweight and obese nondiabetic women: a possible role of L-Arginine/Nitric Oxide pathway

Wang Qiuyi (CN) The impact of oral contraceptives, metformin and lifestyle modification on the Metabolism Disorder in Polycystic Ovary Syndrome Women: A Randomized Controlled Trial

Ghaffarpasand Fariborz (IR) Serum Levels of Anti-histone and Anti-double Strand DNA Antibodies before and after Laparoscopic Ovarian Drilling in Women with Polycystic Ovarian Syndrome

Vangopoulos Vassileios (GR) Do the newer phenotypes of PCOS as derived from Rotterdam criteria represent patients with serious metabolic dysfunction?

Ghaffarpasand Fariborz (IR) Metformin versus Chromium picolinate in Clomiphene Citrate-Resistant Patients with Polycystic Ovary Syndrome: A Randomized Clinical Trial

Falbo Angela (IT) The risk of a persistent glucose metabolism impairment after gestational diabetes mellitus is increased in patients with polycystic ovary syndrome

Scaramuzzi Francesca (IT) Distinctive features of Italian female to male transsexuals: hyperandrogenism and insulin resistance with polycystic ovarian syndrome

Gambera Alessandro (IT) Alternative Insulin-Sensitizers (Lipoic acid and Inositol) in Polycystic Ovary Syndrome (PCOS)

Busacca Matteo (IT) Two different dosages of ethinyl-estradiol in association with drospirenone in normal weight women with polycystic ovary syndrome: comparison of clinical efficacy and metabolic impact. A long term randomized study

Ormazabal Paulina (CL) High insulin and testosterone disrupt glucose uptake in cultured endometrial stromal cells

17.30 - 19.00

ORAL PRESENTATION

OP6 Pregnancy

CHAIRMANSHIP: MELLO GIORGIO (IT) RIZZO NICOLA (IT)

Lebedeva Olga (RU) Low expression of NF- κ B and superoxide dismutase as a risk factor of postpartum endometritis

Ehlert Ulrike (CH) Psychobiological stress reactivity during healthy pregnancy in humans

Borzsonyi Balzs (HU) Gene expression patterns of the Bcl-2 and Bax Genes in premature birth: Interaction between apoptosis and other pathogenetic factors

Salazar Danny (EC) Methylenetetrahydrofolate reductase gene polymorphism (C677T and A1298C) prevalence in nulliparous gestations complicated with preeclampsia

Genovese Valeria (IT) The decrease of soluble HLA-G concentration in cord blood plasma after delivery correlates with the physiological induction of parturition

Borzsonyi Balzs (HU) Regulation of apoptosis in intrauterine growth restriction: a study of Bcl-2 and Bax gene expression in human placenta

Capittini Cristina (IT) Coeliac disease and miscarriage: the susceptibility HLA-DQ8 heterodimer is more frequent in abortion-prone women

HALL 9

10.10 - 11.10

ORAL PRESENTATION

OP10 Gynecological Oncology

CHAIRMANSHIP: BOLIS PIERFRANCESCO (IT) MARCHIONNI MAURO (IT)

Jamieson Stacey (AU) Constitutive NFkB signalling in the molecular pathogenesis of granulosa cell tumours of the ovary

Bernaudo Stefanie (CA) Cyclin G2 plays a role in suppressing epithelial ovarian cancer metastasis.

Arqué Gonzalez Maria (ES) The impact of prophylactic bilateral salpingo-oophorectomy on quality of life in women with an increased hereditary risk for breast and ovarian cancer

Wincewicz Andrzej (PL) Comparison of EPO and EPOR with STAT3 and HIF-1 α in human invasive ductal breast cancers

Garcia Natália (BR) Immunohistochemical evaluation of caspase 3 and bax expression in uterine leiomyomas and myometrium

Pfeiler Georg (AT) Impact of Body Mass Index (BMI) on the efficacy of aromatase inhibitors in postmenopausal patients with breast cancer? a prospective study on serum hormone levels

Polak Kinga (IT) LH and FSH promote breast cancer cell migration and invasion

11.40 - 13.10

ORAL PRESENTATION

OP18 Menopause

CHAIRMANSHIP: GADDUCCI ANGIOLO (IT) PENNA CARLO (IT)

Scarabin Valérie (FR) Elevated endogenous estradiol as an independent predictor of coronary heart disease and ischemic stroke in older postmenopausal women: The Three-City cohort study

Armeni Eleni (GR) Prevalence of subclinical atherosclerosis in menopausal women with low to medium calculated cardiovascular risk

Escalante Carlos (CR) Hormone replacement therapy decreases DNA and lipid oxidation in postmenopausal women: a possible role in ageing and cardiovascular risk?

Sassarini Jenifer (GB) Enhanced peripheral vascular reactivity seen in flushing women is further enhanced by HRT

Karaflou Maria (GR) Estrogen plus progestin treatment: Effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women

Ding Ting (CN) Changes of endocrine and ultrasound markers as ovarian aging in modifying the Stages of Reproductive Aging Workshop (STRAW) staging system with subclassification of mid reproductive age stage

Perfilyev Andrey (RU) Postmenopausal period in acromegalic women

Pelletier Georges (CA) Effects of ovariectomy and dehydroepiandrosterone (DHEA) on vaginal innervation in the rat

Lakshmanaswamy Rajkumar (US) Beneficial effects of ovarian hormones in postmenopausal mouse model.

Lei Zhenmin (US) Improvement of brain amyloid deposition in LH receptor knockout (LHRKO)/APP bigenic mice via upregulation of IL6 expression

16.00 - 17.30

ORAL PRESENTATION

OP15 Gynecology

CHAIRMANSHIP: CAMPAGNOLI CARLO (IT) FAMBRINI MASSIMILIANO (IT)

Gentilini Davide (IT) Gene expression analysis of peripheral blood mononuclear cells in women with endometriosis identifies genes involved in other non-gynaecologic chronic inflammatory diseases

Greaves Erin (GB) Sp1 is a pivotal regulator of ER β -dependent vascular function in the human uterus

Arnold Julia (DE) Neuroimmune-modulatory alterations in non-lesional peritoneum distant to peritoneal endometriosis

Oldeweme Jeannette (DE) Estrogen-dependent sympathetic nerve fibers remodelling seems to be disturbed in AM uteri

Arnold Julia (DE) Neuroendocrine regulations of the sensory and sympathetic nerve fibre imbalance in peritoneal endometriosis

Dmitrovic Romana (HR) An RCT of vaginal sildenafil citrate versus placebo in the treatment of primary dysmenorrhea

Leone Roberti Maggiore Umberto (IT) Letrozole combined with norethisterone acetate compared with oral contraceptive pill in the treatment of ovarian endometriomas

Morotti Matteo (IT) Norethisterone acetate in rectovaginal endometriosis: five years treatment

LIST OF POSTERS

**Posters must be set up on Friday
from 13.00 to 16.00 and dismantled
the same day from 19.30 to 20.00.**

Poster session is scheduled on Friday
from 17.30 to 19.30.

Each poster in the space must be
attached in the area of the assigned
number.

Poster without number please refer
to the congress secretariat.

Gynecological Endocrinology

1. Study of gene expression of prolactin and prolactin receptor in the mice uterus with metoclopramide-induced hyperprolactinemia throughout the estrous cycle.
Regina Gomes, Regina C. Teixeira Gomes, Carina Verna, Gabriela C. Cristofani Maioral, Roberta B. Wolff, Ricardo S. Simões, Edmund Chada Baracat, Helena B. Nader, José M. Soares Júnior Brazil
2. The gene expression prolactin and prolactin receptor' study in mice lactimal gland with metoclopramide-induced hyperprolactinemia
Regina Gomes, Carina Verna, Regina C. Teixeira Gomes, Gabriela C. Cristofani Maioral, Roberta B. Wolff, Vivien J. Coulson-Thomas, Helena B. Nader, Ricardo S. Simões, José M. Soares Júnior Brazil
3. Effects of metoclopramide-induced hyperprolactinemia on the on tibial epiphyseal growth plate of ovariectomized rats after hormonal replacement
Regina Gomes, Roberta B. Wolff, Regina C. Teixeira Gomes, Carina Verna, Gabriela C. Cristofani Maioral, Thais C. Rampazo, Manuel J. Simões, Ricardo S. Simões, José M. Soares Júnior Brazil
4. Effects of Basal Media and Supplements on Diethylstilbestrol-Treated Immature Mouse Primary Granulosa Cell Growth and Regulation of Steroidogenesis In Vitro
Ting Ding, Luo A, Yang S, Lai Z, Wang Y, Shen W, Jiang J, Lu Y, Ma D, Wang S China
5. Influence of metoclopramide-induced hiperprolactnemia in the bone tissue of female mice and their offspring after breastfeeding: histochemical analysis.
Regina Gomes, Carina Verna, Gabriela C. Cristofani Maioral, Ricardo S. Simões, Edmund C. Baracat, José M. Soares Júnior, Regina C. Teixeira Gomes Brazil
6. Estrogen promotes B cell activation in vitro through down-regulating CD80 molecule expression
Li Li, Yibing Fu, Li Li, Xiaowen Liu, Chunyan Ma, Jie Zhang, Yulian Jiao, Li You, Zi-jiang Chen, Yueran Zhao China
7. The endometrial macrophage: phenotype and location suggest a key role in regulation of tissue angiogenesis during the menstrual cycle
Uma Thiruchelvam, Philippa TK Saunders, Hilary OD Critchley United Kingdom
8. Does leptin level influence on bone mineral density in obese children?
Mariya Vishnevskaya, Solintsava Anjalika Belarus
9. The prevalence of metabolic syndrome in the patients that assist to the gynecologist consults in hospital universitario de caracas (huc) - october 2011
Tamara Sofia Engberts Hoogesteyn, Gonzalez, Yennifer; Pizzi, Rita; Zambrano, Efigenia; Parilli, Maria Fernanda Venezuela
10. Increased MMP-2 activity in overweight and obese women is independent of aging.
Veronica Miksztowicz, Miksztowicz V, Siseles N, Fernandez Machulsky N, Schreier L, Berg G. Argentina
11. Prospective evaluation of bone mass in women with gonadal dysgenesis under hormone therapy - a 5-year analysis
Dácio Quadros Netto, Elaine Cristina Candido; Mateus Ocanha Jorge; Cassia Raquel Teatin Juliato; Cristina Laguna Benetti-Pinto Brazil
12. Ovarian folliculogenesis in persistent estrous rat models: morphometric analysis
Rodrigo Marcondes, Katia C Carvalho, Gisele Giannocco, Natália Garcia, Jose M Soares JR, Vinicius C Amaral, Manuel J Simoes, Gustavo A R Maciel, Edmund C Baracat Brazil
13. A case of reversible secondary amenorrhea due to genital tuberculosis: a long way to the diagnosis
Vera Bain, Sylvia A Y Hayashida, Katia C Carvalho, Walter Pinheiro, Dani Ejzenberg, Sidney T N Arazawa, Gustavo A R Maciel, Edmund C Baracat Brazil
14. Predictive value of clinical markers and paraclinical exams in ovarian reserve
Karen Colmenares, Centeno Indira, Benjamin Isaac, Cuevas Susan, Pizzi, Rita, Katirae, Babak Venezuela
15. Regulation of plasminogen activator inhibitor (PAI-1) by Estradiol through c-Fos and c-Jun.
Santhosh Gopal, Gopal.S, Garibaldi.S, Goglia.L, Russo.E, Genazzani.AR, Genazzani.AD and Simoncini.T Italy
16. Association between estrogen deficiency and high fat diet on adiposity and pancreatic islet function
Aluana Santana Carlos, Costa, CAS; Santos, AS; Gaspar-reis, RP; Nascimento-Saba, CCA Brazil

17. Effect of dydrogesterone, dehydro-dydrogesterone, progesterone and medroxyprogesterone acetate on T47D breast cancer cell migration and invasion
Veronica Tosi, Goglia L., Pisaneschi S., Russo E., Gopal S., Genazzani A.R., Simoncini T. Italy
18. Gonadal proteccion with GnRH analogues in patients receiving chemphtherapy for hematological neoplasia
Rita Pizzi, Anna Caterina Russo Di Novella, Mauricio Salazar, Neyra Peña Nuñez, Indira Centeno Venezuela
19. The combined resection of endometrium - hormonal therapy alternative.
Elena Afanasyeva, Gromova A.M., Afanasyev E.G, Afanasyeva E.E., Gromova O.L. Ukraine
20. Clinical implications of the discordances between anti-Müllerian hormone (AMH) and antral follicle count (AFC)
Nataša Stojanović, Miro Šimun Alebić Croatia
21. Variability in endometrial proliferative responses to neurogenically-induced reproductive signals.
Fitzgerald Spencer, Fitzgerald Spencer Megann Thompson Limen Qi United States
22. Evaluating knowledge and attitude of high school girls towards reproductive health in Bandar-abbas, Iran
Soghra Fallahi, Jahanshahi K, Mahboobi H, Sharif N, Jahangiri Z, Khoorgui T Iran, Islamic Republic
23. Effects of Testosterone in Human Umbilical Vein Endothelial Cells.
Aulona Gaba Austria
24. Gene estrogen receptor polymorphism as a risk factor in the breast cancer
Marilene Alicia Souza Angela Maggio Da Fonseca Vicente Renato Bagnoli José Maria Soares Edmund Chada Baracat Brazil
25. The effect of estrogen therapy on bone mineral density of adolescent girls diagnosed with hypogonadism after hematopoietic stem cell transplantation
Hiroko Komura, Kodama M, Shimizu S, Hashimoto H, Mitsuda N Japan
26. Total disappearance of invasive macroprolactinoma after cabergoline treatment (case report)
Irena Ilovayskaya, Galina Mel'nichenko Russian Federation
27. Effects of recombinant activins on steroid synthesis in human granulosa-lutein cells
Hsun-Ming Chang, Christian Klausen, Peter C.K. Leung Canada
28. Mayer-rokitansky-kuster-hauser syndrome associated to hyperprolactinemia: a new syndrome?
Nícolas Cayres, Miriam Monteiro Álvares; Miriam da Silva Wanderley Brazil
29. Müllerian anomaly with heamatometra and cervical agenesis: case report
Miriam Da Silva Wanderley, Nicolas Thiago Nunes Cayres de Souza ; Miriam Monteiro Alvares; Benedito Pinto. Brazil
30. Cortistatin and its receptors are expressed in endometriotic tissues and cells and inhibit PDGF-induced endometrial cell motility.
Marta Annunziata (Italy), Raul Luque (Spain), Mario Duràn-Prado (Spain), Alessandra Baragli (Italy) Cristina Grande (Italy), Manuel D. Gahete (Spain), Francesco Deltetto (Italy), Elena Delpiano (Italy), Marco Camanni (Italy), Ezio Ghigo (Italy), Justo Castaño (Spain), Riccarda Granata (Italy)
31. Hyperandrogenism with women smokers and its role in the prediction of smoking cessation treatment success
Michaela Duskova, Kateřina Šimůnková, Martin Hill, Hana Hrušková, Hana Pospíšilová, Eva Králíková and Luboslav Stárka Czech Republic
32. Androgen insensitivity. Two cases and Revision of Pathophysiological Basis.
Yennifer González, Indira Centeno, Rita Pizzi, Efigenia Zambrano, Maria Fernanda Parilli Venezuela
33. Different prolactin isoforms in gynaecological pathologies
Pasquale Scagliola, Gambera Alessandro, Bondi Valentina, Consoli Anna, De Leone Sara, Bugari Giovanna, Iacobello Carmelo & Sartori Enrico Italy
34. Rare genetical cause of primary gonadal failure
Maria Georgina Blanco, Nolting, M; Blanco, MG; Perez Lana, MB; Straminsky, V; Onetto, C Argentina
35. Relationship between Anthropometric index (Waist to Hip Ratio) and Premenstrual Syndrome
Mahboubeh Taebi, Fadai. S, Taebi. M Iran, Najaf Abad Azad University Iran, Islamic Republic

36. Can prokineticin 1 (PK1)/endocrine gland vascular endothelial growth factor (EG-VEGF) directly affect human luteal cells function?
Anna Tropea, Federica Romani, Elisa Scarinci, Alessandra Familiari, Stefania Catino, Carola Palla, Maria Letizia Uras, Andrea Ciardulli, Antonio Lanzone, and Rosanna Apa Italy
37. Effect of phthalates on human luteal cells
Anna Tropea, Federica Romani, Elisa Scarinci, Alessandra Familiari, Stefania Catino, Carola Palla, Maria Letizia Uras, Andrea Ciardulli, Antonio Lanzone, and Rosanna Apa Italy
38. Is DHEA more efficient in diminished ovarian reserve patients with higher FSH levels?
Yavuz Tokgöz, Hikmet Hassa Yunus Aydın Vehbi Nagihan Eskin Turkey
39. Remenstrual syndrome in female medical students: a cross sectional study
Tatiana Belokrinitskaya, Frolova N.I., Suturina L.V. Russian Federation
40. Putative role of the SOS1/RAS pathway in the pathogenesis of hirsutism
Costanzo Moretti, Laura Guccione, Paola Di Giacinto, Laura Chioma, Francesca Amati, Davide Lauro e Giuseppe Novelli, Italy
41. Female sexual dysfunction - the hormones, the brain or the partner
Johannes Bitzer, Switzerland
42. Endocrine-dependent gynecological puberty pathology as an unfavourable background for occurrence of obstetric complications in reproductive age
Iryna Tuchkina, M.Lisova, L.Zobina Ukraine
43. Changes in the course of women's menstrual cycle caused by smoking or exposure to tobacco smoke - preliminary study
Anna Sędziak, Ewa Florek - Marek Chuchracki Maciej Hassan-Bartz - Maksymilian Kulza - Poland
44. Estrogen regulate adipocyte metabolism through leptin signaling pathway
Wenjuan Li, Liangzhi Xu, Yan Chen, li mu, Wenming Xu, Jing Zhuang, Tingting Li, Jing Zhan, Dan Shan China
45. Estroprogestinic therapy and ovarian reserve in young women with hypergonadotropic ovarian failure.
Francesca Papini, Maria Ruggiero, Olga Di Berardino, Giovanna Simi, Maria Elena Obino, Gersia Araujo Viana, Vito Cela, Paolo Giovanni Artini, Andrea Riccardo Genazzani Italy
46. Peripheral precocious puberty of non-neoplastic ovarian origin: clinical presentation and follow up of 33 pediatric patients
Ludovica Fiore, Einaudi S, Matarazzo P, Tessaris D, Feyles F, Peiretti V, de Sanctis L, Lala R Italy
47. Differential diagnosis between Swyer syndrome and complete androgen insensitivity syndrome - case report
Elsa Nunes, Mónica Santos; Carla Silva; Carla Rodrigues; Fernanda Geraldês; Fernanda Águas Department of Women`s Health, Hospital Center of Coimbra, Portugal Portugal
48. The Vanishing Pituitary Mass
Marilyn Lee, Raja C Rajasoorya Singapore
49. Slowly progressive adolescent hyperandrogenism may hide an ovarian thecoma
Laura Gaspari, Paris F, Zoubir S, Taourel P, Giacalone PL, Sultan C France
50. Influence of functional hyperprolactinaemia on the reproductive system of women.
Negina Adkhamova, Professor D.K.Najmutdinova Uzbekistan
51. Health status and sexual function in adult women with turner's syndrome
Cristina Ros, Camil Castelo-Branco* MD, PhD Spain
52. Assessment of hirsutism and associated factors in Brazilian women: necessity of definition of local standards
Gabriela Freitas, Sylvia A Y Hayashida, Alvaro Anzai, Daniella Curi, Jose M Sores Jr, Jose A Marcondes, Gustavo A R Maciel, Edmund C Baracat Brazil
53. Twenty four hours urinary Prolactin (24UP) is the best marker to differentiate normal from micro/ macroadenoma: Prolactinoma is a natural family planning not a disease entity
Zahra Talaei Rad, Kiumars Pirkalani, Sina Masoumi, Apena Esfandiari, Kobra Zarei Iran, Islamic Republic
54. Clinical features and causes of hyperandrogenism.
Maria Parilli, Maria F. Parilli, Efigenia Zambrano, Tamara Enhbert, Yennifer Gonzalez Venezuela

55. Fetal pituitary - adrenal stress responses
Katarzyna Kosinksa-Kaczynska, Iwona Szymusik,
Dorota Bomba-Opon, Miroslaw Wielgos Poland
56. Effects of hyperprolactinemia on the murine uterine
prolactin gen and prolactin receptor expressions
Vinicius Cestari Amaral, Vinícius Cestari do Amaral;
Kátia Cândido Carvalho; Rodrigo Rodrigues
Marcondes; Gustavo Arantes Rosa Maciel; Maria
Candida Pinheiro Baracat; José Maria Soares
Júnior; Edmund Chada Baracat. Brazil
57. Menstruation cycle resembles parametric oscillation
and subject to exact prediction: Mathematical
model explaining hypothalamic behavior in
response to stress, multiple pregnancies risk and
external stimuli
Zahra Talaei Rad, Kiumars K. Pirkalani, Gita
Shareghi Ghahraman, Bahman Khodabakhsh,
Mohammad Nazari, Hadi Haddadmanesh, Majid
Mehdizadeh, Mohammadali Khodabakhsh, Isar
Khodadad, Hossein Bigdeli, Apena Esfandiari, Kobra
Zarei Iran, Islamic Republic
58. An acute effect of light on reproductive hormones in
women: the role of spectrum
Oksana Sergeeva, K.V. Danilenko Russian
Federation
59. The structure and features of the hormonal status in
women with stress-related menstrual disorders.
Nyurzhanna Khadzhieva, Khadzhieva
Nyurzhanna, Kuznetsova Irina Russian Federation
60. Influence of abdominal obesity on the calculated
androgen parameters in the young women with
different syndromes in Georgia
Diana Chanukvadze, Kristesashvili Jenara Georgia
61. Copper 380 and Aquaporin (AQP3) a new
mechanism of action.
ali farid elshayp, Ali Farid Mohamed Ali 1, Lila Ali
Farid Mohamed Ali 2, Mostafa fouad 3, Omar el
daly 4 MOHAMED ALI FARID 5, YASMIN Ali farid 6.
Samer Samir 7 Egypt
62. Thyroid and parathyroid dysfunction as a risk factor
for osteoporosis in women
Branka Arsenovic, Vuksanovi M, Djurica S, Belji -
Živković Serbia
63. Steroid hormone hypersensitivity: clinical
presentation and management
Alek Itsekson, Matityahu Zolty, Daniel S. Seidman.
Michael Alesker, Howard Carp Israel
64. Estetrol increases Brain-derived Neurotrophic Factor
(BDNF) in selected brain areas and in plasma
Diana Daino, Russo N, Santoro AN, Casarosa E,
Russo M, Giannini A, Bucci F, Pluchino N, Genazzani
AR Italy
65. Effects of cyclic and daily estradiol treatment on
food intake and bones of ovariectomized adult rats
Aluana Santana Carlos, Gaspar-Reis, RP; Santos,
AS; Costa, CAS; Lisboa, PC; Nascimento-Saba, CCA.
Brazil
66. Effects of different bariatric surgery procedures on
plasma total antioxidant capacity in women with
severe obesity
Antonio Mancini, S. Raimondo, R. Festa, C. Di Segni,
M. Persano, A. Pontecorvi, A. Silvestrini, E. Meucci, S.
Marchitelli and R.M. Tacchino. Italy
67. Effects of beta-ecdysone on metabolic parameters
Dana Seidlova-Wuttke, Wolfgang Wuttke Germany
68. Effect of opium on ovarian cells apoptosis in
diabetic and non-diabetic rats
Majid Asiabanha Rezaei, Gholamreza Asadikaram,
Maryam Darabi Iran, Islamic Republic
69. What is the major estrogen binding protein in the
follicular fluid?
Yaakov Bentov, Navid Esfandiari and Robert F.
Casper Canada
70. Evaluation of the relationship between endogenous
gonadotropins and female sexual function
and psychological status in predialysis and
hemodialysis patients.
Zehra Kurdoglu, Zehra Kurdoglu, Assist. Prof.;
Yasemin Usul Soyoral, Assist. Prof.; Mehmet
Tasdemir, M.D.; Mertihan Kurdoglu, Assist. Prof.
Turkey
71. Alterations of adipose tissue accumulation during
and after cigarette smoke exposition, in young
female mice
Rejane Pontes Gaspar Reis, Santana AC, C.A.S.
Costa, E.P.G. Souza, Y.A. Villaça, A.S. Santos,
Gonzalez GPL, C.C.A. Nascimento-Saba Brazil
72. Involvement of b-type natriuretic peptide in the
heart hypertrophy in a female rat model of obesity
induced by high-fat diet.
Gleisy Kelly Neves Gonçalves, Najara de Oliveira
Belo Brazil

73. Posttraumatic amenorrhea: the role of diagnostic and operative hysteroscopy in the prevention, diagnosis, differential diagnosis and treatment
Ruggero Pulcinella, L.Giannone, E.Candelori, E.Giannone Italy
- Estrogen receptor α and β cooperate with GPR30 in the regulation of estrogen-induced ERK activation in primary human endometrial stromal cells.
Iveta Yotova, Quan P, Pateisky P, Gaba A., Szabo L., Kurz Ch., Tschugguel W. and Yotova I. Austria
- Thalassemia minor associated with multiple pituitary insufficiency
Imre Zoltan Kun, Zsuzsanna Szanto, Galafteon Oltean Romania
- Plasma concentrations of nitric oxide and asymmetric dimethylarginine in sickle cell anemia patients
Manizheh Kadhodaei Elyaderani, Morad Rostami, Mohammad pedram, Bizhan keykhaei, Saleh Shaneh Iran, Islamic Republic
- Serum homocysteine and asymmetric dimethylarginine levels in patients with
Ibrahim Gulhan, Giray Bozkaya, Ferda Bilgir, Levent Kebapcilar, Oktay Bilgir, Mustecep Kavrut, Erbil Dogan Turkey
- Effect of pth (1-34) in females suffering from osteoporosis
Snezana Djurica, Djurica S, Vuksanović M, B. Arsenović Republic of Serbia
- Insulin resistance in adolescents with menstrual irregularities
Isabel Bouzas, Isabel Bouzas, Daniela rodeiro, Lenora Leão, Maria Cristina kuschinir, Claudia Braga Brazil
- Hypogonadotropic hypogonadism associated with chromosomal abnormalities
Nouha Bouayed Abdelmoula, Tunisia
- Turner Syndrome In Adulthood In Current Practise
Sarah Billebeaud, Pienkowski.C, lesourd.F, Ponsar. C, lorenzini.f France

Contraception

74. Progestogen-only contraceptive pill compared with combined oral contraceptive in the treatment of pain symptoms caused by endometriosis in patients with migraine without aura
Matteo Morotti Morotti, Valentino Remorgida, Pierluigi Venturini, Simone Ferrero Italy
75. Metabolic effects of the LNG-IUS for long time users
Ineta Vasaraudze, D.Rezeberga, A.Lejnieks Latvia
76. Comparison of effectiveness of Pentoxifylline, Pentoxifylline + Low dose oral contraceptive pills (LD) and Low dose oral contraceptive pills alone in treatment of pain in endometriosis
Aida Najafian, Ataollah Ghahiri, Mojdeh Ghasemi, Alireza Najafian Iran, Islamic Republic
77. Influence of Combined Oral Contraceptive Pill Containing Drospirenone 3 mg and Ethinylestradiol 20 mcg on Circadian Arterial Stiffness Indicators in Perimenopausal Women
Victoria Mychka, Tolstov S.N. Salov I.A. Kirillova M.Yu. Russian Federation
78. Amenorrhea and BMI as independent determinants of patient satisfaction in LNG-IUD users: cross sectional study in a Central European district
Eveline Stoegerer-Hecher, Sylvia Kirchengast, Johannes C Huber, Beda Hartmann Austria
79. A Study on the Effectiveness of Educational Intervention on Knowledge Regarding Emergency Contraception among the Higher Secondary Students of Public Higher Secondary School in Dharan Municipality.
Dev Kumari Shrestha(Rai), Ms OmKumari Rai Devkumari Shrestha(Rai) Nepal
80. Bee Propolis as a Novel source of contraception
Ali Farid Elshayp, Ali Farid Mohamed Ali, Lila Ali Farid Mohamed Ali, Mostafa fouad, Omar el daly MOHAMED ALI FARID, YASMIN Ali farid Samer Samir Egypt
81. Hormone withdrawal-associated symptoms (headache and pelvic pain) in women taking combined oral contraceptives: comparison of estradiol valerate / dienogest versus ethinylestradiol/levonorgestrel
Melanie West, Gerardo Macías, Gabrielle Susanne Merki-Feld, Susanne Parke, Uwe Mellinger, Marco Serrani United Kingdom

82. The effect of a Levonorgestrel-releasing intrauterine device (Mirena) in the treatment of myoma-related menorrhagia.
Terenzio Boni, Terenzio Boni, Federica Tomao, Pierangelo Faiano, Maria Pastore, Claudia Marchetti, Santomauro Mariapia, Stephanie Lio, Pierluigi Benedetti Panici. Italy
83. Hormone withdrawal-associated symptoms (headache and pelvic pain) in women taking combined oral contraceptives: comparison of estradiol valerate / dienogest versus ethinylestradiol/levonorgestrel
Marco Serrani, Gerardo Macías, Gabrielle Susanne Merki-Feld, Susanne Parke, Uwe Mellinger Germany
84. Efficacy and safety of Femarelle (DT56a) compared to Estrogen Progesterone Replacement Therapy (EPT).
George Labos, Eftixios Trakakis, Paraskevi Pliatsika, Areti Avgouleas, Vassilis Vaggopoulos, Dimitrios Kassanos1, Irene Lambrinoudaki Greece
85. Failures of contraception: women at risk or women in risky situation?
Danielle Hassoun, Dr Danielle Hassoun France
86. The comparison of levonorgestrel IUD (Mirena) Vs oral
Mojgan Karimi Zarchi, Mojgan Karimi zarchi, Razieh Dehghani Firooz abadi, Shokoh Taghipoor, Ziba Dehghani Iran, Islamic Republic
87. Continuous oral contraception and Leuprolide in the treatment of Endometriosis associated pelvic pain
Ali Farid Elshayp, Ali Farid Mohamed Ali, Lila Ali Farid Mohamed Ali, Mostafa Fouad, Omar El Daly, Mohamed Ali Farid, Yasmin Ali Farid, Samer Samir Egypt
88. Levonorgestrel-releasing IUD for treatment of idiopathic menorrhagia.
Eriseida Ndoni, Redi Hoxhallari, Erjola Piluri, Astrit Bimbashi Albania
89. Myomectomy and hormonal contraception after forty
Vlatka Tomic, Jozo Tomic, Djurdja Zigmundovac-Klaic Croatia
90. Oral contraception pills reduce human embryonic stem cell differentiation to Germ like cell (breaking topic) updated trend
Ali Farid Elshayp, Ali Farid Mohamed Ali 1, Eremelando V. Cosmi2, Sana El Shayp3 Lila Ali Farid Mohamed Ali 4, Mostafa Fouad 5, Omar El Daly 6 Mohamed Ali Farid 7, Yasmin Ali Farid 8. Samer Samir 9 Egypt
91. Oral micronized progesterone combined with vaginal progesterone gel for luteal support
Vlatka Tomic, Jozo Tomic, Djurdja Zigmundovac-Klaic Croatia
92. Green tea extract as a novel method of oral contraception
Ali Farid Elshayp, Ali Farid Mohamed Ali 1, Lila Ali Farid Mohamed Ali 2, Mostafa Fouad 3, Omar El Daly 4 Mohamed Ali Farid 5, Yasmin Ali Farid 6. Samer Samir 7 Egypt
93. A Novel Nano Copper (T cu 380A) Intrauterine device updated trend.
Ali Farid Elshayp, Ali Farid Mohamed Ali 1, Lila Ali Farid Mohamed Ali 2, Mostafa Fouad 3, Omar El Daly 4, Mohamed Ali Farid 5, Yasmin Ali Farid 6. Egypt
94. Synergistic effect of contemporaneous endometrial curettage and insertion of levonorgestrel system in treating menorrhagia
Yves Muscat Baron, Muscat Baron Y, Craus J, Camillero Agius Rodianne, Brincat M, Malta
- New Approach to Male Contraception
Wayne Bardin, C. Yen Cheng United States

PCOS

95. Role of ghrelin in women with PCOS
Krzysztof Katulski, Katulski K., Nawrot R., Goździcka-Józefiak A., Męczekalski B. Poland
96. Satisfaction score and metabolic effects of the use of levonorgestrel-releasing intrauterine system in nonobese women with polycystic ovary syndrome
Adriana Valerio da Silva, Silva AV, Martins WP, Ferriani RA, Vieira CS. Brazil
97. CD4+CD28 null T lymphocytes are expanded in hyperinsulinemic PCOS women: can metformin-oral contraceptive combined therapy modify this cardiovascular risk marker?
Anna Tropea, F. Sagnella, M. F. Gangale, F. Moro, A. Morciano, D. Martinez, C. Palla, A. Ciardulli, M. L. Uras, E. Scarinci, A. Teti, A. Lanzone, R. Apa Italy

98. The association between PCOS and psoriasis: results from a pilot study.
Anna Tropea, F. Moro, A. Morciano, D. Martinez, A. Tropea, M. F. Gangale, F. Sagnella, C. Palla, A. Ciardulli, M. L. Uras, E. Scarinci, A. Teti, A. Lanzone, R. Apa Italy
99. Prevalence of thyroperoxidase and thyroglobulin antibodies in patients with Polycystic Ovary Syndrome
Scilla Del Ghianda, S. Del Ghianda, E. Benelli, E. Rinaldi, A. Burelli, R. Cionini, M. Tonacchera, P. Vitti, E. Pucci and F. Latrofa. Italy
100. DYSLIPIDEMIA AND POLYCYSTIC OVARY SYNDROME
Scilla Del Ghianda, Benelli E., Rinaldi E, Burelli A., Salvetti G., Del Ghianda S., Sieli R., Pucci A., Tonacchera M., Piaggi P, Vitti P, Pucci E. Italy
101. Ghrelin and leptin as markers of metformin treatment efficacy in insulinresistant PCOS women
Mitko Mitkov, Maria Orbetzova Bulgaria
102. Metabolomic biomarkers of impaired glucose tolerance and type 2 diabetes mellitus with a potential for risk stratification in women with Polycystic Ovary Syndrome: a systematic review
Nicolas Galazis, C. Iacovou, Z. Haoula, W. Atiomo United Kingdom
103. Subclinical hypothyroidism in Polycystic Ovary Syndrome - is it necessary to treat?
Elaine Candido, Vanessa Ribeiro Santana Berini Piccolo; Dacio Leonel De Quadros Netto; Cristina Laguna Benetti-Pinto; Cassia Raquel Teatin Juliato Brazil
104. Comparison of thrombophilic disorders among women with recurrent abortion with and without PCOS patients
Ashraf Moini, Shahin Tadayon, Bitá Eslami Iran, Islamic Republic
105. Prevalence of Autoimmune Thyroiditis in Patients with Polycystic Ovary Syndrome
Klaida Zaimi, Yllka Themeli, Shuaip Beqiri, Kozeta Mustafaraj, Jonela Lulo, Juxhin Gjoshe, Arjan Shtylla, Elton Peci, Valbona Bajrami. Albania
106. The frequency of polycystic ovaries in adolescents. Our experience.
Panagiotis Tsikouras, Alexandros Dafopoulos, Stefanos Zervoudis, Sophia Bouchlariotou, Spyros Liatsikos, Georgios Maroulis, Georgios Galazios, Alexander Tobias Teichmann and Georg Friedrich von Tempelhoff Greece
107. Adiponectin, tumor necrosis factor- α , insulin-like growth factor binding protein-3 levels and insulin resistance in women with polycystic ovary syndrome
Hye-Jin Lee, JY Oh, YS Hong, YA Sung, HW Chung, ES Cha Republic of Korea
108. Is the ovulatory phenotype of polycystic ovary syndrome associated with adrenal hyperandrogenism?
Sylvia Hayashida, Gustavo A R Maciel, Jose M Soares Jr, Jose A M Marcondes, Michele P Rocha, Cristiano G R Barcelos, Alvaro Anzai, Maria C P Baracat, Edmund C Baracat Brazil
109. The metabolic syndrome in Italian adolescents with the polycystic ovary syndrome
Roberta Manca, Daria Perini, Franca Fruzzetti, Andrea Riccardo Genazzani Italy
110. D-chiro-inositol treatment in patients with polycystic ovary syndrome
Mariagrazia Stracquadanio, L. Ciotta, M. Stracquadanio, I. Pagano, C. Formuso, S. Di Leo, A. Cianci Italy
111. Differential insulin response to myo-inositol administration in obese PCOS patients
Annalisa Campedelli, Federica Ricchieri, Susanna Santagni, Alessia Prati, Giovanna Bosco, Giulia Despini, Erica Rattighieri Elisa Chierchia, Paolo G. Artini, Alessandro D. Genazzani Italy
112. Bone mineral density in adolescents with polycystic ovarian syndrome
William WK To, Margaret WN Wong Hong Kong
113. Clinical presentation in patients with polycystic ovarian syndrome
Maria Belen Perez Lana, Nölting, Manuel; Pérez Lana, María Belén; Galluzzo, Liliana; Blanco, Georgina; Ochoa, Jimena; Stemberg, Karina Argentina
114. Tsh and insulin resistance associated with clinic and metabolic parameters of polycystic ovary syndrome
Vanessa Ribeiro Santana Berini Piccolo, Vanessa Ribeiro Santana Berini Piccolo, Cássia Raquel Teatin Juliato, Heraldo Mendes Garmes, Daniela Angerame Yela, Dacio Leonel De Quadros Netto, Cristina Laguna Benetti-Pinto Brazil
115. PCOS as a reason of recurrent miscarriage
Olena Ryabenko, Olena Molchanova Ukraine

116. Anti-Müllerian hormone, menarche, ovarian volume and serum levels of reproductive hormones in normal women and women with polycystic ovary syndrome
Marina Dimitraki, Dimitraki A.M., Koutlaki G.N., Zervoudis S., Nikas I., Mantrantzi J., Gourovandis V., Psillaki A., Galazios G., Liberis V. Greece
117. Anti-Müllerian Hormone in Patients with Polycystic Ovary Syndrome
Tatiana Chebotnikova, T.V.Chebotnikova, A.V.Ilyin, G.A.Melnichenko Russian Federation
118. Anti-Müllerian hormone serum concentrations in ovulatory and anovulatory PCOS women.
Elena Grodnitskaya, Kurtser M. A. Russian Federation
119. Distinguishing PCOS phenotypes to eliminate heterogeneity and unravel pathophysiology
Sofia Makridima, Vangopoulos V, Basios G, Trakakis E, Kellaris V, Panagopoulos P, Chrelias C Greece
120. PCOS: Should we screen for Metabolic Syndrome and Insulin Resistance in women diagnosed with PCOS?
edlira bylykbashi, Erinda Kosturi, Ilir V. Bylykbashi. Orjana Janushaj Albania
121. news treatments for polycystic ovary syndrome
ivana de sanctis, ivana de sanctis Italy
122. The impact of oral contraceptives, metformin and lifestyle modification on the Metabolism Disorder in Polycystic Ovary Syndrome Women: A Randomized Controlled Trial
wei huang, Qiuyi Wang, M.D. Yong Song, M.D. Wei Huang, M.D., Ph. D. Li Xiao, M.D. Qiushi Wang, M.D. Guimei Feng, M.D. Dong Liu, M.D. China
123. Anti-Müllerian Hormone in Patients with Polycystic Ovary Syndrome
Tatiana Chebotnikova, T.Chebotnikova, A.Ilyin, G.Melnichenko Russian Federation
124. Serum myeloperoxidase and adenosine deaminase activities in polycystic ovary
Zehra Kurdoglu, Zehra Kurdoglu, Assist. Prof., Halil Ozkol, Assist. Prof., Mertihan Kurdoglu, Assist. Prof. Turkey
125. Chronic inflammatory factors, encoding gene polymorphisms, and their role as modulators of the clinical appearance in the polycystic ovary syndrome (PCOS)
Nikolaos Athanasopoulos, Nikolaos Vrachnis, Zoi Iliodromiti, Pandelis Tsimaris, Vasilios Karountzos, Efthimios Deligeoroglou Greece
126. Long term morbidities of polycystic ovary syndrome (PCOS)
Pasquale Scagliola, Scagliola Pasquale, Gambera Alessandro, Consoli Anna, Fratus Chiara & Sartori Enrico Italy
127. Is Anti-Müllerian Hormone an ultrasensitive marker of Polycystic Ovary Syndrome?
Galina Davydova, G.A.Melnichenko, G.M.Savelyeva, Ilyin A.V. and Chebotnikova T.V. Russian Federation
128. Long Term Consequences of Polycystic Ovarian Syndrome
Salma Abdi Mahmoud, Liu Jinying, Hong Zang China
129. Three-dimensional (3D) sonography in PCOS
Andras Szilagyi, Szilágyi A, Arany A, Vizer M. Department of Obstetrics and Gynecology, University Teaching Hospital of Kaposvar, and Department of Obstetrics and Gynecology, University of Pécs, Hungary
130. Ovarian stimulation in PCOS: improve the quality while lowering the risks
Pieraldo Inaudi, Italy
131. Study of association between autoimmune thyroiditis (AT) and polycystic ovary syndrome (PCOS).
Annalisa Montanaro, R. Forleo, C. Cipri, F. Sestini, C. Fioravanti, F. Pacini. Italy
132. Effects of six months inositol treatment on clinical, endocrine and metabolic features in obese women with Polycystic Ovary Syndrome
Valentina Immediata, Romualdi D., Busacca M., Di Florio C., Gagliano D., Selvaggi L., Lanzone A., Guido M. Italy
133. Ferritin levels in female-to-male transsexuals with Polycystic Ovary Syndrome
Miriam Menacho Roman, Menacho M, Becerra A, Pérez-López G, Villar R, Del Rey Jm dpt. Of Biochemistry, Hospital Universitario Ramón Y Cajal, Madrid. Spain

134. Myeloperoxidases and polycystic ovary syndrome
Alessandra Lorenti Ribeiro, Alessandro Scapinelli, Sonia Tamanaha, Ricardo Manoel De Oliveira, Ingrid Kowastch, Wilson Mathias Junior, Tsutomu Aoki, Jose Mendes Aldrighi Brazil
135. Predictors of insulin resistance and correlation with anthropometry in women with Polycystic Ovarian Syndrome.
Natalia Gonzalez,
136. Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study
Olga Maria Di Berardino, P.G. Artini, V. Cela, F. Papini, G. Simi, S. Pinelli, E. Carletti, A.R. Genazzani Italy
- The phenotype of hirsute women: a comparison of polycystic ovarian syndrome and 21-hydroxylase deficient non-classic adrenal hyperplasia
Duarte Pignatelli, Jorge Beires and Ricardo Azziz. Depts. of Gynecology of Hospital S João, Porto, Portugal, and Georgia Health Sciences University, Augusta, GA, USA. Portugal
- Clinical and laboratory parameters of polycystic ovary syndrome in adolescents between 10 and 19 years
Isabel Bouzas Lenora Leão Maria Cristina Kuschnir Daniela Rodeiro, Claudia Braga Brazil
- Treatment of dostinex at women with the polycystic ovary syndrome
Tetiana Arkhyapkina, T. L. Arkhyapkina, L. P. Liubimova Ukraine
140. Maternal second trimester serum 25-hydroxyvitamin D level - relationship with obstetric complications and presence of multivitamin supplementation
Man-Kin Chung, Zhi-Yang Hu, Theresa KW Cheung, Goldie J Gu, Tak-Yeung Leung, Tze-Kin Lau, Terence T Lao Hong Kong
141. Influence of thyroid hypofunction and autoimmunity on maternal and fetal outcomes
Valentina Velksoka Nakova, Velkoska Nakova V, Zisovska E, Simeonova Krstevska S, Krstevska B. The Former Yugoslav Republic of Macedonia,
142. Fetal anomalies diagnosed before the third trimester - does maternal gestational diabetes play a role?
Yvonne Kwun Yue Cheng, Terence T Lao, Yuen-Ha Ting, Man-Kin Chung, Theresa KW Cheung, Tak-Yeung Leung Hong Kong
143. Understanding the pathophysiology of threatened miscarriage
Jean Calleja-Agius, Olga Tsar, Mark Brincat Malta
144. Quality of life during pregnancy: the impact of the women's way of life
Jelena Dotlic, Milan Terzic, Dragan Babic, Slobodanka Janosevic, Tatjana Pekmezovic Serbia
145. Calcium, phosphate and vitamin D metabolism during pregnancy and labor.
Ewa Chotkowska, Ewa Hinek, Monika Hanyż, Tomasz Maciejewski Poland
146. Regulation of thyroid receptors mRNA and protein expression by hyperthyroidism in corpus luteum of rats in late pregnancy
Paola Navas, Jahn GA; Hapon MB Argentina
147. Successful ultrasound monitoring of Parvovirus B19 infection in pregnancy: a case report
Gaia Pasquali, Valentina D'Ambrosio, Elisa Bevilacqua, Alessia Gasbarri, Renato La Torre, Antonella Giancotti Italy
148. Screening and management of bacterial vaginosis in pregnancy
Merita Krasniqi, M. Krasniqi, Z. Dervishi, S. Shala, A. Daka, Sh. Fetiu, M. Ramosaj, D. Ukella, Q. Daka Albania
149. Prospective study of 162 deliveries with the help of VE
Merita Krasniqi, Z. Dervishi, M. Krasniqi, S. Shala, D. Ukella Albania

PREGNANCY

137. Pregnancy at women with portal hypertension
Ana Lupaşcu, only Ana Lupascu Republic of Moldova
138. Pregnancy complications in morbidly obese gravidas
Erinda Kosturi, Dr.E. Kosturi, Dr.E. Bylykbashi PhD.I.V. Bylykbashi Albania
139. Monthly variation of preterm birth in Hong Kong - Relationship to Available Sunlight
Man-Kin Chung, Terence T Lao, Zhi-Yang Hu, Yuen-Ha Ting, Tak-Yeung Leung Hong Kong

150. The effect of lead on concentration of the pregnancy-associated plasma protein A (PAPP-A) in blood of non-smoking and smoking pregnant women
Magdalena Chelchowska, Katarzyna Jabłonka-Salach, Joanna Gajewska, Tomasz Maciejewski, Jadwiga Ambroszkiewicz, Teresa Laskowska-Klita, Jan Barciszewski Poland
151. low maternal glucose challenge test and the risk for IUGR fetus
Amit Damti Pazit Gavriel Grace Younes Ron Auslander Shlomit Riskin-Mashiah Israel
152. Factors influencing the choice of cesarean section in pregnant women who referred to Imam Ali hospital of Andimeshk county 2010
Mahnaz Motamedi, Mojgan Montazeriyan Sousan Heydarpour Seyed Mahmoud Latifi Iran, Islamic Republic
153. Relationship between progesterone and endometrial paracrine mechanisms during post-implantation development
Fitzgerald Spencer, Fitzgerald Spencer, Megann L. Thompson and Limen Qi United States
154. Does age influence in the future of patients with ASCUS?
Diana Shahini, Albania
155. Maternal second trimester serum vitamin D level between multiple pregnancy and singleton pregnancy
Zhi-Yang Hu, Man-Kin Chung, Theresa KW Cheung, Goldie J Gu, Tak-Yeung Leung, Tze-Kin Lau, Terence T Lao Hong Kong
156. The impact of maternal body mass index on second trimester parathyroid hormone and 25-hydroxy Vitamin D levels in Chinese pregnant women
Zhi-Yang Hu, Man-Kin Chung, Theresa KW Cheung, Goldie J Gu, Tak-Yeung Leung, Tze-Kin Lau, Terence T Lao Hong Kong
157. Is There a Seasonal Effect on Fetal Growth and Newborn Size?
Terence T Lao, Man-Kin Chung, Zhi-Yang Hu, Lai Wa Law, Tak-Yeung Leung Hong Kong
158. Women's Access to CAC(Comprehensive Abortion Care) Services in BPKIHS, Dharan, Nepal
Dev Kumari Shrestha(Rai), Authors: Shrestha DK, Chettri S. PokharelN, Rai Nepal
159. Pregnancy Outcome in Type 1 Diabetic Women with Diabetic Nephropathy
Yllka Themeli, Valbona Bajrami, Klotilda Zaimi, Kozeta Mustafaraj Jonela Lulo, Shuaip Beqiri, Arjan Shtylla, Elton Peci Albania
160. Study of icteric newborns admitted to the Behbahani hospital of Behbahan
Zary Tahannejad, Somayeh, Ghanevaty Iran, Islamic Republic
161. prevalence and frequency of some factors on preterm labor in
Fahimeh Yousefinezhad, Iran, Islamic Republic
162. Difference between old and new criteria for gestational diabetes mellitus in Japanese woman
Kanako Mori, Yoshiyuki Hamamoto, Yukiko Kawasaki, Sachiko Honjo, Kanta Fujimoto, Hisato Tatsuoka, Atsuko Matsuoka, Hiroki Ikeda, Yoshiharu Wada, Hiroyuki Koshiyama Japan
163. Cesarean delivery "en caul" in Japan: results of a national survey of maternal and perinatal centers in Japan
Koichiro Takagi, Mitsue Muraoka Japan
164. Frequency and causes of cesarean section in women who refer to maternal and child clinics of Ahvaz at 2010
Leyla Karimi,, Afshari Poorandokht, Sadeghi Simin Iran, Islamic Republic
165. Study of Hepatitis B (HBs Ag) Prevalence rate in pregnant women referred to
Zary Tahannejad, Maryam Moslem Iran, Islamic Republic
166. Detection of streptococcus agalactiae colonization and antimicrobial susceptibility evaluation in pregnant women from a university hospital in Brazil: comparison with the model proposed by screening centers for disease control and prevention (cdc)
Nícolás Cayres, Hugo Leonardo Gonçalves de Oliveira Magalhães; Alberto Carlos Moreno Zaoneta; Paulo Sérgio França; Miriam da Silva Wanderley Brazil
167. Meningitis and pregnancy: a case report and literature review
Bouchra Fakhir, K. Abdi. B. Fakhir, A. Aboulfalah, H. Asmouki, A. Soummani Morocco
168. Diabetes insipidus in pregnancy - a case report
Ewa Hinek, Ewa Chotkowska, Tomasz Maciejewski Poland

169. Threatened abortion in the early terms of pregnancy and placenta insufficiency
Vira Pyrohova, Hychka N., Pyrohova V. Ukraine
170. The effect of coelomic fluid on the production of cytokines by the first trimester human placenta
Jean Calleja-Agius, Shanthi Muttukrishna; Eric Jauniaux Malta
171. The role of the nitric oxide pathway during childbirth and its potential effect in peri-natal period
Silvia Pisaneschi, M. A. Sanchez, S. Begliuomini, F.A.L. Strigini, P. Ghirri, A. Boldrini, A.R. Genazzani, F. Coceani, T. Simoncini Italy
172. The evaluate the effect of iron deficiency anemia on pregnancy outcome in pregnant women
mahnaz motamedi, mojgan montazerian Iran, Islamic Republic
173. Domestic Violence During Pregnancy in Iran
Elham NeisaniSamani, Elham Neisani Samani, M.D Irene Moridi, MD, Iran, Islamic Republic
174. Os calcis bone mineral density changes as measured by quantitative ultrasound in pre-existing and gestational diabetic pregnancies
William WK To, Margaret WN Wong Hong Kong
175. Prevalence and frequency of some factors on preterm labor in
Marzeyeh Nabipour, Gholamreza Zohuorzargar Delaram Zohuorzargar Iran, Islamic Republic
176. Serum progesterone levels in gestations complicated with threatened preterm labor
Maryann Daza, Kleber Arriaga, Martha Gonzaga, Luis Hidalgo, Faustino R. Pérez-López, Peter Chedraui Ecuador
177. Plasma umbilical vein pro-inflammatory cytokine levels in gestations complicated with severe preeclampsia
Peter Chedraui, Emilio J. Solis, Gustavo S. Escobar, Rita Loja, Cecibel Ramirez, Jasson A. Espinoza, Faustino R. Pérez-López, Luis Hidalgo, Andrea Genazzani, Tommaso Simoncini ECUADOR
178. Detection of gestational diabetes mellitus in young pregnant women
Marzeyeh Nabipour, Gholamreza Zohorzargar Delaram Zohorzargar Iran, Islamic Republic
179. Biochemical indices of occurrence of the pre-eclampsia condition.
Marek Chuchracki, Ewa Florek - Anna Sędziak Grzegorz H. Bręborowicz Poland
180. The effect of smoking on bone metabolism in pregnant women
Magdalena Chelchowska, Tomasz Maciejewski, Jadwiga Ambroszkiewicz, Joanna Gajewska, Teresa Laskowska-Klita, Mariusz Ołtarzewski Poland
181. A case report of neonatal thyrotoxicosis due to maternal assumption of an "iron + herbs liquid extract formula" including iodine rich giant kelp
Stefano Mazzoleni, Daniela Toderini, Giovanna Policicchio, Italy
182. A successful treatment of right Ovarian Pregnancy with a Multidose Methotrexate. A case-report.
Gianluca Di Luigi, Gaspare Carta, Giuseppe Ruggeri, Vincenzo La Posta Italy
183. Diabetic Nephropathy and Retinopathy - complications in pregnancy and labor
Yllka Themeli, Kloida Zaimi, Kozeta Mustafaraj, Jonela Lulo, Valbona Bajrami, Eliota Petani, Arjan Shtylla, Elton Peci, Juxhin Gjoshë, Alma Idrizi, Myftar barbullushi. Albania
184. Clinical and structural features of "mother-placenta-fetus" system in pregnant women with lung tuberculosis
Anna Yakimova, Russian Federation
185.)Pregnancy outcome after illegal induced abortion in Iran
Elham NeisaniSamani, Elham Neisani Samani, Irene Moridi, Laleh Daftari Boshli, Alireza Ejazi Iran, Islamic Republic
186. Screening of pre-eclampsia in the first trimester of gestation
Claudia Sergiampietri, C. Sergiampietri, F. Monacci, M. Schifano, C. Nanini, D. Parrini; A.R. Genazzani and C. Luchi Italy
187. Hyperthyroidism and hypothyroidism in pregnant women
Roman Smolarczyk, Poland
188. Why mothers choose elective cesarean section in ahvaz?
poorandokht afshari, sadeghi simin Iran, Islamic Republic
189. Early first trimester measurement - a difficult task for the trainee in obstetric ultrasound?
Alexandru Comanescu, Fota Cristina, Florea Maria, Oprea Claudia, Cernea Nicolae Romania

190. Determination and prevalence of isolated pathogens from pregnant women with bacteriuria and their antibiotic susceptibility patterns
Manijeh Mehdinejad, Manijeh Mehdinejad, Hamideh Yazdizadeh, Hamideh Amirgholami, Porandokht Afshari Iran, Islamic Republic
191. Relation of Urinary Tract Infection in Pregnancy and Low Birth Weight
Mahvash Heidari, Shiva Yahyapour, Ali Maraghi Iran, Islamic Republic
192. Preliminary study regarding the association between autoimmune thyroiditis and thrombophilia in pregnancy
Lorena Dijmarescu, Magda Manolea, Alice Gavrilă, D. Iliescu, A. Comanescu, Liliana Novac Romania
193. The concentration of marker proteins feto-placental complex among patients with different variants of inherited thrombophilias
Kseniia Khazhilenko, K. Khazhilenko, Isida hospital, Kiev, Ukraine Ukraine
194. Risk Assessment of Thrombophilic States of Pregnancy Women Regarding the Results of Biochemical Markers of the First Trimester
Svetlana Shyianova, Khazhilenko K., Isida hospital, Kiev, Ukraine Ukraine
195. Spontaneous pre-labor uterine rupture in primigravida women:
Giorgio Bogani, Stefano Uccella; Antonella Cromi; Jvan Casarin; Davide Sturla; Giorgio Formenti; Fabio Ghezzi Italy
196. Outcomes of pregnancies complicated by gestational diabetes mellitus in Misurata
Fathi Essadi, Dr Muftah Suwan Dr Bashir Elmadani Libyan Arab Jamahiriya
197. Evaluation of outcomes with different methods of childbirth labor induction
Vladislava Novikova, Novikova V. A., Penzhoyan G. A., Fedorovich O. K. Russian Federation
198. Pregnancy outcome in patients previously treated for endometriosis
Ambrogio P Londero, Angelo Calcagno, Giorgia Pizzamiglio, Tiziana Grassi, Serena Bertozzi, Lorenza Driul, Diego Marchesoni Italy
199. Maternal pre-pregnancy body mass index and its relation with miscarriage
Ambrogio P Londero, Lorenza Driul, Claudia Caisutti, Tiziana Grassi, Serena Bertozzi, Angelo Calcagno, Arrigo Fruscalzo (Germany), Diego Marchesoni Italy
200. Frequency of gestational diabetes, diagnosed according to IADPSG criteria, in Caucasian women
Chiara Signori, Bonin C, Zambotti F, Dall'Alda M, Donati M, Moretta R, Di Sarra D, Bettinazzi F, Moghetti P. Italy
201. A study on gene environmental interaction in adverse pregnancy outcomes
Rahul Pathak, MD Mustafa, Kiran Guleria, Rafat S. Ahmed and B.D. Banerjee India
202. The predominance of Th17 lymphocytes and decreased number and function of Treg cells are present in preeclampsia.
Dorota Darmochwał-Kolarz, Kludka-Sternik M, Tabarkiewicz J, Kolarz B, Rolinski J, Leszczynska-Gorzela B, Oleszczuk J. Poland
203. Antenatal corticosteroids in women at risk for preterm delivery: an evidence update
Elisa Bevilacqua, Valentina D'Ambrosio, Gaia Pasquali, Alessia Gasbarri, Maurizio Marco Anceschi Italy
204. The prevented massive blood loss in the postpartum period
Vladislava Novikova, Novikova VA, Penzhoyan, Fedorovich OK, Lebedenko E. S., Muzychenko VP. Russian Federation
205. Preterm placental abruption and early preterm birth
Vira Pyrohova, Smykh Z., Pyrohova V., Ohabska I. Ukraine
206. The forceps as aid during cesarean section
Anca Nicolae, Dr. Benedict Ancar, Romania
207. Serum iron concentrations a possible biomarker of preeclampsia
Vanja Fenzl, Vanja Fenzl Croatia
208. Itsha, a novel prediction index of maternal thyroid impairment in the early pregnancy
Costanzo Moretti, Alessandro Dal Lago, Elena Vaquero, Natalia Lazzarin, Laura Guccione, Paola Di Giacinto, Giuseppina Ruggiero, Caterina De Carolis, and Costanzo Moretti Italy

209. Clinical and ultrasound management of twin pregnancy
Valentina D'Ambrosio, Pasquali Gaia, Muto Brunella, Squarcella Antonia, Bevilacqua Elisa, La Torre Renato, Giancotti Antonella Italy
210. Comparison of low birth weight in short inter pregnancy interval with suitable interval
Nooshin Mehdinejad, Hamideh Amirgholami, Manijeh Mehdinejad Iran, Islamic Republic
211. Potential Use of PAI-1 in Early Diagnostics of Gestational Diabetes.
Karlina Elksne, Zane Pauniņa, Antra Jurka, Peteris Tretjakovs, Dace Rezeberga, Aivars Lejnietis Latvia
212. First trimester PAPP-A plasma levels and fetal growth: correlation with fetal biometry, uterine arteries flow and endothelial function in the prediction of impaired growth.
Martina Schifano, C. Nanini, C. Sergiampietri, F. Monacci, RM Bruno, L. Ghiadoni, D. Parrini, AR Genazzani, C. Luchi Italy
213. Control of gestational diabetes with the newly described instillation of insulin into the auditory channel via a piezoelectric pump: A comprehensive approach and a novel option
Kiumars Pirkalani, Zahra Talaei Rad, Sina Masoumi, Apena Esfandiari Iran, Islamic Republic
214. The efficacy of TENS versus Lidocaine on Episiotomy pain
Parichehr Khedri, Maryam Yasrbi Iran, Islamic Republic
215. The survey of ghrelin concentration in serum and cord blood and its correlation with infant growth parameters
Hossein Hadinedoushan, Abbas Aflatounian, Fatemah zare Iran, Islamic Republic
216. Are maternal age and parity as a risk factor for gestational diabetes?
Azar Aghamohammadi, Azade Aghamohammadi Abbas Rajabi Iran, Islamic Republic
217. Kurdish women's experiences of induced abortion: A qualitative study
Fariba Ebtekar, Haliza Mohd Riji and Zhila Abed Saeedi Iran, Islamic Republic
- Activating gper in myometrium - a surprising oxytocic effect?
Oana Sorina Tica, Eugen Brailoiu, Andrei Adrian Tica Romania
 - Pregnancies after bariatric surgery: importance of management
Johanny plana, guyard-boileau B, cazals I, lorenzini.f France
 - Vanishing fetal goiter. a case report and review of literature. Presenting author- R. Bhanvadia, Dept. of endocrinology . Sir Ganga Ram Hospital, New Delhi. India
Roopal Panchani, A. Saini, N. Dimri, N. Gupta, T. Varma, S. Tripathi. India
 - Maternal and perinatal morbidity while comparing insulin analogs lispro and aspart with regular insulin for glycemic control in gestational diabetes mellitus.
Roopal Panchani, A. Saini, T. Varma, S. Kumar. Department of Endocrinology. Sir Ganga Ram Hospital. New Delhi. India
 - The antropometric parameters of newborns in patients with gestational diabetes mellitus
Violeta Mladenovic, Violeta Mladenovic, Aleksandar Djukic, Mirjana Varjadic, Djuro Macut Serbia
 - The problem of virus-bacterial infections in obstetrics pathology
Vladimir Kuzmin, Russian Federation
 - Infections risk factors of premature labor
Vladimir Kuzmin, Russian Federation
 - The relationship between endometrial thickness and pregnancy rates in GnRH antagonist down-regulated ICSI cycles.
Tugba Kinay, Tasci Y, Dilbaz S, Cinar O, Demir B, Haberal A. Turkey
 - Diagnossis of gender at 11-13+6 weeks ultrasound - a difficult task for the trainee in obstetric ultrasound?
Cristina Fota, Florea Maria, Comanescu Alexandru, Oprea Claudia, Cernea Nicolae Romania
 - Autoimmune thyroid disease and pregnancy
Đurica S, Vuksanović M, Arsenović B Serbia
 - Prospective study of 162 deliveries with the help of VE
Zeqir Dervishi, Z.Dervishi, M.Krasniqi, S.Shala, D.Ukella Albania

Gynecologic oncology

218. Telomerase and ubiquitin gene expression in HPV-related cervical lesions
Cristina Daniela Rusanu, Anca Botezatu, Iulia V. Iancu, Irina Huica, Adriana Plesa, Gabriela Anton Romania
219. PvuII polymorphism in Estrogen Receptor α gene (ESR1) in patients with cytological high grade lesions and HR-HPV infection
Manuela Atzori, M. Marini, M. Piga, R. Lussu, A. De Montis Italy
220. Proteomic Biomarkers of Ovarian Cancer in Women with Polycystic Ovary Syndrome (PCOS). A Systematic Review and Biomarker Database Integration.
Nicolas Galazis, L Olaleye, C. Iacovou, Z. Haoula, R. Layfield, W Atiomo United Kingdom
The use of gonadotrophin releasing hormone (GNRH) analogue in endometrioid adenocarcinoma of the ovary: A case report and discussion
Mohamad Nasir Shafiee, Lim Ps, Shuhaila A, Nazimah I, Hashim O Malaysia
221. A case of hyperprolactinemia in patient with metastatic breast cancer.
Tatiana Vasilieva, Dzeranova Larisa K., Pigarova Ekaterina A., Manchenko Oksana V. Vladimirova Victoria P. Russian Federation
222. Factors associated with endometrial hyperplasia
Eleonora Candelori, L.Giannone, E.Giannone, S.Bono Italy
223. Metabolism of progesterone in endometrial cancer
Maša Sinreih, Beranič N., Hevir N., Šinkovec J., Šmuc T., Lanišnik Rižner T. Slovenia
224. Fsh secreting hypophysis tumor - a new therapeutic option
Elaine Candido, Dácio Leonel de Quadros Netto, Oswaldo Grassioto, Heraldo Mendes Garmes, Cristina Laguna Benetti-Pinto Brazil
225. Ovarian function preservation by GnRH agonists during chemotherapy with cyclophosphamide in breast cancer patients - A double blind randomized control trial clinical
Mojgan Karimi Zarchi, Maryam Nakhaie Moghadam, Mohammad Forat Yazdi, Soraya Teimoori, Hamid reza Soltani Iran, Islamic Republic
226. Fertility Sparing treatments in young patients with gynecological cancers: A large Iranian experience and the literature review
Mojgan Karimi Zarchi, Azamsadat Mousavi, Omid Amini Rad, Esmat Barooti, Soraya Teimoori, Fatemeh Ghaemmaghami, Mitra Modares Gilani, Nadereh Behtash Iran, Islamic Republic
227. The evaluation of cervix uteri in patients affected with external genital condiloma.
Diana Shahini, Elsa Kone University of Tirana, Department of Morfology. Albania
228. Effect of continuous vs. sequential estradiol/ progestogen on the proliferation of human breast cancer cells overexpressing PGRMC1
Alfred O. Mueck (Germany), Xiangyan Ruan (China), Helen Schneck (Germany), Hans Neubauer (Germany), Harald Seeger (Germany), Tanja Fehm (Germany)
229. Overexpression of PGRMC1 - a potential mechanism for increased breast cancer risk during combined treatment with estrogen and norethisterone
Alfred Mueck (Germany), Helen Schneck (Germany), Xiangyan Ruan (China), Hans Neubauer (Germany), Harald Seeger (Germany), Michael A Cahill (Australia), Tanja Fehm (Germany), Salman M Hyder (USA)
230. Abdominal fat in corelation with chronic proinflammatory status, risk factor for endometrial cancer
Razvan Ciortea, N. Costin, B.Chiroiu, N.Miron, M.Oancea, A. Măluțan, C. Iuhas, R. Mocan, D. Miha Romania
231. The combined value of CA125 determination and echographic ovarian images, in establishing a presurgical diagnosis of benign, borderline and malignant ovarian tumor
Ruxandra Stanculescu, Russu Manuela, Vladescu Teodora, Bausic Vasilica, Teodorescu Andreea Romania
232. Sexual Health after Cancer
Jennifer Blake, Lauran Adams, Cathy Doyle, Fay Sliwin, Marg Fitch, Lisa Barbera Canada
233. Biological and psychological evaluation of female sexuality changes after gynecological or breast cancer treatment
Dennis Vaidakis, Makris G.M., Poulakaki N., Zarkadas S., Karatrasoglou H., Panoskaltsis Th. Greece

234. National epidemiological study on behaviour, knowledge, attitudes of greek adolescents in relation to hpv virus
Theodoros Panoskaltsis, Vaidakis D, Barbuni N, Merakou K, Zervas J, Kourea-Kremastinou T, Moustaki E, Paraskevaidis E, Creatsas G Greece
235. Young cervical cancer patients: hrt or no hrt? Qualities of life compared.
Federica Tomao, F. Tomao, G. Perniola, T. Boni, F. Bellati, I. Palaia, V. Di Donato, C. Marchetti, A. Musella, M. Giorgini, D. Savone, L. Imperiale, S. Lio, L. Salerno, P. Benedetti Panici Italy
236. Role of inflammation in the development and progression of endometrial hyperplasia
Anatoliy Kubyshkin, Kovalenko Yevgeniya, Tatarchuk Tatyana, Rybalka Anatoliy, Filonenko Tatyana Ukraine
237. The dynamics of reduced/oxygenized glutathione ratio in women with benign breast disease after 3 months usage of herbal medicine mastodinon
Tatiana Belokrinitskaya, L. Popova, L. Suturina, L. Kolesnikova, L. Grebenkina Russian Federation
238. Conservative Treatment of Early Endometrial Cancer (EC)
Giuseppe Laurelli, Scaffa C., Gregg S. Italy
239. New approaches in the pathogenic mechanisms of endometrial and/or endocervical hyperplastic processes
Madona Jugeli, M. Jugeli¹; B. Tkeshelashvili; L. Zakaraia; N. Museridze; L. Javashvili; N. Adamia; L. Jvarsheishvili; D. Tananashvili Georgia
240. Hormone-secreting ovarian tumors - the way of diagnosis and management
Dariusz Szpurek, Poland
241. Visceral fat trough its products, a risk factor for endometrial cancer
Oana Roxana Buta, O. Buta, R. Ciorte, N. Costin, N. Miron, A. Malutan, D. Mihu. Romania
242. No significant contribution of BRCA1 genomic rearrangement in familial breast cancer in Sri Lanka
Sumadee De Silva K H Tennekoon, E H Karunanayake, I Amarasinghe and P Angunawala Sri Lanka
243. Evaluation of "see-and-treat" approach in women with cervical high-grade squamous intraepithelial lesions
Mihaela Grigore, Mihaela Grigore, Sergiu Teleman, Cristina Terinte Romania
244. Longitudinal study of female sexual function after pelvic radiotherapy
Ana Rodrigues, Rubina Teixeira, Tânia Teixeira, Sofia Conde, Paula Soares, Isabel Torgal Portugal
245. Diagnostic hysteroscopy and breast cancer
Eleonora Candelori, L. Giannone, V. My, E. Giannone Italy
- IGFR1 receptor and GLUT1 are associated with STAT3 in human primary invasive ductal breast cancers.
Andrzej Wincewicz, Urszula Sulkowska, Mariusz Koda, Luiza Kanczuga-Koda, Stanislaw Sulkowski Poland
 - Low bone mineral density in middle-aged breast cancer survivors: prevalence and associated factors
Delio Marques Conde, Aarão Mendes Pinto-Neto, Lúcia Costa-Paiva, Edson Zangiacomi Martinez, Eliceia Marcia Batista Brazil
 - Bone Mineral Density in Postmenopausal Women with and without Breast Cancer
Delio Marques Conde, Aarão Mendes Pinto-Neto, Lúcia Costa-Paiva, Edson Zangiacomi Martinez, Eliceia Marcia Batista Brazil
 - Angiogenesis in Squamous Cervical Lesions
Alexandru Comanescu, Fota Cristina, Florea Maria, Oprea Claudia, Cernea Nicolae Romania
 - An impact of oxidative stress on proliferative activity of gynecological cancer cells
Irina Bulavina, Katharina D'Herde, Marc Bracke, Marina Yu Eliseeva, Ospan A Mynbaev Moscow state university of medicine & dentistry, Moscow, Russia
Ghent university, Ghent, Belgium Russian Federation

Infertility and medically-assisted procreation

246. Is ultrasound monitoring of the ovaries during ovulation induction by clomiphene citrate essential? A systematic review
Nicolas Galazis, M. Zertalis, C. Iacovou, Z. Haoula & W. Atiomo United Kingdom
247. Effects of antisense oligodeoxynucleotides (AsODNs) on embryo quality and pregnancy rate in PCOS and endometriosis IVF treatment cycles.
Elena Zakharova, Zaletova Victoria Russian Federation

248. Effects of inositol administration in semen parameters of patients undergoing to an IVF cycle
Ferdinando Antonio Gulino, Giuffrida E, Leonardi E, Lenzo L, Rubbino G, Fauzia M, Valenti O, Palumbo MA Italy
249. Role of laparoscopy in unexplained infertility
Gabriella Rubbino, Genovese F, Valenti O., Giuffrida E., Gulino F, Fauzia M., Palumbo M. A. Italy
250. Thyroid autoimmunity in reproductive endocrine diseases
Tünde Bartha, Sándor E; Bhattoa HP, Nagy VE, Jakab, A Hungary
251. Timing of Oocytes retrieval on IVF results
Eleonora Giuffrida, Rubbino G., Gulino FA, Valenti O., Iemmola A., Palumbo MA Italy
252. Ovarian sensitivity index (fsh units per retrieved oocyte) is correlated with amh levels and may be used as a marker of ovarian responsiveness to gonadotropins in ivf
Valentina BIASONI, BIASONI V., Patriarca A., Chiadò A., Benedetto C. and Revelli A. Italy
253. Premature ovarian failure and infertility
Nelliija Seimuskina, A.Tirane,M.D.,A.Vigule, med. stud. Latvia
254. Outcomes of IVF as secondary infertility treatment
Valentina Spadoni and Andrea Borini Italy
255. Immunotherapy for patients with recurrent pregnancy loss: myth of past or an option for the future
Ginna Ortiz Olivera, Ortiz G, Mendoza J.C Colombia
256. Ultrasound, hysteroscopy and hysterosalpingography to assess uterine cavity in patients attending fertility consultation
Susan Cuevas, Benjamin, Isaac; Centeno, Indira; Colmenares, Karen; Medina, Randolpho; Pizzi, Rita Venezuela
257. Immuno-histochemical localization of endothelial nitric oxide synthase in testicular cells of men with non-obstructive azoospermia.
Khadijeh Foghi, Marefat Ghaffari Novin, Zahra Madjd Jabbari, Tohid Najafi, Mohammad Hasan Heidari Iran, Islamic Republic
258. A cause of male infertility factor of a married couple
Merita Krasniqi, M.Krasniqi, Z.Dervishi, S. Shala, M.Ramosaj, SH.Fetiu,Q.Daka, A.Daka Albania
259. The effect of social stress on mouse blastocyst
farzad rajaei, Reza Mahmoudi Iran, Islamic Republic
260. The analysis of fertility in female mice exposed to air pollution during pregnancy
Luiz Fernando Portugal Fuchs, Luiz Fernando Portugal Fuchs, Paula Chaves Mari, Thiago Hideki Gonçalves, Mariana Matera Veras, José Maria Soares Júnior, Paulo Hilário Nascimento Saldiva, Edmund Chada Baracat Brazil
261. 2*3 (3 Doses and 2 ways of Injection of Granulocyte Colony Stimulating Factor (G-CSF) a New Modality of Treatment of Repeated Implantation Failure Following IVF/ICSI.
ali farid elshayp, Ali Sanna 1, Lila Ali 2 Egypt
262. Embryonic stem cell like cells derived from human endometrium, fallopian tube and ovary. The effect of Bee venom to differentiate into germ cells (modern trend)
Ali Farid Elshayp, Erlemando Cosmic, ElAtar Osama Egypt
263. Long term reproductive outcome after hysteroscopic proximal tubal cannulation- a retrospective outcome analysis
Grace Wing Shan Kong, Jacqueline Pui Wah Chung Christopher John Haines Hong Kong
264. Small Amount of Testosterone Administration Improves Ovarian Response to Ovulation Induction in Poor Responders
Kozo Aisaka, Haruko Hiraike, Hiroe Hyodo, Yumiko Ikezuki, Seiichiro Obata, Yuichiro Miyamoto, Osamu Hiraike, Hironobu Hyodo, Hiroyuki Mori Japan
265. The Role of Androgen Supplementation In The Improvement Of IVF Success Rates In Older Women
Elizabeth Anne Claessens, Blanco Mejia S, Maroleanu M, Ryan EAJ Canada
266. Hormonal and surgical characteristics of infertile patients with endometriosis
stefanie aust, Zahra Oshafu; Johannes Ott Austria
267. The effect of transdermal testosterone gel pretreatment for 3 or 4 weeks on antral follicle count, anti-Müllerian hormone and IVF/ICSI outcome in poor responders
Chung-Hoon Kim, Jin-Young Min, M.D., Jun-Woo Ahn,M.D., Sung-Hoon Kim,M.D., Hee-Dong Chae,M.D., Byung-Moon Kang,M.D., Ph.D. Republic of Korea

268. The effect of ovulation triggering with human chorionic gonadotropin plus GnRH agonist in GnRH antagonist cycles for IVF
Chung-Hoon Kim, Jin-Young Min, M.D., Jun-Woo Ahn, M.D., Sung-Hoon Kim, M.D., Hee-Dong Chae, M.D., Byung-Moon Kang, M.D., Ph.D. Republic of Korea
269. Infertility and Sexual life: focus on psychological aspects
chiara nanini, Maria Ruggiero, Valeria Valentino, Andrea Riccardo Genazzani. Italy
270. Recurrent pregnancy loss and autoimmune thyroiditis
Vira Pyrohova, Pyrohova V.I., Shurpyak S.A., Golubka I.M. Ukraine
271. Anti-Müllerian hormone (AMH) predicting ovarian response in controlled ovarian hyperstimulation
Konstantinos Chaidogiannos, Chaidogiannos K., Trakakis E., Vagopoulos V., Basios G., Siristatidis C., Kassanos D. 3rd Department of Obstetrics and Gynecology, Medical School, University of Athens Greece
272. AntiMüllerian Hormone (AMH): Prognostic Value in Assisted Reproductive Technology (ART)
Alessandro Gambera, Perotti A, De Leone S, Bugari G, Iacobello C, Scagliola P, Omodei U & Sartori E Italy
273. Successful pregnancy by intraperitoneal insemination in an infertile patient with failure of recanalization of isthmus stenosis after laparoscopic radical trachelectomy
Jin-Young Min, Chung-Hoon Kim, M.D., Sung-Hoon Kim, M.D., Hee-Dong Chae, M.D., Byung-Moon Kang, M.D. Republic of Korea
274. How does the thyroid function influence the effectiveness of infertility treatment with ART?
Vitalina Vustenka, Kvashenko V.P., Akimova I.K. Ukraine
275. Etiological treatments for couple's infertility: a single-center retrospective analysis.
Giuseppina Pompa, Astorri Anna Laura, Grande Giuseppe, Giampietro Antonella, Lecca Antonella, Fruscella Erika, Milardi Domenico, Marana Riccardo. Italy
276. Fertility preservation in oncological patients: our experience.
Giovanna Simi, Dr. V. Cela, Dr. P.G. Artini, Dr.ssa M. Ruggiero, Dr.ssa O.Di Berardino, Dr.ssa Papini, Dr.ssa L.Freschi, Dr. N. Pluchino, Prof. A.R.Genazzani Italy
277. Effectiveness of a low gonadotrophin-releasing hormone antagonist dose in preventing premature luteinizing hormone rise during controlled ovarian stimulation
Gian Mario Tiboni, Gian Mario Tiboni, Emiliana Leonzio, Elisabetta Gabriele, Adalisa Ponzano, Ilde Verna, Franca Giampietro Italy
278. Cytogenetic findings and reproductive outcome of infertile couples referred to an assisted reproduction program
Gian Mario Tiboni, Gian Mario Tiboni, Ilde Verna, Franca Giampietro, Emiliana Leonzio, Adalisa Ponzano, Gianna Gabriella Impicciatore Italy
279. Prevention of OHSS in ART
Svetlana Zhukovskaya, Petrova E., Zhukovskaya S. (Jr.) Belarus
280. Role of Toll-like receptors 1 and 2 in development of miscarriages
Olga Lebedeva, S. Pakhomov, N. Starceva, O.I. Ivashova, M.I. Churnosov Russian Federation
281. Incidental hyperprolactinemia as a substrate of infertility.
Radoslaw Maksym, Maciej Barczentewicz, Oksana Furman Poland
282. Age is a factor determining the management protocol for election support program luteal phase for ivf?
Ginna Ortiz Olivera, Mendoza J.C, Ortiz G, Cubillos J, Càceres L, Arango A, Ruiz H, Colombia
283. Impaction of autologous eye tears treatments on reproductive aberration breaking topic, updated trend
Ali Farid Elshayp, Ali. Farid, Ali Sanna, Lila Ali Mohamed Ali Farid, YASMIN Ali farid, Samer Samir Egypt
284. Unexplained infertility: characteristics of the endometrium.
Anna Shurshalina, Kellet E, Korneeva I, Demura T., Ezhova L. Russian Federation

285. Will male factor dominate partners' infertility?
Piotr Jedrzejczak, Poland
286. Dydrogesterone in recurrent abortion
Eriseida Ndoni, Astrit Bimbashi, Redi Hoxhallari,
Anika Dokle Albania
287. Thrombophilia and autoimmune thyroiditis in
recurrent spontaneous abortion
Maria Magdalena Manolea, Alice Gavrilă, Lorena
Dijmarescu, D. Iliescu, Simona Neamtu, Liliana
Novac Romania
288. Effect of Nano Gold on Ovarian Hyper Stimulation
in Rats
Ali Farid Elshayp, Ali Farid Mohamed Ali 1, Gamal
I 2, Sana El Shayp 3, Samir Shaker 4 Lila Ali Farid
Mohamed Ali 5,, Mohamed Ali Farid 6, Yasmin Ali
farid 7. Samer Samir 8 Egypt
289. Anti-Müllerian Hormone level in infertile women with
thyroid autoimmunity: our experience
Vitalina Vustenko, Kvashenko V.P., Akimova I.K.
Ukraine
290. Natural Pregnancy Prognosis For Ivf/Icsi Candidates
Using Duofertility
Oriane Chausiaux, Jonathan Hayes, Cormac Long,
Sharon Morris, Gareth Williams, Shamus Husheer
United Kingdom
291. Basil, Ocimum basilicum, and Androgens Roles on
spermatogenesis in rats.
Arash Khaki, Zahra Ghanbari, Fatemeh Fathi Azad,
Mohamad Nouri, Amir Afshin Khaki Iran, Islamic
Republic
292. Comparative Study of Serum Leptin Levels in
Infertile Oligospermic and Fertile Normospermic Men
Maryam Dehghankhalili, Talieh Kazerooni - Khatereh
Aminian Iran, Islamic Republic
293. Levels of benzene in patients affected by
oligoasthenoteratospermia
Silvia Picarelli, Silvia Picarelli, Armando Salerno,
Pasquale de Rosa, Roberta Vallone, Carlo Alviggi,
Ida Strina, Giuseppe de Placido Italy
294. Evidence for the occurrence of receptor in sperm for
sperm agglutinating factor isolated from Escherichia
coli
Kiranjeet Kaur, Kiranjeet Kaur, Siftjit Kaur, Praveen
Rishi, Shrawan Kumar Singh and Vijay Prabha India
295. Comparison of reproductive outcomes using IVF-ET
and ICSI in ART cycles in which only one or two
oocytes are retrieved.
Maria Elena Obino, Elena Carletti, Sara Pinelli,
Francesca Papini, Elena Casarosa, Vito Cela, Paolo
Giovanni Artini, Andrea Riccardo Genazzani Italy
296. Role of Inhibin B In Infertility
Enachescu Irina, dr. Carmen Constantinescu, dr.
Anca Br ȩla, prof.univ.dr. Mihai Br ȩla Romania
297. The polymorphism of PAI-1 gene and endometrial
receptivity in recurrent IVF failures.
Anna Shurshalina, Okhtyrskaya T., Yavorovskaya K.,
Demura T., Ezhova L. Russian Federation
298. The impact of autologous human peripheral blood
mononuclear cells on reproductive aberrations
ali farid elshayp, Ali. farid 1, Ali Sanna 2, Lila Ali 3
Mohamed Ali Farid 4, Yasmin Ali Farid 5. Samer
Samir 6 Egypt
299. Differential effects of coenzyme q10 administration
in idiopathic and varicocele-associated male
infertility
Antonio Mancini, R.Festa, E.Giacchi, S.Raimondo,
F.Principi, A.Pontecorvi, GP Littarru Italy
300. Pregnancy rate in each of the main PCOS
phenotypes in patients undergoing an IVF cycle
Jorge Rodríguez-Purata, Tur-Padró, Rosa; Mancini,
Fulvia; Rodríguez, Ignacio; Coroleu-Lletguet,
Buenaventura; Barri-Ragué, Pedro Spain
301. Dheas supplementation as a promising treatment
for improving follicular microenvironment in poor
responder patients
Sara Pinelli, Giovanna Simi, Maria Ruggiero, Olga
Maria Di Berardino, Maria Elena Obino, Vito Cela,
Paolo Giovanni Artini, Andrea Riccardo Genazzani
Italy
302. Recovery of Spermatogenesis by Allium cepa in
Toxoplasma gondii infected Rats.
Arash khaki, Elham Ghadamkheir, Laya Farzadi,
saedeh shojaee, shahin Ahmadi. Iran, Islamic
Republic
- Anti-Müllerian hormone - a regulator of
folliculogenesis and a predictor of ovarian response
Gurpreet Singh Kalra United Kingdom
- The first successful retrieval of spermatozoa in non
mosaic klinefelter syndrome at Sfax Tunisia
Nouha Bouayed Abdelmoula, Nouha Abid Tunisia

- The level of lipid peroxidation measured in follicular fluid and blood plasma from women attending to an in vitro fertilization
Marta Borowiecka, I. Połać, J. Wojsiat, R. Krasinski, P. Radwan Poland
- Comt polymorphism and the risk of endometriosis-related infertility
Bianca Bianco, Denise Maria Christofolini, Juliana Souto Teles, Caio Parente Barbosa Brazil

Menopause aging

303. Comparison of age- related ovarian endocrine and ultrasound markers to predict the final menstrual period
Ting Ding, Jingjing Jiang, Xiaofang Du, Aiyue Luo, Shuhong Yang, Zhiwen Lai, Ding Ma and Shixuan Wang China
304. A possible role of oxidative stress in bone resorption and postmenopausal osteoporosis
Eleonora Cremonini, Cremonini G., Bonaccorsi G., Cervellati C., Castaldini C., Ferrazzini S., Capatti A., Christodoulou P., Bergamini C.M., Casali F., Fantini G.F, Patella A.,Massari L. Italy
305. PREMATURE OVARIAN FAILURE AND AUTOIMMUNE DISEASES
Maja Ivanisevic, Ivanišević M, Barać M, Stefanović A, Kadija S, Jeremić K, Vujović S, Serbia
306. Isoflavone supplementation in postmenopausal women and its impact on quality of life
Jelena Dotlic, Milan Terzic, Una Vasic, Jelena Micic, sanja Maricic, Tihomir Mihailovic, Milica Berisavac Serbia
307. Effects of surgical menopause and estrogen/ progesteron therapy on circulating progenitor cells
Lorenzo Goglia, S. Pacini, E. Casarosa, E. Russo, S. Gopal, M. Petrini, A.R. Genazzani, A.D. Genazzani, T. Simoncini Italy
308. Vitamin D deficiency in osteoporotic Brazilian postmenopausal patients: the need for better treatment.
Luana Gallo, Sylvia A Y Hayashida, Jose M Sores Jr, Erika Mendonca, Fulvia Beretta, Vicente R Bagnoli, Gustavo A R Maciel, Edmund C Baracat Brazil
309. The physiotherapy effects on the early and late postmenopausal women
Caroline Caliό, Caroline L Caliό, Isabel C Espόsito Sopreso, Mauro Abi Haidar, Helena Hachul, Maria Cāndida P Baracat, Edmund C Baracat, Josę Maria Soares Jr Brazil
310. Presentation and management of POF: Findings from the West London POF database
Kate Maclaran, Kate Maclaran, Nick Panay United Kingdom
311. Prognostic imaging and laboratory properties of cystic ovarian structures in the peri- and postmenopause
Balazs Erdodi, Balazs Erdodi, Zoltan Toth, Attila Jakab Jr. Department of Obstetrics and Gynecology, University of Debrecen, Debrecen, Hungary
312. Bone turnover markers in postmenopausal women with deficient calcium intake
Elena Atanasova, Biljali S, Boshku A The Former Yugoslav Republic of Macedonia,
313. Hormonal Replacing Therapy in Women with Menopausal Symptoms and Evaluation of the Effects on Cardiovascular System
Victoria Mychka, Kuznetsova I.V. Yureneva S.V. Voichenko N.A. Kirillova M.Y. Akarazkova E.S. Uspenskaya J.B. Russian Federation
314. The comparison of Research Diagnostic Criteria for Temporomandibular Disorders to Resonance Magnetic results in menopausal women: a study of diagnostic accuracy.
Alessandra Pucci Mantelli Galhardo, Alessandra Pucci Mantelli Galhardo, Claudia da Costa Leite, Eloisa Maria Santiago Gebrim, Regina Lucia Elia Gomes, Josę Maria Soares Jr, Wanderley marques Bernardo, Carlos Gil, Edmund Chada Baracat Brazil
315. Pain sensitivity of temporomandibular dysfunction in menopausal women
Alessandra Pucci Mantelli Galhardo, Alessandra Pucci Mantelli Galhardo, Maria Cāndida P Baracat, Josę Maria Soares Jr, Carlos Gil, Edmund Chada Baracat Brazil
316. Bone mineral mass as a risk factor for temporomandibular disorders
Alessandra Pucci Mantelli Galhardo, Alessandra Pucci Mantelli Galhardo, Maria Candida P Baracat, Ricardo dos Santos Simōes, Josę Maria Soares Jr, Carlos Gil, Edmund Chada Baracat Brazil

317. Effects of raloxifene, genistein-rich soy extract and conjugated estrogen and their associations on bone structure of ovariectomized rats.
Fernanda L F Condi, Fernanda L. F. Condi, José Maria Soares-Jr, Rodrigo Marcondes, Walcy R. Teodoro, Edwin R. Parra, Maria Cândida P Baracat, Ricardo dos Santos Simões, Manuel de Jesus Simoes, Edmund C Baracat Brazil
 318. Conjugated estrogen-raloxifene association or soy extract effects on collagen in bone rats
Fernanda L F Condi, Fernanda L. F. Condi, José Maria Soares-Jr, Rodrigo Marcondes, Walcy R. Teodoro, Edwin R. Parra, Maria Cândida P Baracat, Ricardo dos Santos Simões, Manuel de Jesus Simoes, Edmund C Baracat Brazil
 319. Vitamin D receptor gene polymorphisms and treatment response in a premenopausal osteopenic woman
selva lima, Dra Lima,S; Vaglio,A Uruguay
 320. The impact of menopause and HRT in gingival tissue and alveolar bone
Robert Qirko, Margareta Cipo, Dritan Shpati, Arben Rugia Albania
 321. X/Autosomal Translocation in the Xq Critical Region associated with Premature Ovarian Failure
Gwennaëlle Rege, G Rege, A. Firquet, A Béliard, M Nisolle, JM Foidart, A Pintiaux Belgium
 322. Fitoestrogens and breast tightness in menopause women on HRT
Emilija Bulajic, Montenegro
 323. Dosage tsh in postmenopausal women for diagnostic of thyroid tumors
Leopoldo Tinoco, Carrillo Sonia Nicolalde Angelo Pozo Chela Tinocodiana Ecuador
 324. The climacterics and menopauses: parapsychological evolution bio-neuro-endocrine female
Sabrina Anna Nervi, Italy
 325. Treatment of two types menopausal syndrome with polyclonal serum derived at specific-tissue saturation therapy
Dr. Sabrina Anna Nervi (Italy) Marirosa Binda (Switzerland)
 326. Climacterium and depression
Miriam Da Silva Wanderley, Fabrício Mendes Ferreira; Patrícia Sales Marques da Cruz; Lorena de Souza e Cássia; Nicolas Thiago Nunes Cayres de Souza ; Miriam Monteiro Alvares. Brazil
 327. The lumbar DXA parameters analyze and high risk fracture patients evaluated by Heel Quantitative Ultrasound - a study in 343 women
Mara Carsote, Cristina Ene, Simona Albu, Corina Grigoriu, Gabriela Voicu, Catalina Poiana, Mihai Coculescu, Romania
 328. The low risk fracture postmenopause women - Quantitative Ultrasound analyze in 143 patients
Mara Carsote, Catalina Poiana, Mara Carsote, Simona Albu, R.Baloescu, V.Radoi, Corina Grigoriu, Andreea Geleriu, M.Coculescu Romania
 329. Intervertebral disc height in premenopausal women, treated and untreated postmenopausal women and postmenopausal women with osteoporotic vertebral fractures
Yves Muscat Baron, Y M. Baron, N Felice, M Brincat, N Calleja. Department of Obstetrics and Gynaecology, Mater Dei Hospital. Department of Obstetrics and Gynaecology, Mater Dei Hospital. Malta
 330. Relationship between Sexual Dysfunction with Educational level and Intelligence Coefficient in Climacteric patients
S. I. Adriana Vilarino, ; Lioy, G; Fernandez, M, Urthiague, M; Mural J,Lange D ; Snaidas, L; Provenzano, S; Dotto, J; Contreras Ortiz, O Argentina
 331. Role of sex hormones as predictors of bone loss in women with premature ovarian failure
Maria Belen Perez Lana, Nolting, Manuel; Onetto, Claudia; Straminsky, Vanesa; Galluzzo, Liliana; Perez Lana, Maria Belen Argentina
 332. Low blood lycopene levels are associated with increased risk of coronary artery disease and osteoporosis in menopausal women
Rahul Pathak, India
- Correlation between menopausal symptom intensity and insomnia in postmenopausal women
Danny Salazar, Peter Chedraui, Glenda San Miguel, Winston Jaramillo, Cristian Cando, Flor López-Alvarado, Luis Hidalgo, Faustino R. Pérez-López, (Ecuador) Andrea Genazzani, Tommaso Simoncini (Italy)

333. Implications of dehydroepiandrosterone in patients with premature ovarian failure and Hashimoto's thyroiditis
Peter Frigo, Philipp Pecnik, Michael Hermann, and Johannes Ott Austria
334. Efficacy and acceptability of a new non-hormonal mucoadhesive vaginal moisturizer gel for the management of vaginal atrophy
José Estevez, Juan Luis Delgado, Maria de la Calle, Jose Luis Gallo, Concepcion Nieto, Ramón Usandizaga Spain
335. Evaluation of vaginal trophism in peri-and postmenopausal women with and without hormone therapy
Pierino Russomanno, Authors: Juan Manuel Sanchez & Pierino Russomanno Cols.:Lima, S; Dinardi, M; Caussade, A; Bozzolo, A Uruguay
336. Sexual dysfunction in Russian peri- and postmenopausal women: the impact of type 2 diabetes mellitus
Anna Pogorelova, MD Tatyana U. Berketova, Prof. Galina A. Melnichenko, MD Anton K. Ragozin Russian Federation
337. Low bone density in cais adult women despite long term oestrogen HRT
marta berra, Marta Berra, Maria Cristina Meriggiola. Italy
338. Assessing the Glucocorticoid therapy as a significant risk factor in postmenopausal bone evaluation
Maria Cristina Moruzzi, Lassandro AP, Moruzzi MC, Riccardi MT, Vacca L, Leoni F, Pastore R, Scambia G, Villa P, Italy
339. Risk of adnexal masses subjective ultrasonography false negative result according to menopausal status
Rafal Moszynski, Szpurek D., Szubert S., Sajdak S. Poland
340. Related Factors of Uncomfortable Breathing, Coughing and Snoring during Usual Sleep Habit in 50- 60 years old women in Tehran
Neda Nazem Ekbatani, Simin Taavoni, Hamid Haghani, Iran, Islamic Republic
341. Assessment of menopausal symptoms among middle age women in Tehran, Iran
Neda Nazem Ekbatani, Fatemeh Darsareh, Simin Taavoni Fatemeh Darsareh Iran, Islamic Republic
342. Alternative treatment for uterine bleeding at women in perimenopause
Ruxandra Stanculescu, Other authors: Bausic Vasilica, Bratila Elvira, Cucu Andrei Romania
343. Clinical experience in diagnosis, management and treatment of adolescents with Primary Ovarian Insufficiency (POI) during the past 7 years
Vasileios Karountzos, E. Deligeoroglou, P.Tsimaris, K. D. Dimopoulos, E. Stergioti, N. Athanasopoulos, A. Deliveliotou, G.K. Creatsas Greece
344. Endogenous testosterone associates with subclinical atherosclerosis in healthy recently menopausal women
Eleni Armeni, Stamatelopoulos Kimon, Creatsa Maria, Rizos Demetrios, Georgiopoulos Georgios, Kazani Maria, Alexandrou Andreas, Kazani Aikaterini, Augoulea Areti, Karaflou Maria, Papamichael Christos, Lambrinoudaki Irene Greece
345. The Practice of Hormone Replacement Therapy in Women of Borneo Island
Syed Alwi Syed Abdul Rahman, Kristen FitzGerald Kamarudin Kana Zuraini Arabi Malaysia
346. Menopausal Symptoms and Correlated Factors in 45-60 Years Old Women, Tehran, 2011
Neda Nazem, Fatemeh Darsareh, Simin Taavoni, M. Iran, Islamic Republic
347. Clinical presentation of polycystic ovary syndrome in perimenopausal period and postmenopause
Galina Davydova, G.M.Savelyeva, G.A.Melnichenko, Ilyin A.V. and Chebotnikova T.V Russian Federation
348. Morphological and functional changes on adipose tissue in ovariectomized rats fed high fat diet
Aline Sousa Santos, Santos AS; Santana AC; Costa CAS; Gonzalez GPL; Gaspar-Reis RP; Alves SS; Nascimento-Saba CCA Brazil
349. Two years monitoring of hormone endometrial regulation in perimenopausal dysfunctional uterine bleeding
Manuela Russu, Stănculescu R, Nastasia Ș Romania
350. Metabolic Effects of Estrogen and Testosterone Therapy in Relation to Serum Metabolites in Postmenopausal Women
Hong Zang, Thomas Moritz, Gunnar Norstedt, Angelica Lindén Hirschberg, and Petra Tollet-Egnell China

351. Sleep disturbances in menopausal women
laura ganzitti, L. Ganzitti, M. Della Martina, E. Vogrig,
S. Xodo, D. Rinuncini, S. Lorenzut, M. Sommaro, A.
Fontana, G. Fabiani¹, G.L. Gigli, D. Marchesoni Italy
352. The Effect of Surgical Menopause on the
Cardiovascular System and the Role of Hormone
Replacement Therapy
Svetlana Yureneva, S. Moiseenko, E. Maychuk
State Medical Dental University, Moscow Russian
Federation
- A Atypical Fracture Due to prolonged
Bisphosphonates use
Tarun Varma, R Bhanvadia, A Saini, N Gupta, S
Tripathi. Department of Endocrinology Sir Gangaram
Hospital, New Delhi, India
- Correlation between static balance control and fear
of falling in young postmenopausal women
Nicolas Mendoza, Martínez-Amat A, Lomas-Vega R,
Granados-Vicente M and Hita-Contreras F. Spain
- Stabilometric parameters associated with falls in
50 to 65 years old postmenopausal population.
Nicolas Mendoza, Martínez-Amat A, Romero-Franco
N, Lomas-Vega R, Hita-Contreras F. Spain
- Definition of national norms of quality of life, and
manifestation of climacteric syndrome in Armenian
women population in 40 - 60 age group.
Evelyn Manvelyan, A. Tadevosyan, Armenia
- Efficacy of hormone treatment on climacteric
symptoms in post-menopausal women with uterine
myomas.
Victoria Kolesnikova, Zaydieva J.Z., Gorenkova
O.S., Kolesnikova V.A., Chechneva M.A. Russian
Federation
- Study of pupulation for weight increase, Androidic
obesity, Gynoidic obesity and factors connected
with it in menopause and non- menopause women.
Fereshte Ebrahimian, Rashidi.h Iran, Islamic
Republic
- Menopause And Cardiovascular Risk: Prospective
study of a population of 1651 menopausal women.
Fathia Djezzar, Pr A.Bakhti Algeria
- The importance of colpocytogram in the ths
monitorization in the climacteric neogenital atrophy
Florentina Tanase, Lorena Dijmarescu, Alexandru
Comanescu, Nicolae Cernea, Carmen Popescu,
Draghici Ileana, Voicu Ciprian Romania
- Thrombin and plasmin activity in plasma of
postmenopausal Polish women after hormone
therapy
Marta Borowiecka, I. Połać, J. Wojsiat, M. Kędzierska,
P. Nowak Poland
- Diet intervention to improve cardiovascular risk
factors among Iranian postmenopausal women
Parvin Abedi, Mary Huang Soo Lee, Mirmalini
Kandiah, Zaitun Yassin, Davood Shojaezade,
Mostafa Hosseini, and Reza Malihi Iran, Islamic
Republic

Gynecology

353. Association of metalloestrogen cadmium and
endometriosis
Nalinda Silva, K Tennekoon H Senanayake S
Samarakoon Sri Lanka
354. Detection of endometrial aromatase mRNA as a
possible marker to screen for endometriosis and
adenomyosis
Jozef Hatok, Pavol Zubor, Karol Kajo, Jan Danko and
Peter Racay Slovakia
355. Pathological study of uterine fibroids in women of
reproductive age
Maryna Lapotka, Belarus
356. Immunohistochemical studies - the need for
pathogenetic treatment of uterine fibroids
Maryna Lapotka, Belarus
357. Deep Endometriosis: Diagnostic Imaging
Gustavo Corrêa de Almeida Teixeira, Bernardo
Corrêa de Almeida Teixeira; Arildo Corrêa Teixeira
Brazil
358. Effects of chlormadinone acetate (CMA) on
prostaglandin biosynthesis in human endometrial
explants
Katrin Roth, A. Stein, S. Gradowski, L. Fischer,
W.R. Deppert, A. Hanjalic-Beck, W.R. Schäfer, H.P.
Zahradnik Germany
359. Investigation of estrogen sulfotransferase (SULT1E1)
expression in different human endometrial in vitro
models
Melissa Straßer, L. Fischer, W.R. Deppert, A.
Hanjalic-Beck, W.R. Schaefer Germany

360. Systematic review and mixed treatment comparison of HMB treatments
Anna Filonenko, Kyle Fahrbach,¹ David Hoaglin,¹ Noah Haber,¹ Nicholas Meader,¹ Ian Fraser,²
¹United BioSource Corporation, London, United Kingdom; ²University of Sydney, Sydney, NSW, Australia Germany
361. Can progesterone metabolism at the pre-receptor level contribute to decreased progesterone action in endometriosis?
Nataša Beranič, Tea Lanišnik Rižner, Slovenia
- Inflammatory cytokine and hormone levels in serum and peritoneal fluid of ovarian endometriosis patients
Vida Kocbek, Kocbek V. (Slovenia), Mueller (Switzerland), Lanišnik Rižner T. (Slovenia), Bersinger N.A.(Switzerland),
362. Uterine arteriovenous fistula - a rare condition
Andreia Relva, Andreia Relva, Íris Bravo, José Metello, Isabel Simões Reis, Pedro Sá e Melo Portugal
363. Treatment of endometriosis with local acetylsalicylic acid injection - experimental study in rabbits
Rogerio Saad-Hossne, Juliana Menezes Siqueira Adriana Beatriz Barreto Brazil
364. Isolated fallopian tube torsion: tow rare cases report and review of literature
Bouchra Fakhir, Aitbenkaddour Y., Aboulfalah A., Asmouki H., Sommani A. Morocco
365. Use of a murine endometriosis interna model for the characterization of drugs that effectively treat endometriosis in patients
Christiane Otto, Jenny Schkoldow, Elisabeth Krah, Iris Fuchs, Hannes-Friedrich Ulbrich Germany
366. Comparison evaluation of urogenital Mycoplasma frequencies in non- pregnancy women with urogenital tract infections by multiplex PCR and cultivation methods
Mojtaba Moosavian, Hosein Motamedi, Susan Maleki, Nahid Shahbazian Iran, Islamic Republic
- Hysteroscopic endometrial ablation as an alternative treatment for adenomyosis comparing with conservative treatment
Robert Qirko, (Albania) Halim Kosova (Albania) Olga Lebedeva, (Russia) Odeta Hoxhaj (Albania) Albert Cakoni (Albania)
367. In vitro evaluation of the protective and reparative effect in relation to damage caused by external agents on the vaginal epithelium
Franco Gasparri, Valentina Giannini, Claudio Benvenuti Italy
368. Efficiency of combined therapy for treating symptoms of endometriosis
Ainur Tuletova, Kazakhstan
369. Efficiency of surgery and glandular therapy of endometrioms
Ainur Tuletova, Doshanova A.M. Kazakhstan
370. Changes in sexuality in elderly women
Dennis Vaidakis, Makris G.M., Zarkadas S., Karatrasoglou H., Ferenidou F. Greece
371. Efficacy and tolerability of a new detergent in feminine care
Ellis Martini, Erica Terreno, Rossella E. Nappi, Maria Grazia Matarazzo, Antonio Cianci, Vincenzo De Leo Italy
372. Antimicrobial activity of a wetting solution for sanitary pads
Paola Portaluppi, Elena Tacconi, Claudio Benvenuti Italy
373. Optimization of examination and treatment for patients with ovarian endometrioid affection
Khorina Elena, E.A.Khovrina, I.V.Kuznetsova. Russian Federation
374. Endometriosis in adolescence: Challenges in diagnosis and treatment
Vasileios Karountzos, P.Tsimeris, K. D. Dimopoulos, E. Stergioti, N. Athanasopoulos, E. Deligeoroglou Greece
375. Parasitic myoma mimicking an adnexal mass
Anabela Serranito, Anabela Serranito, Claudia Tomas, Silvia Couto, João Saraiva, Fátima Romão, Teresa Avillez Portugal
376. Role of eating behaviour as a risk factor of uterine myoma in Armenian women of reproductive age settled in south region of Georgia
Natia Kajaia, L. Luashvili, N. Kajaia, T. Gagua, M. Jugeli, D. Gagua, L. Djvarsheishvili, L. Djavashvili, N. Chogovadze, B. Tkeshelashvili Georgia

377. Peculiarities of metabolic disorders and incorrect eating behavior in georgian women of reproductive age with uterine myoma
Natia Kajaia, B. Tkeshelashvili, L. Luashvili, T. Gagua, M. Jugeli, D. Gagua, L. Djvarsheishvili, L. Djavashvili, N. Aladashvili, N. Kajaia, Georgia
378. Bilateral Ovarian Torsion in an 18 Year Old Girl With Polycystic Ovaries
Valerie To, Richard N Brown Canada
379. Ultra sound guided injection of peripheral blood mononuclear cell a new modality for treatment of hepatic endometriosis case report and review of the literature
Ali Farid Elshayp, Ali Farid M Ali 1 Ahmed Eldory 2 Ibrahim Khalil 3 Lila Ali Farid Mohamed Ali 4, Mohamed Ali Farid 5, Yasmin Ali Farid 6. Samer Samir 7 Egypt
380. What are hereditary angioedemas?
Laurence Bouillet, France
381. Primary isolated hydatid cyst of breast: a case report and iconography
Bouchra Fakhir, B. Fakhir, K. Abdi, A. Aboufalah, H. Asmouki, A. Soummani Morocco
382. Are teenagers well informed about sexuality?
Angela Santos Neves, Ana Claudia Rodrigues, Diana dos Santos, Gil Correia, Cláudia Vicente, Joana Silva, Regina Belo Portugal
383. Dyspareunia and quality of sex life in women with rectovaginal endometriosis during treatment with norethisterone acetate
Umberto Leone Roberti Maggiore, Valentino Remorgida, Martina Di Luca, Pier Luigi Venturini, Simone Ferrero Italy
384. Sexual transmission diseases risky behaviors and pathological dependency and sexual crimes.
Saverio Costantino, A. Pistuddi, C. Dominoni, A. Lucchini, A.L. Romanò, O. Todarello. Italy
385. Lesbian Israeli women Preferences of Obstetricians and Gynecologists
Hadar Amir, Dr. Ruth Gofen Prof. Ami Amit Prof. Foad Azem Israel
386. Bladder endometriosis: effectiveness of modified american urologic association symptom index in the clinical evaluation.
Dario Garcia-Rojo, Naim Hannaoui, Angel Prera, Jordi Antoni, Jesus Muñoz, Eduardo Vicente, Carlos Abad, Josep Pubill, Jose Luis Gonzalez-Sala, Raul Martos, Josep Gual, Miriam Barrio, Juan Prats. Spain
387. Comparison of various progestins in the preoperative treatment of endometriotic cysts
Roxana Daniela Matasariu, Tirnovanu Mihaela Camelia, Gonta Olga, Holicov Monica, Dumitrascu Irina Romania
388. Stem cell preservation for nuclear accidents.
Karl-Heinz Preisegger, Martina Freigassner Austria
389. Pelvic Pain -questionnaire a first level for Endometriosis-screening
Maria Paola Simeone, Prof Ettore Cicinelli Dr. Maria Paola Simeone Italy
390. Angiogenesis and inflammatory response in endometriosis - the role of danazol treatment
Maria Szubert, Katarzyna Kowalczyk-Amico, Agata Szulawska, Markus Duechler, Małgorzata Czyż, Jacek Suzin Poland
391. Endometriosis: DHEA and DHEA-S in plasma and in saliva
Natalia Russo, Daino D, Santoro A.N, Freschi L, Pluchino N, Casarosa E, Genazzani A.R. Italy
392. Nano Silver effect on Endometriosis in Baboons with induced disease, a placebo Controlled Randomized Study
Ali Farid Elshayp, Ali Farid Mohamed Ali 1, Gamal I 2, Sana El Shayp 3, Samir Shaker 4 Lila Ali Farid Mohamed Ali 5, Mohamed Ali Farid 6, Yasmin Ali Farid 7. Samer Samir 8 Egypt
393. Diagnostic value of endometrial thickness determined by transvaginal sonography in infertile women with endometrial polyps
Yong Song, Licong Shen, Wei Huang, Haike Lei, Qiushi Wang, Huili Zhu China
394. MISSION Study: The 4th follow up
Marie-Christine Micheletti, P. De Reilhac (France), M. Espié (France), T. Maudelonde (France), J.Y. Reginster (Belgique), J.-P; Daurès (France), P. Mares (Monaco)
- Intercellular endo-myometrial interaction with adenomyosis.
Gulnara Makhmudova, - Russian Federation

- Is IT easy to do?
Maria Florea, A Comanescu, D. Iliescu, Cristina Fota, Stefania Tudorache, Claudia Oprea, Florentina Tanase, N. Cernea Romania
- Conservative management assessment of the uterine fibromioma
Florentina Tanase, Nicolae Cernea, Alexandru Comanescu, Lorena Dijmarescu, Alina Dobrinescu, Ovidiu Sirbu Romania
- Study of telomerase expression in endometriosis
Bianca Bianco, Fernanda Mafra, Denise Christofolini, Fábila Vilarino, Gustavo Mendonça André, Bianca Bianco, Caio Parente Barbosa Brazil

Pelvic floor and gynecologic surgery

- 395. Rupture of Endometriotic Cysts Managed by Laparoscopic Surgery
haruhiro kondo, Juichiro Saito, Midori Tamura, Nao Suzuki, Bunpei Ishizuka Japan
- 396. Comparison of pelvic floor muscle strength between women undergoing vaginal delivery, cesarean section, and nulliparae using a perineometer and digital palpation
Elicéia Marcia Batista, Délio Marques Conde, Waldemar Naves Do Amaral, Edson Zangiacomi Martinez Brazil
- 397. Hysteroscopic surgery and changes in the uterine cavity with administration of dienogest
Juichiro Saito, haruhiro kondo, chie nishijima, takafumi nako, seido takae, yasuna wada, tomohiro iida, bunnpei ishizuka Japan
- 398. Diagnostic Hysteroscopy: Pictures In Recurrent Abortion
Luigi Salvatore Papadia, Italy
- 399. Operative hysteroscopy: obstetric outcomes in recurrent abortion
Luigi Salvatore Papadia, Italy
- 400. Use of the Perineal Card in association with trans-perennial ultrasounds to detect early signs of pelvic floor dysfunction
Ida Matula, P.Mannella, A. Gozzoli, A.R.Genazzani, T.Simoncini Italy
- 401. Comparative study of posterior urethral bladder angle and postsurgical urinary retention in the treatment of urinary incontinence
ida matula, P.Mannella, A.R.Genazzani, T.Simoncini Italy

- 402. Percutaneous Tibial Nerve Stimulation in the treatment Overactive Bladder of
Eleonora Russo, P. Mannella, V. Tosi, I. Matula, L. Goglia, S. Gopal, T. Simoncini, A.R. Genazzani. Italy
- 403. Vaginal cuff dehiscence after minimally invasive radical hysterectomy: a systematic review
Stefano Uccella, Giorgio Bogani; Antonella Cromi; Jvan Casarin; Giorgio Formenti; Maurizio Serati; Fabio Ghezzi Italy
- 404. Research on a pattern of 60 patients who were cured in the outpatient of gastroenterology (a.O.U.P.): Relationship between anal disease and sexual dysfunction
Caterina Palla, Elisabetta Donati, Chiara Nanini, A.R. Genazzani Italy
- 405. Pain and hysteroscopy: evaluation of the compliance of patients undergoing diagnostic examination
Piacenti Ilaria, L. Giannone, E.Candelori, E. Giannone Italy
- Using Transcutaneous Electrical Nerve Stimulation
Azar Aghamohammadi, Azade Aghamohammadi Abbas Rajabi Iran, Islamic Republic



European
Society
of
Gynecology



Société
Européenne
de
Gynécologie

10 Congress of the
European Society of Gynecology
Congrès de la
Société Européenne de Gynécologie
Square Meeting Centre, Bruxelles 17/21 Sept 2013

www.SEG2013.com



— 16 —
WORLD CONGRESS
OF gynecological
endocrinology ♀
IV CONGRESSO ISGE ITALIA



MARCH 5-8 2014 — FIRENZE ITALY
WWW.GYNECOLOGICALENDOCRINOLOGY.ORG